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There is direct or circumstantial evidence that several viruses that cause no obvious disease 
in bats have spilled over into humans and other species causing serious and often fatal disease. The 
reasons for the lack of disease in bats or for the spillover of these viruses from bats are poorly 
understood. While there is considerable literature on the interactions of these viruses with their 
secondary hosts or their surrogates, little is known about the interactions of bat viruses in their 
natural hosts. We used a coronavirus detected in little brown bat (Myotis lucifugus) and a 
herpesvirus, detected in the big brown bat (Eptesicus fuscus), as models to understand the factors 
that might alter bat-virus relationships. We demonstrated that a coronavirus (Myotis lucifugus 
coronavirus – Myl-CoV) detected in the intestines of little brown bats, could persist in them during 
the 4 months of hibernation. Using this coronavirus-bat model, we showed that the stress of fungal 
infection by Pseudogymnoascus destructans (Pd), which causes bat white-nose syndrome (WNS), 
led to a 60-fold increase in viral replication in intestines than bats with virus alone. Increased viral 
replication correlated with the severity of Pd-related pathology and the intestine of fungus-infected 
bats showed changes in gene expression suggesting suppressed innate antiviral response and 
increased apoptotic responses. Our results suggest that the systemic effects of WNS leads to a 
resurgence of virus replication and increases the potential of virus shedding. Using a bat cell 
culture model, we showed that viral persistence could be disrupted by artificially suppressing the 
host cell’s antiviral response and was mediated through similar pathways that were observed 
during in-vivo experiments. To ascertain whether the effect of stressor could disrupt viral 
persistence in other bat-virus relationships, I studied the big brown bat herpesvirus. As 
herpesviruses inherently establish life-long latent infections in their hosts and reactivate 
periodically in response to stress, we used this model to study the effects of natural stressors on 
 iii 
the bat-virus relationship. We characterized the herpesvirus and developed techniques for 
detecting the virus as well as for monitoring the adaptive antibody response against the virus. We 
showed that the bat gammaherpesvirus reactivates at the end of hibernation and was accompanied 
by a lower antibody level, which subsequently increased upon arousal. Our studies on coronavirus 
and herpesvirus show that bats have a long-term balanced and benign relationships with viruses 
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Chapter 1: Introduction 
Bats are implicated as hosts for viruses which may have spilled over to other species 
including humans. My thesis focuses on the effect stressors might have on bat-virus relationships 
and if these effects alter viral shedding. My review initially focuses on literature on how bats and 
their viruses interact, specifically on the bat antiviral response, inflammation due to viral infection 
and the effect of stress on viral spillover. This follows an introduction to the bats in North America, 
which would aid in understanding the host species that we have studied. The literature review then 
describes current knowledge about viruses that are similar to the ones we have studied i.e., 
coronavirus and gammaherpesvirus. I have described the genome organization and life cycles of 
these viruses, their interaction with host pathways, their pathogenesis and the evidence for viral 
spillover to other species. For the gammaherpesvirus, I have reviewed factors that influence virus 






Chapter 2: Literature review - Immune system modulation and viral 
persistence in bats: understanding the mechanisms behind spillover 
2.1. Copyright 
ã 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open 
access article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license. 
 
This manuscript has been reformatted from the original version for inclusion in this thesis. 
 
2.2. Citation 
Subudhi, S., N. Rapin, and V. Misra. “Immune System Modulation and Viral Persistence 




Bats harbor a myriad of viruses and some of these viruses may have spilled over to other 
species including humans. Spillover events are rare, and several factors must align to create the 
“perfect storm” that would ultimately lead to a spillover. One of these factors is the increased 
shedding of virus by bats. Several studies have indicated that bats have unique defense mechanisms 
that allow them to be persistently or latently infected with viruses. Factors leading to an increase 
in the viral load of persistently infected bats would facilitate shedding of virus. This article reviews 
the unique nature of bat immune defenses that regulate virus replication and the various molecular 





Over the past few years, the interest in bat research has increased because of the range of 
viruses that they harbor and the potential of spillover to humans and other vertebrates [1]. In some 
instances, there is direct evidence that viruses have spilled over from bats to other vertebrates. For 
example, Nipah virus spilled over from bats to humans and pigs leading to outbreaks in South-east 
Asia and Hendra virus continues to spillover into horses and humans in Australia [2–6]. In other 
instances, the evidence of virus spillover from bats is circumstantial. For example, in case of 
ebolaviruses, serological evidence and the detection of viruses related to the ebolaviruses in bats 
[7,8] suggests that they are reservoirs of the virus. Recent discoveries of filoviruses in bats of 
China and Sierra Leone have further bolstered this claim [9,10]. However, viruses linked to 
specific Ebola virus disease (EVD) epidemics have not yet been detected in bats. Although bats 
harbor many diverse viruses, their spillover to other animals is extremely rare [11]. One of the 
reasons is that for a spillover event to take place several factors such as pathogen shedding, 
environmental conditions, pathogen persistence in environment and recipient host susceptibility, 
should all be conducive to transmission. This would result in the “perfect storm” required for 
spillover. A review by Plowright et al. describes the factors that could lead to such a perfect storm 
[12]. Here, we focus on one of the initial events affecting this spillover, i.e. an increase in pathogen 
shedding.  
Pathogen shedding by bats is a complex phenomenon regulated by host antiviral defenses 
and viral factors. A host’s defenses attempt to control virus infection but viruses have evolved 
mechanisms to counteract them [13]. When the host defenses are suppressed, or if the virus is able 
to circumvent the host immune system, virus replication is enhanced, leading to an increase in 
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virus shedding. The route of shedding is highly dependent on the tissue in which the virus 
replication occurs. For example, increased replication in the kidney would lead the bat to shed the 
virus in urine, whereas intestinal replication would result in dissemination through feces. 
Therefore, it becomes important to study what factors might be responsible for decreasing 
the host defense or factors that allow the virus to circumvent host immune response. But before 
exploring factors affecting virus-host interactions, it is imperative to understand the viruses present 
in bats and the bat immune defenses. In 2013-14, bat immunology was at a nascent stage and 
Schountz and Baker et al. had summarized the preliminary knowledge about it in their reviews 
[14,15]. In 2017, Schountz et al. again reviewed bat immunology but the article also laid out gaps 
in our understanding of host pathogen interactions in bats [16]. Here, we include more recent 
advances in characterizing the bat immune system including a possible link between the evolution 
of flight in bats and viral persistence. Following that section, we discuss the factors identified so 
far that upset the balanced bat-virus relationship, potentially leading to the spillover of viruses. 
One must be cautious when interpreting the literature on bat defenses. The order Chiroptera 
contains more than 1200 species [17]. Due to this diversity, the information obtained from one 
species may not apply to others. For instance, in the black flying fox (Pteropus alecto), the 
interferon gene locus is contracted whereas in Egyptian fruit bat (Rousettus aegyptiacus), this locus 
is expanded [18,19]. Other examples are discussed later in this review. 
2.5. Bats have an efficient and varied antiviral response 
It has been observed that viruses which severely affect other mammals, including humans, 
are apparently non-pathogenic for bats [20]. This adaptability of bats to harbor many viruses 
without showing overt pathology suggests that bats have evolved immune mechanisms that allow 
for benign virus-host relationships.  
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The immune response has two primary components, innate and adaptive. The host initially 
responds to infection by activating innate mechanisms. Genes such as those for sensing and 
repairing DNA damage and the inflammatory process are under positive selection in black flying 
foxes and David’s myotis (Myotis davidii) [21]. For instance, there are mutations in the coding 
sequence of p53 functional domains that are unique to these bats. Interferons are the primary innate 
effector molecules that control viral replication. Several types of interferon have been identified 
in bats, especially Type I and Type III. Type I interferon is induced after virus infection in Egyptian 
fruit bats whereas type III interferon is induced similarly in pteropid bats [22,23]. It is interesting 
to note that interferon genes in black flying foxes have contracted in terms of diversity. The number 
of variants of interferon present in these bats is lower compared to those in the gene loci of ten 
other vertebrate species. Despite this decrease in interferon gene diversity, black flying foxes 
express these variants at higher basal levels than other mammalian species. This suggests that the 
interferon and interferon stimulated genes are constitutively expressed in these bats [18]. In 
contrast, a recent study of the genome of Egyptian fruit bats shows expanded diversity of Type I 
interferon genes. This, as well as expansion of various other immune genes, suggests novel modes 
of antiviral defense in bats of various species [24]. Novel modes of antiviral defenses could exists 
in other species of bats and future studies would help in revealing them. 
Cruz-Rivera et al. showed that in cultured cells of black flying foxes, interferon-stimulated 
genes (ISGs) were expressed at higher levels than their human counterparts. They also 
demonstrated that an antiviral effector 2-5A-dependent endoribonuclease (RNase-L) is a unique 
downstream ISG gene, which is stimulated directly by interferon in bat cells [25]. The activated 
RNase-L can then cleave viral mRNA. In contrast, in human cells, RNase-L is not directly 
stimulated by interferon  but via an intermediate molecule, 2’,5’-oligoadenylate (2-5A) synthetase 
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[26]. Similarly, direct activation of RNase-L was also observed in in-vivo experiments with 
Jamaican fruit bats (Artibeus jamaicensis) [27]. Inactivation of the RNase -L gene renders bat cells 
more susceptible to virus infection and direct induction of RNase-L may provide bats with an 
additional layer of antiviral defense [25].  
These studies suggest that in bats of several species, higher level of interferon and ISGs 
are always present in their cells, which makes them better prepared to control viruses. Overall, 
bats seem to possess either an “always ON” interferon strategy plus or a better antiviral ISG 
defense strategy. 
2.6. Bats suppress the pathological effects of excessive virus-induced inflammation 
While bats are well prepared to control viral infections, they also have mechanisms to avoid 
over-induction of inflammatory genes. Such excessive inflammation is detrimental in vertebrates 
of other species, such as humans, and is linked to pathology [28]. So, it is beneficial for the bats to 
have evolved mechanisms that would allow them to control excessive inflammation. Cell culture 
experiments have shown that cells of several species of bats have an inhibitor molecule (cRel) 
binding site in the promotor region of tumor necrosis factor alpha (TNFa), a key inflammatory 
cytokine. In cells of big brown bats (Eptesicus fuscus), stimulated with poly I:C, a surrogate for 
double-stranded viral RNA, cRel actively suppresses TNFa expression [29]. Genome analysis of 
black flying foxes and David’s myotis have also demonstrated positive selection pressure on the 
cRel gene [21]. This suggests that many bats have a mechanism to suppress the expression of 
TNFa, thereby maintaining a balanced response to viral infection.  
Several species of bats control inflammation by having a mutation at a highly conserved 
serine residue in one of the key adaptor molecules for sensing damaged DNA, i.e., stimulator of 
interferon genes (STING), which reduces its functionality. STING senses damaged DNA or 
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dsDNA from viruses and induces an interferon response. The replacement of serine at position 358 
by other amino acids makes bat STING less effective in activating interferons [30]. In addition to 
possessing a less effective STING, the pyrin and HIN domain (PHYIN) genes, which are involved 
in microbial DNA sensing and formation of inflammasome, are absent in bats [21,31]. These 
findings demonstrate some of the reasons for reduced inflammation in bats during viral infection. 
Mechanisms to modulate inflammation may have evolved to mitigate the detrimental effects of 
flight. Excessive exposure to cytosolic DNA in bat cells during flight might have posed a strong 
natural selection pressure to reduce the activation of bat DNA sensors.  
 Unique immune features and relationship with the evolution of flight: The unique 
features of bats, whereby they tolerate viral infections without excessive inflammation while 
suppressing viral replication, leads to the obvious question - What is so special about bats? The 
answer to this has been linked to the evolution of the ability to fly. The increased rate of 
metabolism accompanying flight would lead to higher levels of oxygen-free radicals [32,33]. This 
makes bats more prone to generating damaged DNA [34]. As mounting an immune response is 
energetically expensive [35] and would be detrimental, bats probably evolved mechanisms to 
suppress activation of immune response due to damaged DNA generated via flight, thereby leading 
to reduced inflammation. This would also explain why bats of certain species live longer than 
expected given their high metabolism and small size [36]. In bats the evolutionary suppression of 
inflammation and consequent susceptibility to virus infection is counteracted by constitutive 
expression of innate immune genes or novel genes to target viruses as described earlier. This model 





Figure 2.1. Evolution of tolerance to DNA damage and unique antiviral immune response in 
bats. Development of flight necessitated the evolution of bats with the ability to modulate the 
consequences of increased metabolic activity by suppressing inflammation (left). Inflammation 
was suppressed by dampening the activation of DNA sensors, such as STING, and reducing levels 
of inflammatory cytokines, such as TNFa (center). These traits were positively selected but a 
reduced inflammatory response made it advantageous for virus replication (lower right). Increased 
susceptibility of cells to virus replication was compensated by selection of more effective antiviral 
measures, such as higher constitutive expression of Interferons or unique ISG expressions (upper 
right). (Abbreviations used: cGAS - cyclic GMP-AMP Synthase, GTP – Guanosine triphosphate, 
cGMP – cyclic guanosine monophosphate, STING - Stimulator of interferon genes, TBK1 – 
TANK binding kinase 1, IRF3 – Interferon regulatory transcription factor 3, cRel, TNFa - Tumor 




2.7. Viral persistence in bats 
Over the past few years, numerous viruses have been detected in bats and these viruses 
seldom cause any overt disease (with the exception of Tacaribe virus and rabies virus) [1,16,37]. 
Detection of virus and absence of disease has led researchers to suggest that bats are likely the 
reservoirs of these viruses. Asymptomatic infections have been observed in bats for human 
pathogens such as henipaviruses (Nipah and Hendra viruses), coronaviruses (Middle Eastern 
Respiratory Syndrome coronavirus (MERS-CoV)) and filoviruses (Marburg virus and 
ebolaviruses) [38–40]. For a species to be a viral reservoir, the virus needs to persist in the 
population. Two probable ways in which this can happen are: 1) virus infection and clearing from 
infected individuals is an ongoing process and introduction of naïve individuals maintains the virus 
in the population, 2) individuals infected with the virus are able to maintain the virus in the form 
of a persistent infection. Although either or both of these possibilities may influence the bat-virus 
relationship, there is considerable evidence for the maintenance of some viruses in bat populations 
by continued, low level persistence.  
A study done by Sohayati et al. done on captive large flying foxes (also known as Malayan 
flying fox; Pteropus vampyrus) showed the possibility of recrudescence of Nipah virus (NiV) [41]. 
Regular sampling was done for over a period of one year to study the presence of virus and level 
of antibody against it. The authors discovered that one bat had a waning antibody titer with 
subsequent detection of virus in the urine. Following virus shedding, the antibody levels increased 
in this animal. As virus was undetectable in earlier samples of the same bat, the authors suggest 
that the virus may have persisted, probably in certain organs or cells, rendering it undetectable in 
blood, throat swab or urine. Within two weeks after NiV was isolated from the bat, two other male 
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bats seroconverted and demonstrated an increase in antibody titers, suggesting that recrudescence 
led to horizontal transmission.  
Other studies on Marburg virus transmission among Egyptian rosette bats (R. aegyptiacus) 
showed that bats naturally infected by other experimentally inoculated bats, seem to have a 
prolonged incubation period [42,43]. Furthermore, the infected bats remained viremic and shed 
infectious virus for up to three weeks, after which there was no detectable virus in blood, oral 
swabs and urine samples. Despite the lack of detectable virus, even 4 months after initial infection, 
experimentally inoculated bats were able to transmit the virus to other contact bats [43]. One of 
the ways in which this can be explained is that Marburg virus persisted in the bats (probably in the 
spleen [42]), and a decrease in antibody levels led to increase in viral load which could then be 
shed to infect other bats/animals. 
A bat coronavirus was also shown to persistently infect North American little brown bats 
(Myotis lucifugus) (Chapter 4) [44]. Little brown bats in captivity were able to harbor the 
coronavirus in their intestines and lungs during hibernation for a period of 4 months. In addition, 
there was no significant pathology seen in the bat tissues.  
To further bolster the claim of viral persistence in wild bats, a population level study was 
performed to understand the circulation of zoonotic viruses in bat populations and the involved 
immune mechanisms (maternal antibody and acquired immune response) using mathematical 
modelling [45]. The study used sero-surveillance of an African henipavirus in straw-colored fruit 
bats (Eidolon helvum). While repeated introduction of virus and birthing of pups might drive viral 
dynamics in a large panmictic population of bats, prolonged infectious periods or latent infection 
of bats are required to explain henipavirus persistence in small populations (natural or colony of 
captive). They found that if repeated introduction of virus into small populations was the only 
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mechanism, then acute infections would have to be about 40 days in duration. This estimate is 
considerably longer than the current estimates of the detectable infectious period for henipaviruses 
in fruit bats, which is approximately 7 days [46]. Therefore, prolonged or latent infection has to 
occur in some bats for describing persistence of henipavirus in small populations. 
2.8. Stress-induced spillover – a molecular perspective 
 Spillover events are complex and usually require successful alignment of several 
contributing factors [47]. One such critical factor is increased shedding of virus by bats. This factor 
is influenced by the host response and virus replication. Plowright et al. proposed a hypothesis 
which states that viruses infect naïve susceptible bats leading to acute infection. This subsequently 
progresses to a chronic or latent infection. The virus then reactivates from time to time in response 
to a variety of physiological and environmental triggers. This hypothesis is called as the SILI 
hypothesis: Susceptible-Infectious-Latent-Infectious [47]. As described above, the bat immune 
system is unique and virus infection probably persists in many bats.  
Several factors may alter long-term, low level viral persistence in bats. Suppression of the 
immune response holding active virus replication in check would allow the virus to replicate to 
higher levels. This could happen in stressful conditions that affects the immune system. In other 
animals, a variety of stressors lead to reactivation of latent herpesviruses as reviewed by Grinde 
[48,49]. In neurons latently infected by herpes simplex virus -1 (HSV-1), viral replication is 
inhibited by the recruitment of CD8+ T cells which secrete interferon-g (IFN-g) and suppress viral 
transcription factors via non-cytolytic granzyme mediated degradation [50]. During stress, there is 
a reduction of HSV-specific CD8+ T cells capable of producing IFN-g. This contributes to 
reactivation of the virus [51]. Studies on murine gammaherpesvirus-68 (MHV-68) in mice have 
shown that latent gammaherpesviruses are sequestered in cells in the spleen and can be reactivated 
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by stress [52,53]. Stressors, such as unfolded protein responses and hypoxia, can induce the 
expression of viral immediate early genes that help in initiating the lytic cycle of virus thereby 
reactivating it [54]. 
Arousal from hibernation is a stressful event for bats [55]. Many big brown bats are latently 
infected with a gammaherpesvirus [56]. Gerow et al. demonstrated that the virus reactivates from 
latency when big brown bats arouse from hibernation, leading to detection of the virus in blood 
(Chapter 8) [57]. This reactivation was also associated with a low level of antibodies against the 
virus. Following hibernation, the antibody levels increase, which subsequently drives the virus into 
latency.  
In pteropid bats, immunological stress was suggested as a contributing factor in henipavirus 
shedding [41]. As described earlier, Sohayati et al. suspected that the recrudescence of NiV 
infection was triggered by waning antibody levels and an increased level of stress due to a 
combination of factors such as confinement in a cage, and physiological and behavioral changes 
during breeding season.  
Secondary infections in humans are immunologically stressful [58]. Little brown bats are 
particularly susceptible to a frequently lethal fungal infection known as the white-nose syndrome, 
caused by Pseudogymnoascus destructans [59–61]. A study looking at the effects of white-nose 
syndrome fungus on a persistently infecting coronavirus showed that bats having the fungal 
infection in wings had 60 times more coronavirus in their intestines as compared to fungal 
uninfected bats (Chapter 5) [62]. The intestines of the fungus-infected bats exhibited a gene 
expression profile suggesting suppression of the innate antiviral response, which may have 
contributed to unrestrained viral replication. This suggests that secondary infections in bats 
persistently infected with viruses could increase the potential of viral shedding. 
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These studies indicate that waning antibody levels and suppression of innate immune 
response due to stress might be some of the factors leading to an increase in viral levels in 
persistently infected bats (Figure 2.2). 
 
Figure 2.2. Model showing effect of stress on persistent viral infection. Viruses persistently 
infect bats due to their reduced inflammation (reduced DNA sensor activation and decreased 
inflammatory cytokine levels) and their effective antiviral immune response (Increased 
constitutive expression of interferons and unique ISG expressions), as depicted in Figure 2.1. 
Stressful events alter the balance between host and virus and lead to an increase in virus replication, 
thereby leading to viral shedding. 
 
 
2.9. Future Directions for understanding bat-virus relationship 
The unique features of bat immune responses that promote viral persistence may exert 
evolutionary pressures on the virus as well. Bats have superseded rodents in harboring greater 
number of viruses and also having greater proportion of zoonotic viruses [63]. It is, therefore, 
crucial to understand how evolutionary pressure may have a role in the emergence of new viral 
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strains. A recent study found that henipavirus genomes are best adapted to pteropid bats [64]. 
Adaptation of genomes refers to better capability of the virus to use host cellular machinery for its 
replication and protein synthesis, which is usually governed by natural selection, and diversity in 
codon usage bias may contribute to it. Codon usage is an interspecies bias where one codon is 
selected over other synonymous codons in a particular species [65]. Natural selection for viral 
variants works by selecting codons matching host tRNA abundance. It also selects for variants 
with the advantage of not activating innate response genes, such as those for toll-like receptor 9. 
Codon bias analysis suggested that henipaviruses have the highest level of adaptation to pteropid 
bats. It would be interesting to study whether other viruses also show such codon bias towards 
their reservoir hosts. We might be able to use such codon bias studies in the future to identify 
reservoir hosts of spilled over viruses. Due to coevolution with the reservoir host, the viruses would 
have a codon bias specific towards their reservoir host. Apart from codon bias, natural selection 
based on receptor utilization also has a role to play in the evolution of viruses. Variation in the 
efficiency of bat coronaviruses to recognize human receptors show that the viral spike protein 
evolved in a stepwise manner to infect human cells [66]. Despite several other receptor-binding 
studies [67,68], the mechanism of adaptation to new hosts is not definitively understood. 
Although there is some evidence for the increase in virus replication and shedding in bats 
under stress, a direct link of this to spillover events has yet to be discovered. Future controlled 
experiments aimed at studying transmission dynamics in the presence and absence of stress in bats 
would lead to a more definitive answer. It is also important to look into various factors that might 
stress bats such as habitat destruction (deforestation), pregnancy, change in seasons and climate 
change. Additionally, the molecular mechanisms leading to the waning of antibodies and other 
aspects of adaptive immune response in bats is not known. A holistic picture of bat immune 
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systems and the factors leading to an increase in viral replication might help us further understand 
viral spillovers. 
 
2.10. Bats of North America 
 Most species of bats in North America are insectivorous. They have only one pup per year 
during early summer and hibernate during the winter [69]. They roost in natural settings, such as 
trees, caves or rock crevices, and also in man made structures, such as mines, buildings and 
bridges. Some bat species are dependent on nectar and pollen for nutrition. Several species that 
spend the summer month in northern latitudes migrate south during winter to locations where food 
resources are available. The average life span of North American bats is 5-10 years, but some of 
them are known to live up to 40 years [70,71].  
 Bats in North American belong to four families, namely Vespertilionidae, Phyllostomidae, 
Mormoopidae and Molossidae. There are at least 32 species of bats belonging to the 
Vespertilionidae family, making it the most diverse family of North American bats. These bats are 
most likely to come in contact with humans. They have a small to mid-sized body, are dark brown 
in color, consume insects, and hibernate during winter. The two most commonly occurring species 
in this family are the big brown bat (Eptesicus fuscus) and the little brown bat (Myotis lucifugus). 
The genus Myotis is the most diverse genus and it comprises of bats that are adapted to capture 
insects in open spaces, in and around vegetation. Some of these bats like to forage over water 
bodies where they consume hatches of insects emerging from water. Other species of bats in the 
family Vespertilionidae include the Western and Eastern pipistrelles (Pipistrellus hesperus and P. 
subflavus), the migratory hoary and red bats (Lasiurus spp.), the long-eared bats belonging to the 
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genus Plecotus, Euderma and Idionycteris, the pallid bat (Antrozous pallidus) and the evening bat 
(Nycticeius humaeralis) [72]. 
 There are five species of bats belonging to the family Phyllostomidae, also known as New 
World leaf-nosed bats, that are found in the Southern United States. Three of these bat species rely 
on nectar and pollen for food, namely Southern long-nosed bat (Leptonycteris curasoae), Mexican 
long-nosed bat (L. nivalis), and Mexican long-tongued bat (Choeronycteris Mexicana) [72]. The 
other two species are the California leaf-nosed bat (Macrotus californicus), which feeds on insects, 
and the hairy-legged vampire bat (Diphylla ecaudata), which primarily feeds on blood of wild 
birds [73–75]. 
 The third family of bats found in North America is that of Molossidae, or free-tailed bats, 
which comprises of six species. These are the Brazilian free-tailed bat (Tadarida brasiliensis), the 
pocketed free-tailed bat (Nyctinomops femorosaccus), the big free-tailed bat (N. macrotis), and 
three species of mastiff bats (Eumops) [74,76]. The family Mormoopidae is represented by only a 
single species of bat, i.e., ghost-faced bat (Mormoops megalophylla) [73]. 
 
2.11. Coronavirus as a model for studying bat-virus relationship 
2.11.1. Coronavirus detected in bats 
 After the SARS (Severe acute respiratory syndrome) epidemic, bats were identified as the 
hosts for coronaviruses and within the past 15 years, more than thirty complete coronavirus 
genomes and many more partial genomes have been recovered from various bat species. In most 
cases, these detected coronaviruses have not been isolated from bats, possibly due to lack of 
conducive cell culture. Coronavirus belongs to the order Nidovirales and family Coronaviridae. 
Coronaviridae comprises of two subfamilies, namely Coronavirinae and Torovirinae [77]. There 
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are four genera known for the subfamily Coronavirinae, namely, Alphacoronavirus, 
Betacoronavirus, Gammacoronavirus and Deltacoronavirus [78]. Among these four genera, only 
Alphacoronavirus and Betacoronavirus have been found in bats [79]. Bat coronaviruses have been 
detected in North and South America, Asia, Europe, Africa and Australia. The global distribution 
and detection rate in bats are high for both Alphacoronaviruses and Betacoronaviruses [80,81].  
2.11.2. Genome organization and structure of the virion 
Coronaviruses contain a non-segmented, positive-sense RNA genome of approximately 
30kb in size. It is the largest known genome for any RNA virus [77,78]. The genome has a 5’ cap 
and a 3’ poly-A tail, which makes it act like a mRNA for translation of proteins. The replicase 
gene, which codes for RNA dependent RNA polymerase (RdRp) gene occupies 2/3rd of the 
genome (~20kb). The remaining ~10kb of the genome contains structural and accessory proteins. 
The organization of coronavirus genome is 5’-leader-UTR-RdRp-Spike(S)-Envelope(E)-
Membrane(M)-Nucleocapsid(N)-3’UTR-poly-A tail (Figure 2.3). Accessory genes are usually 
interspersed in between the structural genes. Although these accessory genes are not imperative 
for virus replication in tissue culture, they play an important role in pathogenesis of the virus in 
vivo and variants that have a replicative advantage may be selected in particular species [82]. 
 Coronaviruses virions are enveloped and approximately 125nm in size [83]. They are 
spherical in shape with club-like projections. These projections make the virion look like a crown, 
ergo “Corona” name was given. The virus particle contains four main structural proteins, namely 
spike, membrane, envelope and nucleocapsid. The spike protein is used by the virus for entry into 
the host cell. The S1 domain of the spike that interacts with host receptor is also known as the 
receptor binding domain, and is highly variable [84]. This variability determines the host species 
tropism for the coronavirus [85]. The membrane protein exists as a dimer in the virion and 
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promotes membrane curvature as well as binding to the internal nucleocapsid protein [86]. The 
envelope protein is found in small quantity in virion, but has a role as an ion channel and is required 
for pathogenesis of coronaviruses [87]. Nucleocapsid is present in the interior of the capsid and 
binds to the RNA aiding the packaging of the RNA into the virion [88]. Some Betacoronaviruses 
also contain a fifth structural protein, known as the hemagglutinin-esterase (HE) which binds to 
sialic acids on surface glycoproteins, which helps in enhancing the entry of the virion [89].  
 
Figure 2.3. Genome organization and structure of coronaviruses  
 
2.11.3. Life cycle of coronavirus 
The attachment of the coronavirus is mediated largely via spike protein. The receptor 
binding domain in the S1 region of spike protein interacts with host receptors [78]. Most 
coronaviruses use peptidases for the attachment but the function of the peptidases in attachment is 
unclear, as entry of the virion occurs even in the absence of the enzymatic domain. 
Alphacoronaviruses usually utilize aminopeptidase N (APN) receptor [90], SARS-CoV and HCoV 
NL63 utilize the angiotensin-converting enzyme-2 (ACE2) as their receptor [91,92], murine 
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hepatitis virus (MHV) utilizes CEACAM1 as its receptor [93] and MERS-CoV uses dipeptidyl-
peptidase-4 (DPP4) as their receptor [94]. 
Following attachment of spike with host receptor, entry of virus into host cell cytosol 
occurs via acid dependent proteolytic cleavage of spike protein by cathepsin, which occurs in the 
cytoplasm or endosome [95]. It cleaves the S1 domain of spike exposing the fusion domain in the 
S2 domain [84,95]. The fusion domain has heptad repeats which form a six-helix bundle that 
allows the virus and cell membranes to combine [84]. This is followed by the release of the virion 
into the cytoplasm.  
Following release into the cytoplasm, the viral genome functions as an mRNA and is 
translated to produce the replicase protein. The replicase gene encodes 2 ORFs namely rep1a and 
rep1b which translates into pp1a and pp1ab protein [96]. The replicase gene has an RNA 
pseudoknot that causes a ribosomal frameshift resulting in the two proteins [97]. The viral RNA 
produces genomic and sub-genomic RNAs. These sub-genomic RNAs serve as mRNAs for the 
various structural and accessory genes. For the production of these genomic and sub-genomic 
RNAs, the RdRp protein has a unique mechanism. Every sub-genomic RNA also contains a leader 
sequence, which is shared by all subgenomic RNAs that possess coding sequences for viral 
proteins. The sub-genomic RNAs are produced by negative strand sub-genomic RNA which 
contains anti-leader sequence at 3’-end of it [98,99]. So, while synthesizing the negative strand, 
the RdRp jumps at the end of coding sequences to the leader sequence and joins the two non-
contiguous sequences. It is still unclear, how RdRp bypasses all the other coding sequences to the 
5’end of the genome to include the leader sequence. What determines the shift from making 
negative sense sub-genomic RNA to making full length negative sense genomic RNA, is also not 
known. In addition to these basic mechanisms, coronaviruses also have a mechanism of 
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recombining using homologous and non-homologous recombination [100]. This is crucial for viral 
evolution as it allows exchange of segments in between viruses. 
From the negative sense full length genomic RNA, positive sense genomes are synthesized 
and from positive sense sub-genomic RNAs, spike, envelope and membrane proteins are made in 
the endoplasmic reticulum-Golgi intermediate compartment (ERGIC) [101,102]. Coronavirus 
genomes are first encapsidated using the nucleocapsid protein and then uses the ERGIC for viral 
envelopment. Membrane protein interacts with nucleocapsid protein to guide the assembly of 
virion [103]. The formed virions are then transported to the cell surface via vesicles and 




Figure 2.4. Schematic diagram depicting coronavirus replication. Coronavirus life cycle in the 
cell begins with the attachment of spike protein in the virion to cellular receptors. Following entry, 
the positive sense genomic RNA is released into the cytoplasm. Genomic RNA encodes for RNA 
dependent RNA polymerase protein (RdRp), structural proteins (S, M, E and N) and non-structural 
proteins. A non-coding segment upstream of E protein, known as UpE, is targeted by quantitative 
PCRs to detect the amount of MERS-CoV RNA in the cell. Following the release of positive sense 
genomic RNA into the cytoplasm, it is translated to produce RdRp, which then produces negative 
sense and more positive sense genomic RNA. This positive sense genomic RNA then aids in the 
production of subgenomic negative sense RNA, which subsequently helps in producing 
subgenomic positive sense RNA. Positive sense subgenomic RNA translates to produce structural 
and non-structural proteins. Protein translation takes place in the endoplasmic reticulum, and 
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subsequently, these proteins are processed in the Golgi bodies. Positive sense genomic RNA and 
structural proteins of the virus are then assembled and released via exocytosis. 
 
2.11.4. Coronavirus interaction with host pathways 
To control virus infections, host, in case of certain virus infections, induces apoptosis to 
control virus replication. But in case of coronaviruses, the virus engages in induction of apoptosis 
for efficient virus production [104]. The coronavirus exploits this mechanism to destroy immune 
cells which would otherwise limit virus production [105]. Apoptosis can be induced by either an 
extrinsic pathway, mediated via death ligands binding to death receptors, or an intrinsic pathway, 
regulated via pro-apoptotic or anti-apoptotic Bcl2 (B-cell lymphoma 2) family proteins which 
subsequently induces MOMP (mitochondrial outer membrane permeability) [106]. During 
coronavirus infection, viral proteins target both extrinsic and intrinsic apoptosis pathways. For 
example, SARS-CoV has evolved proteins that are pro-apoptotic like S, E, M, N, ORF-6, -7a and 
-9b [107–110].  
During coronavirus infection, pattern recognition receptors, such as toll-like receptors 
(TLRs), retinoic acid inducible gene-I (RIG-I) and melanoma differentiation-associated protein 5 
(MDA5), sense the viral infection and trigger signaling pathways, such as mitogen activated 
protein kinase (MAPK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
kB), to produce interferons [107]. Secreted interferons can bind to interferon receptors, in an 
autocrine or paracrine manner, to stimulate janus kinases – signal transducer and activator of 
transcription proteins (JAK-STAT) signaling pathway which induces interferon stimulated gene 
production [111]. Coronavirus proteins, such as SARS-CoV N, E, ORF-3a and -7a and MERS-
CoV PLPro, ORF-4a and -4b, are known to inhibit NF-kB pathway whereas [112,113]. MERS-
CoV M, ORF-4a, -4b and -5 are known to inhibit IRF3 [114]. SARS-CoV ORF-3b and -6 inhibit 
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at a downstream signaling just prior to ISG production [107,115]. MAPKs are a serine or threonine 
kinases that are induced in response to stressors and ultimately results in the regulation of cellular 
processes like cell survival, cytokine production and apoptosis [116]. Coronaviruses have been 
shown to induce MAPK activation. Inhibition of p38 activation, one of the key adaptors in MAPK 
pathway, has suppressed the HCoV-229E-induced cytopathic effects and led to a decrease in viral 
titers [117]. The observation on c-Jun N-terminal kinases (JNK) activation, another key adaptor of 
MAPK, has shown that the pathway could have an anti-apoptotic (HCoV-229E and SARS-CoV) 
or pro-apoptotic role (IBV) depending on the strain of virus [118].  
The primary organelle in the cell that handles protein synthesis, folding, processing and 
post-translational is the endoplasmic reticulum (ER) [119]. However, if the level of protein 
production exceeds the capacity of the ER, then misfolded or unfolded protein starts to accumulate. 
This eventually initiates a cascade of signaling pathways, known as the unfolded protein response 
(UPR) [120]. There are three primary ER transmembrane sensors that initiate UPR, namely protein 
kinase R (PKR) like endoplasmic reticulum kinase (PERK), inositol requiring protein 1 (IRE1) 
and activating transcriptional factor 6 (ATF6) [121]. UPR activation leads to restoration of ER 
homeostasis by enhancing protein folding, decreasing protein translation or producing more 
chaperones and other proteins aiding in folding. In case the UPR response is not able to restore 
homeostasis, then the cell triggers apoptosis mechanisms [120]. During viral infections, the virus 
hijacks the host protein translation machinery including ER and exploits it to produce viral 
proteins. This initiates the UPR response which works as an antiviral response. However, 
coronaviruses have evolved viruses that target the various signaling pathways of UPR such as 
SARS-CoV E, ORF-3a, -8ab [118].  
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2.11.5. Coronavirus pathogenesis 
 Coronaviruses usually have a predilection to cause disease in the respiratory system or in 
the gastrointestinal system [77]. Two of the deadly coronaviruses infecting human beings, namely 
SARS-CoV and MERS-CoV, primarily cause respiratory illness. The SARS-CoV infection leads 
to massive inflammation in the lungs and has a mortality rate of ~9% [122]. But since SARS-CoV 
transmission was poor, it led to the decline of incidence after 2003. MERS-CoV also leads to 
similar illness as SARS-CoV, but the mortality rate is much higher i.e. ~35% [123]. Other human 
coronaviruses like HCoV-229E, NL63 and OC43 causes common cold and more severe disease in 
neonates, elderly and people with underlying diseases [124].  
 One of the most well-studied coronavirus is the murine hepatitis virus (MHV) which causes 
respiratory, hepatic, enteric and neurologic manifestations in mice [125,126]. Other coronaviruses 
like Transmissible Gastroenteritis Virus (TGEV), Porcine epidemic diarrhea virus (PEDV) and the 
recently identified swine acute diarrhea syndrome (SADS) causes acute gastroenteritis in young 
piglets [127]. This leads to significant morbidity and mortality. Another coronavirus, Porcine 
hemagglutinating encephalomyelitis virus (PHEV) leads to enteric infection but is also able to 
infect nervous system leading to encephalitis. Feline enteric coronavirus (FCoV) leads to 
asymptomatic infection in cats but mutations in persistent infection leads to transformation of the 
virus generating a highly virulent strain known as Feline infectious peritonitis virus (FIPV) [128]. 
This leads to a lethal disease known as feline infectious peritonitis. In chickens, Infectious 
bronchitis virus (IBV) causes respiratory tract infection but some strains can also affect the uro-
genital system leading to renal disease [129]. 
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2.11.6. Animal origins of coronaviruses 
 Global screening of bats has led to the discovery of myriad of coronaviruses in bats. It has 
been thought that most of the coronaviruses have their origin among bats as depicted in figure 2.5. 
MERS-CoV likely spilled over to dromedary camels about 30 years ago and since then has 
circulated in camels [130]. Progenitor of HCoV-229E and NL63 have been detected in African 
bats and camelids probably are the intermediate hosts for HCoV-229E [131,132]. The SADS 
coronavirus is a novel strain of the Rhinolophus bat coronavirus-HKU2 [133]. 
 
Figure 2.5. Animal origin of coronaviruses. Rodents and bats are the known natural hosts for 
coronaviruses. Infection in other species is a result of spillover. Some of the other species, such as 




2.11.7. Evidence of coronavirus peristence in hosts 
 For understanding spillovers, it is important to know about persistence of virus in hosts. 
Persistent infection would put a continuous evolutionary pressure on the virus which would have 
implications in pushing emergence of new variants. Such variants could facilitate spillovers to 
other species. Certain vertebrate hosts show persistence of coronavirus. In cats, feline coronavirus 
infections occur due to two pathotypes, namely feline enteric coronavirus (FECV – ubiquitous 
enteric biotype) and feline infectious peritonitis virus (FIPV – virulent biotype) [134]. Feline 
coronavirus infection occurs via feco-oral route and it can establish persistent infection (FECV) in 
enterocytes. This infection leads to mild, non-specific symptoms and the virus is intermittently 
shed in the feces. The FECV infection converts to FIPV in some hosts, the exact mechanism of 
which is not yet fully understood [135]. It is also interesting to note that coinfection of cats with 
other enteropathogens increases severity of feline coronavirus infection [136]. Another such host 
with persistent infection is in cows for bovine coronavirus. Oral inoculation of bovine coronavirus 
has shown that the virus can persist in the intestines of calfs. The virus is initially excreted at higher 
amounts but subsequently, sheds at low titers. The virus was shown to be present in peyer’s 
patches, 3 weeks after inoculation [137].  
Human coronavirus OC43 and 229E has also been shown to persistently infect human 
neuronal cells [138,139]. It has been hypothesized that SARS-CoV spillover from bats to humans 
occurred via an intermediary host, palm civet cats. Experimental inoculation of palm civet cats 
with two strains of SARS-CoV has shown that the virus can persist for several weeks but clinical 
signs of infection, such as lethargy and elevated temperature, were observed [140]. In case of 
MERS-CoV, spillover occurs from camels to humans [141]. In camels, MERS-CoV causes mild 
upper respiratory tract disease and viral RNA can persist upto 5 weeks [142]. During my thesis, I 
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have characterized persistence infection in bats (Chapter 4) and how this relationship alters in 
response to stress (Chapter 5).    
 
2.12. Gammaherpesvirus as a model for studying bat-virus relationship 
2.12.1. Gammaherpesviruses in bats 
 Herpesviruses have a double-stranded DNA genome and are enveloped. They belong to 
the family Herpesviridae [77]. There are three genera in this family namely, Alphaherpesvirinae, 
Betaherpesvirinae and Gammaherpesvirinae. Gammaherpesvirinae consists of oncogenic viruses 
like Ebstein-Barr virus (EBV) and Kaposi Sarcoma-associated herpesvirus (KSHV). Screening of 
bats worldwide has led to the detection of gammaherpesviruses in numerous bat species [143–
146]. Two gammaherpesviruses isolated from bats are Myotis gammaherpesvirus 8 (isolated from 
a Myotis velifer incautus cell line) [147] and Eptesicus fuscus gammaherpesvirus (Chapter 7) [56].  
2.12.2. Genome, virion structure and lifecycle of gammaherpesviruses 
Gammaherpesviruses are enveloped, spherical or pleomorphic viruses of 150-200nm in 
size [77]. Genomes of gammaherpesvirus are linear and non-segmented dsDNA of about 180kb in 
length. Gammaherpesviruses bind to their surface receptors and enter the cell. KSHV uses Ephrin 
A2 and EBV uses CD21 as their receptors [148,149]. Such receptor binding can also initiate cell 
signals, such as phophoinositide 3-kinase (PI3K), that modify nuclear factors that are crucial for 
viral gene expression [150]. The viral capsids, with the viral genome inside are transported via 
microtubules such that the viral DNA does not activate DNA sensors in the cells [151,152]. The 
viral capsid then interacts with the nuclear pore which subsequently injects the viral genome into 
the nucleus [153]. IFNg inducible protein 16 (IFI16) binds to the viral DNA and activates 
inflammasome pathway. Gammaherpesviruses are unable to inhibit activation of IFI16 and 
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therefore, it suggests that IFI16 probably has a crucial role to play in initiating latent infection 
[154].  
Primary infection of gammaherpesviruses usually results in a slow and abortive lytic 
replication which is sometimes followed by a robust latent infection [54]. Epigenetic mechanisms 
play an important role in the switch from latent to lytic replication. Condensation of viral DNA 
ensures that it is protected from DNA damage. One of the ways the virus achieves this is by 
circularization. Histone modifications and chromatin assemble help in establishing latency. The 
host cell has promyelocytic leukemia nuclear bodies (PML NBs) that chromatin assembly and has 
a role in the intrinsic resistance against viral nuclear infection. However, the virus also codes for 
tegument proteins which destroys the PML NB [155].  
Latent infection by Epstein-Barr virus could be established in four distinct ways [156,157]. 
Type 0 is the most restrictive type, where no viral gene expression occurs and primarily observed 
in resting memory B cells. In case of type 1 latency, expression of Epstein-Barr nuclear antigen 1 
(EBNA1) is observed and this type of latency occurs in proliferating memory B cells or in Burkitt’s 
lymphoma. Type 2 occurs in Hodgkin’s lymphoma where along with EBNA1, other genes like 
LMP1, 2A and 2B are also expressed. Type 3 is the highly permissive latent infection which occurs 
in immortalized cell lines and expression of EBNA1, EBNA2, EBNA3A, EBNA3B, LMP1, 2A 
and 2B are observed. Kaposi sarcoma associated virus shows less variation than EBV. Its latent 
cycle is primarily regulated by latency associated nuclear antigen. It is the KSHV orthologue for 




2.12.3. Reactivation of gammaherpesvirus 
 Reactivation of gammaherpesvirus is crucial for completing the virus life cycle resulting 
in new virus particle production. This reactivation could be stimulated by several stressors such as 
unfolded protein response and hypoxia, or by cellular differentiation signals [158]. For reactivation 
to start, disruption of repressive chromatin status of viral DNA is imperative. Viral Zta for EBV 
and RTA, for both EBV and KSHV, are required for transcription of immediate early genes which 
initiate the lytic replication (Figure 2.6) [54]. Reactivation of KSHV occurs due to chemicals, like 
sodium butyrate or tetradecanoyl-phorbol-13-acetate (TPA), viral coinfection, oxidative stress and 
hypoxia, all of which lead to activation of RTA promoter [159,160]. RTA is also capable of 
autoregulating itself by signaling repressor pathway or by self-ubiquitination [161,162]. LANA 
counteracts the RTA expression by interacting with its promoter. microRNAs from viruses also 
help in maintaining latency of gammaherpesvirus and knockdown of these microRNA also leads 
to reactivation of the virus [163]. 
  







































Figure 2.6. Life cycle of gammaherpesviruses (A) Early events that determine the establishment 
of latent infection in gammaherpesviruses (B) KSHV factors that determine latent vs lytic cycle. 
This figure is inspired from Purushothaman et al [164] and Lieberman [54]. 
 
2.12.4. Gammaherpesvirus interaction with host immune response and pathways 
 KSHV leads to Kaposi sarcoma in HIV patients who have a depleted CD4+ T cell 
population. This suggests that T cell response has an important role to play in the host-pathogen 
interaction in relation to gammaherpesviruses [165]. The virus has developed mechanisms to 
prevent detection by T cells but at the same time has to maintain either latency or lytic replication 
in the host [166]. While latent infection, gammaherpesviruses expresses atleast one latency protein. 
Evolutionarily gammaherpesviruses have selected this protein against MHC-I binding, which is 
advantageous for the virus, as MHC-I binding of viral peptide followed by presentation to CD8+ 
T cells is imperative for developing T cell response. Preventing this presentation allows the virus 
to go undetected in cells. Latency protein for EBV, EBNA-1, also controls its translation and 
degradation, thereby minimising the protein turnover rate [166]. Another strategy employed by 
latency protein is to prevent proteosomal degradation which in turn prevents the formation of 
peptides that can bing to MHC-I for presentation. The EBNA-1 latency protein achieves this with 
the help of central glycine-alanine repeats [167,168]. Similarly KSHV latency associated nuclear 
antigen (LANA) also has a similar central stable region preventing proteosomal degradation [169]. 
For gammaherpesviruses of other species, ORF73 protein aids in the escape of T cell mediated 
response [170,171]. During lytic cycle of gammaherpesvirus, the virus prevents MHC-I 
presentation at several levels such as inhibiting peptide transport across ER membrane, anchoring 
proteins to the ER membrane, or by endocytosing MHC-I from the cell surface by viral proteins 
[172–175]. KSHV vIRF3 protein is also known to inhibit class II transactivator which is necessary 
for inducing MHC-II proteins [176]. In addition to that endothelial cells infected with KSHV also 
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secreted a factor which prevented MHC-II expression in neighboring cells [177]. Overall, this 
prevents CD4+ activation.   
 Gammaherpesviruses have also evolved mechanisms and proteins to inhibit apoptosis and 
autophagy pathways. KSHV targets the extrinsic apoptotic pathway, i.e. pro-caspase 8 and 
activated caspase 3 with the help of vFLIP (viral Fas-associated death domain-like interleukin-1β-
converting enzyme-inhibitory protein bcl2) and K7 proteins [165]. EBV vBcl2 inhibits the intrinsic 
apoptotic pathway, by preventing the oligomerization of Bax/Bak (Bcl2-associated X protein) and 
MHV-68 vMAP (viral mitochondrial antiapoptotic protein), which antagonizes VDAC that 
releases cytochrome c [178–180]. In addition to that KSHV K7 protein inhibits stress-induced 
apoptosis by interacting with calcium-modulating cyclophilin ligand (CAML) leading to an 
increase in cytosolic Ca+2 levels [181]. This mechanism protects cells from mitochondrial damage 
and thereby preventing apoptosis. Gammaherpesviruses have also evolved mechanisms to evade 
autophagy, a homeostatic process that engulfs and digests bulk cytoplam under nutrient-deprived 
conditions. vBcl2 targets Beclin 1, an autophagy regulator molecule, and vFLIP targets LC3 
processing enzyme, a component of autophagosome, ultimately leading to inhibition of autophagy 
[182,183].  
 Like coronaviruses, gammaherpesviruses have also evolved mechanisms to antagonise 
interferon signalling. Gammaherpesviruses target several key interferon regulatory factors such as 
IRF-1, IRF-3, IRF-5 and IRF-7, by interfering with their activation using various viral proteins 
such as KSHV vIRF-1, -2, -3 and EBV PK and Zta [165,184]. KSHV also has mechanism to 
suppress RIG-1 and MyD88 (Myeloid differentiation primary response 88) mediated signalling 
[185,186]. These ultimately lead to inhibition of intereferon production.  
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2.12.5. Pathogenesis of gammaherpesvirus 
 KSHV and EBV are known to cause oncogenesis in humans. Mostly in AIDS (Acute 
immunodeficiency syndrome) patients, KSHV causes Kaposi sarcoma, primary effusion 
lymphoma, and Castleman’s disease [77]. In normal individuals, KSHV infection usually remains 
latent. Ebstein-Barr virus causes Burkitt’s lymphoma. But majority of the pathogenesis 
information comes from studies on MHV68. The acute lytic replication of MHV68 occurs in the 
epithelial and endothelial cells of the lungs [187]. This replication is typically cleared in 12 days 
following which the virus establishes latency in secondary lymphoid organs. The primary 
reservoirs of gammaherpesviruses are B cells, but other cells like macrophages, dendritic cells and 
endothelial cells can also be infected (Figure 2.7). Lymphoma is usually manifested in 





Figure 2.7. Pathogenesis of gammaherpesvirus. (A) Gammaherpesvirus lytic replication occurs 
in fibroblasts, epithelial and endothelial cells whereas latent life cycle has been observed in 
macrophages, dendritic and B lymphocytes. (B) The lytic replication happens during the acute 
stage of infection and latent replication takes place during the chronic stage. This figure is inspired 
from Cieniewicz et al [187]. 
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Chapter 3: Rationale, hypothesis and objectives 
3.1. Rationale to study factors altering bat-virus relationship 
As mentioned in the Introduction and Literature review, bats are potential reservoirs of 
several emerging viral diseases in people and other animals. The circumstances under which these 
viruses spillover from bats to other species is not fully understood. However, several studies 
indicate that bats are likely to be persistently infected with viruses and increase in viral replication 
in response to stressors may increase the possibility of spillover. While there is considerable 
literature on the interactions of these viruses with their secondary hosts, their surrogate laboratory 
animals or cell-lines derived from them, little is known about the interactions of bat viruses in their 
natural hosts. A better understanding on how these viruses replicate in bats and how bats respond 
to them may uncover the reasons for spillovers and may also suggest strategies for mitigating the 
effects of disease caused in other species by bat viruses.  
The objective of my thesis was to test the broad hypothesis that bats have long-term 
balanced and benign relationships with viruses, with whom they have co-evolved, and that a 
variety of stressors disrupt this balance allowing increased viral replication. Since viruses have 
co-evolved with their natural bat hosts over millennia, my objective was to study viruses that 
naturally infect two species of North American bats. I characterized a coronavirus that infects most 
little brown bats (Chapter 4) and a gammaherpesvirus that we isolated from big brown bats 
(Chapter 7). 
 For the little brown bat coronavirus, I had access to tissue samples archived from an earlier 
study of the pathophysiology of white-nose syndrome, a fungal disease that is lethal for most 
species of bats [188]. My objective was to test the hypothesis that the systemic stress of fungal 
infection would lead to changes in gene expression patterns in the intestine of bats, the site of 
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coronavirus persistence and that these changes would lead to increased virus replication (Chapter 
5). 
Since persistent viral infections in the animal, especially a wild-life species, are difficult to 
manipulate and examine in detail, my next objective was to establish a persistent coronavirus 
infection in cultured bat cells and to use this model to confirm my observations from bats and to 
study the molecular triggers that disrupt persistence (Chapter 6). 
To determine if our observations on the effect of stress on the coronavirus-bat relationship 
would be borne out by other viruses as well, I studied the relationship of the big brown bat 
herpesvirus with its natural free-living host. My objective was to test the hypothesis that most bats 
would be latently-infected with the herpesvirus and that the physiological stress of arousal from 
hibernation would lead to reactivation of the latent virus (Chapter 8).  
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Chapter 4: A persistently infecting coronavirus in hibernating Myotis lucifugus, 
the North American little brown bat 
4.1. Copyright 
ã 2017. Microbiology Society explicitly grants the authors permission to reuse their own 
content without seeking further permission, provided that the original source of the material is 
credited appropriately. 
 
This manuscript has been reformatted from the original version for inclusion in this thesis. 
 
4.2. Citation 
Subudhi, S., N. Rapin, T. K. Bollinger, J. E. Hill, M. E. Donaldson, C. M. Davy, L. 
Warnecke, et al. “A Persistently Infecting coronavirus in Hibernating Myotis Lucifugus, the North 




Several authors contributed significantly during this study. Bat samples were obtained from 
a previous experiment in our lab [189]. The initial polymerase chain reaction (PCR) for the 
detection of coronavirus and sequencing was done by NR. CMD and MED analyzed the RNASeq 
data and provided me with sequence reads that did not align with bat genome (non-bat RNASeq 
reads). The phylogenetic analysis of the coronavirus sequences was done by me. Janet Hill and I 
assembled the whole genome of the bat coronavirus using non-bat RNASeq reads obtained from 
bat intestines and also made the phylogenetic tree using complete genomes of 34 representative 
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coronaviruses. I developed antibodies against the bat coronavirus nucleocapsid protein and then 
developed immunohistochemistry assay for the detection of the virus which subsequently helped 
in the detecting the viral infection in the lungs. Trent Bollinger helped us with the pathological 
scoring of the lung tissues infected with virus. I wrote the initial draft of the manuscript and NR, 
MED, CMD, TKB and VM contributed to editing of the various drafts. 
 
4.4. Abstract 
Bats are important reservoir hosts for emerging viruses including coronaviruses that cause 
diseases in people. Although there have been several studies on the pathogenesis of coronaviruses 
in humans and surrogate animals, there is little information on interactions of these viruses with 
their natural bat hosts. We detected a coronavirus in intestines of 53/174 hibernating little brown 
bats (Myotis lucifugus), as well as in the lungs of some of these individuals. Interestingly, presence 
of the virus was not accompanied by overt inflammation. Viral RNA amplified from little brown 
bats in this study appeared to be from two distinct clades. The sequences in Clade 1 were very 
similar to the archived sequence derived from little brown bats and sequences from Clade 2 were 
more closely related to the archived sequence from big brown bats. This suggests that two closely 
related coronaviruses may circulate in little brown bats. Sequence variation among coronavirus 
detected from individual bats suggested that infection occurred prior to hibernation, and that the 
virus persisted up to four months of hibernation in the laboratory. Based on the sequence of its 
genome, the coronavirus was placed in the Alphacoronavirus genus along with some human 
coronaviruses, bat viruses and the porcine epidemic diarrhea virus. Detection and identification of 
an apparently persistent coronavirus in a local bat species creates opportunities to understand the 





In recent years, three coronaviruses (CoV) have emerged to have a significant impact on 
global health and economy. Two of these, that cause Severe Acute Respiratory Syndrome  (SARS, 
[190]) and Middle Eastern Respiratory Syndrome (MERS, [67,191–193]), are human pathogens. 
The SARS outbreak in 2002-2003 led to 8096 cases with 10% mortality in 27 countries [194]. 
Since September 2012, about 1900 cases of MERS have been reported with a mortality rate of 
about 35% [123]. The third coronavirus, porcine epidemic diarrhoea coronavirus (PED-CoV 
[195]),  was introduced into North American commercial pig herds and led to an economic loss of 
almost 2 billion dollars in the United States [196]. These three coronaviruses are believed to have 
spilled over from bats because similar coronaviruses have been detected in bats [197,198]. 
Interestingly, while coronaviruses cause serious and often fatal disease in their secondary hosts, 
such coronaviruses do not cause any clinical disease in their putative reservoir hosts i.e. bats 
[39,199,200]. The reasons for this difference in outcomes of coronavirus infection, and factors that 
lead to virus spillover, are not clearly understood. There are numerous studies on the pathogenesis 
of SARS-CoV, MERS-CoV and PED-CoV in humans and pigs [201–204], but there are few 
reports examining coronavirus interactions with their primary bat hosts [39,200]. Our goal was, 
therefore, to identify coronaviruses in a common and widespread north American bat species and 
study virus-bat interactions within this species. 
Access to a large number of archived samples from an unrelated experiment [188,189,205] 
gave us the opportunity to screen little brown bat tissues for the presence of coronaviruses, to 
determine the sequence of the genome of the virus and to identify specific tissues for which the 
virus had a predilection. Our results suggest that about a third of little brown bats are infected with 
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several distinct clades of an Alphacoronavirus and that the bats retain the virus for up to 4 months 
of hibernation. Since the bats we examined had been maintained as groups in isolated incubators 
or semi-isolated cages, we were able to test the hypothesis that little brown bats in the wild are 
infected with closely related variants of a coronavirus. We predicted that, since the bats were 
randomly assigned to different incubators/cages, 1) prevalence of infection should be similar 
across incubators and cages; and 2) any variation in viral genomes should be evenly distributed 
among cages and incubators. 
 
4.6. Materials and methods 
4.6.1. Bats  
Bat tissues were obtained from two previous experiments [189,205], in the winters of 2010-
2011 and 2011-2012 designed to study the pathogenesis of the fungus, Pseudogymnoascus 
destructans, the causal agent of WNS. Male little brown bats were collected   from two different 
WNS-free caves in Manitoba, Canada under the Manitoba Wildlife Scientific Permits WB11145 
and WB13148. Details of segregation of bats into incubators and cages in the 2010-11 and 2011-
12 experiments are in Table 4.1. Bats were euthanized at the end of the experiment i.e. after 4 
months (year 2010-11) and 3 months (year 2011-12). Bats which succumbed to the WNS-fungus 
infection were removed prior to the end of the experiment. Immediately following euthanasia, 
samples from brain, intestines, liver, kidney, and spleen were preserved in RNAlater (Qiagen, Cat 





Table 4.1. Segregation of hibernating bats 
Year 
Incubator Name & 
Cage Name (if 
applicable) 
Number of 
bats Inoculation type Incubator status 
2010-11 
A 18 Control 
Relative humidity >97%; temperature 
70C 
B 18 
Fungus infected (European 
Strain) 
Relative humidity >97%; temperature 
70C 
C 18 
Fungus infected (American 
Strain) 
Relative humidity >97%; temperature 
70C 
2011-12 
D (C) 21 Control Relative humidity >97%; temperature 
70C D (I) 23 Fungus infected 
E (C) 10 Control Relative humidity 99%; temperature 
70C E (I) 10 Fungus infected 
F (C) 10 Control Relative humidity 95%; temperature 
70C F (I) 11 Fungus infected 
G (C) 10 Control Relative humidity 90%; temperature 
70C G (I) 11 Fungus infected 
H (C) 11 Control Relative humidity 85%; temperature 
70C H (I) 10 Fungus infected 
 
4.6.2. RNA extraction and cDNA preparation  
Bat tissues were homogenized and RNA extracted, using RNeasy® Plus mini kit (Qiagen, 
Cat #74136), as per manufacturer’s protocol. cDNA was prepared using QuantiTect reverse 
transcriptase kit (Qiagen, Cat #205313) as per protocol mentioned in the kit. 
4.6.3. Polymerase chain reactions (PCRs) and plasmid constructions 
The sequence of all primers used in the PCRs are in Table 4.2. Semi-nested PCR primers 
amplified a portion of the RdRp region of the coronavirus genome [188] from cDNA prepared 
from bat tissues. For the primary and secondary reactions, the expected products were 441bp and 
273bp respectively. All amplified products were sequenced using the amplification primers. These 
sequences have been submitted to GenBank, accession number KY820767 to KY820807. 
The Myotis lucifugus coronavirus (Myl-CoV) nucleocapsid gene (1,278bp) was amplified 
from intestines and lungs using forward primer and reverse primer (Table 4.3). The veracity of the 
PCR products was confirmed by sequencing and the products cloned into pCR 2.1-TOPO vector 
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using TOPO® TA Cloning® Kit (Invitrogen, Cat #450641). The sequences were also cloned into 
pGEX-KG protein expression plasmid (a gift from Gerry Weinmaster (University of California, 
Los Angeles, CA)) using BamHI and XbaI restriction sites at 5’ and 3’ ends, respectively.  
 
Table 4.2. Primers used for PCR 









Primary reaction for coronavirus 
detection 







Secondary reaction for 
coronavirus detection 
1 min 273 bp 
5’–ATG GCC TCT GTT AAG 





amplification for TOPO-TA 
cloning 








cloning into pGEX-KG vector 








cloning into P3X-Flag vector 
1 min 30 s 1,296 bp 
 
4.6.4. High-throughput Sequencing and assembling the Myl-CoV genome 
Total RNA from 7 bats (4 from incubator-A and 3 from incubator-B) was sent to The 
Centre for Applied Genomics at The Hospital for Sick Children (Toronto, Canada), where RNA 
quality was assessed using a Bioanalyzer (Agilent Technologies), Poly(A) mRNA was enriched 
using oligo dT-beads, and cDNA libraries were prepared using the NEBNext Ultra Directional 
RNA Library Prep Kit (New England Biolabs). Barcoded libraries were pooled in equimolar 
quantities and sequenced on a HiSeq 2500 System (Illumina) to generate 126 bp paired-end reads.  
 Sequence data quality was assessed using FastQC v0.11.5 [206] and the reads were 
trimmed to remove adapter sequences and low-quality bases using Trimmomatic v0.36 [207] using 
the following settings: Illumina clip:2:30:10, leading:3, tailing:3, slidingwindow:4:15, 
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minlength:36. To identify host sequences, we used TopHat v2.1.1 [208] to align trimmed reads to 
the Ensembl M. lucifugus genome sequence assembly (Myoluc2.0) [209] in strand-specific mode 
(fr-firststrand) . We sorted the unmapped .bam files using samtools v1.2 [210],extracted the non-
host sequences using bedtools v2.26.0 bamtofastq [211], and pooled the resulting sequences for 
transcript fragment (transfrag) assembly. We used Trinity v.2.2.0 to generate transfrags using the 
default parameters and in silico read normalization. We performed local BLASTn to search for 
sequence similarity between the Trinity-based transfrags and a coronavirus reference genome 
(KF430219). The sequence of the entire genome of the Myl-CoV was submitted to GenBank, 
accession number KY799179. 
4.6.5. Myl-CoV nucleocapsid (N) protein purification 
Myl-CoV N-pGEX-KG plasmid was transformed into Escherichia coli BL21 competent 
cells [212]. 500ml of cell culture at OD600 = 0.84 was induced to express Myl-CoV-N-GST with 
1mM isopropylthio-b-D-galactoside (IPTG) at 28.5 0C for 7.5 hours. During protein extraction, 
temperature was maintained at +4 0C. BL21 cells were centrifuged down and resuspended using 
1% Triton X-100 in TNE buffer. 10mg/ml of lysozyme was added for 15mins to accentuate the 
process of bacterial cell wall breakdown. 1ml of Halt™ Protease and Phosphate inhibitor cocktail 
(Thermo-scientific - Cat. #78440) and EDTA was added and the blob of bacteria was sonicated 
for 60 secs on ice. Supernatant was removed after centrifuging the bacteria at 15,000rpm for 
20mins and pellet was treated with 1.5% N-lauroylsarcosine (Sigma L-9150) to further disrupt the 
cells and added onto the supernatant. From SDS-PAGE analysis later, we came to know that the 
N-lauroylsarcosine treatment of the pellet led to the release of fusion protein from the cell. Fusion 
protein was purified from the supernatant using Glutathione Sepharose 4B beads (GE Healthcare), 
followed by elution using 10mM glutathione for 16hours. Elution was done twice to obtain 6.1 
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mg/ml and 4.3 mg/ml protein concentration. Protein was verified using SDS-PAGE 
(Supplementary Figure S4.1.(A)). 
4.6.6. Generation of polyclonal antibodies 
Polyclonal Myl-CoV N anti-serum was generated in rabbits. This was carried out in strict 
compliance of Canadian Council on Animal Care guidelines (protocol 20090050). Two rabbits 
were procured by the Animal Care Unit at the Western College of Veterinary Medicine. On day 1, 
28, 42 and 56, nucleocapsid protein mixed with Titermax was injected into rabbits. Rabbits were 
bled to obtain serum one day prior to each antigen injection. Binding of antibody was verified 
using immunoblot and immunofluorescence (Supplementary Figure S4.1.(B) and (C)), after which 
we proceeded with immunohistochemistry. 
4.6.7. Immunohistochemistry (IHC) 
Formalin-fixed-paraffin-embedded (FFPE) blocks of M.lucifugus tissues were obtained 
from our previous study [189] and sections (4-5 microns) were cut and mounted onto slides. Tissue 
sections were incubated twice in xylene for 15mins each and then rehydrated in graded alcohol. 
Tissue sections were then incubated overnight in 0.5mM PBS for better antigen retrieval. 0.5% 
hydrogen peroxide in methanol was added to tissue sections for 20mins at room temperature to 
block endogenous peroxidase. After distilled water wash, 500ul of Proteinase K (20ug in 1ml) 
treatment for 20mins at 37 0C was performed to enhance antigen retrieval. Slides were blocked 
using 1% bovine serum albumin for 30mins. The serum of the rabbits (56th day bleed) containing 
anti-Myl-CoV N were used as the primary antibodies for staining virus infected cells (1:100 
dilution). For every slide processed, we also stained slides with the serum extracted prior to antigen 
injection (Pre-bleed) as a negative control. Formalin-fixed-Myl-CoV-N-transfected Efk cells were 
used as a positive control. Tissue sections were incubated with the primary antibodies for 3 hours 
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at room temperature, followed by 3X 5mins washes with 0.5mM PBS. Anti-Rabbit-IgG conjugated 
with horse-raddish-peroxidase (HRP) (Zymed) was used as a secondary antibody (1:500 dilution) 
for 30mins at room temperature. After 3X 5mins washes with 0.5mM PBS, color was developed 
using 500ul of diaminobenzidine (30ul Diaminobenzidine; 9ul of 0.5% hydrogen peroxide and 
3ml 0.5mM PBS) for 10mins at room temperature. Counterstaining was done using hematoxylin 
for 30seconds and then decolorized using acetic acid-acetone. Slides were dehydrated using graded 
alcohol and then treated with Xylene before applying coverslips. Formalin-fixed-Myl-CoV-N-
transfected Efk (Eptesicus fuscus kidney) cells [213] were used as a positive control. 
Counterstaining was done using hematoxylin. 
4.6.8. Hematoxylin and Eosin (H&E) staining 
Tissue sections for histopathology were stained with H&E by Prairie Diagnostic Services 
at the University of Saskatchewan. Each lung section was independently assessed for bronchiolar 
epithelial degeneration and inflammation by two veterinary pathologists, blinded to sample 
identity. Five categories of lesions were established: diffuse lung inflammation, inflammation of 
bronchus, bronchiolar epithelial vacuolation, bronchiolar epithelial hyperplasia, and bronchiolar 
epithelial erosion. All lung sections from all bats were examined to determine the range of changes 
and then changes were scored between 0 and 3, with 0 indicating normal and 3 indicating the most 
severe change within the 8 bats examined. The maximum score of 3 would still be considered mild 
within the typical pathology scoring system describing the severity of inflammatory response: 
mild, moderate or severe. 
4.6.9. Electron Microscopy (EM) 
Myl-CoV infected cells in the bronchial epithelium were marked in the corresponding IHC 
slides, so that the specific location could be sampled for electron microscopy (EM). The slide was 
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soaked in Xylene to remove the coverslip, soaked in Xylene:Propylene-oxide (PO) (2:1) and (1:1) 
for 30 mins and 15 mins respectively, followed by 1 hour soaking in PO. PO:Epon (1:1) was 
consistently dropped on the slides for 1 to 2 hours followed by pure Epon for 1 hour. Labelled 
capsules were filled and inverted on the tissues on the slide. Polymerization was done at 650C for 
24 hours. The block was broken off the slide which lifted the section along with it and was then 
sectioned on to 200 mesh copper grids, which were viewed by transmission electron microscope. 
4.6.10. Phylogenetic analysis and sequence alignments 
For the whole genome phylogenetic tree, genome sequences of 33 representative 
coronaviruses and Myl-CoV were aligned using ClustalW (Version 1.83) [214]. Maximum 
likelihood (ML) trees were constructed with MEGA7 [215]. Divergence was estimated by 
Kimura’s two parameter method. Bootstrapping with 1000 replicates was used to estimate the 
confidence of the tree nodes. The generated tree was then annotated using Adobe illustrator CC 
2015.  
For the phylogenetic tree of the RdRp gene segment, sequences obtained from Sanger sequencing 
were used along with corresponding segments from KF430219 and HQ336976. Only sequences 
that were completely unambiguous were used in the analysis. ML trees were constructed in a 
similar manner as that of the entire genome phylogenetic tree. 
4.6.11. Accession numbers 
41 sequences of RdRp gene using sanger sequencing were submitted to GenBank 
(accession number KY820767 to KY820807). Myl-CoV complete genome sequence was 
submitted to GenBank (Accession number KY799179). Nucleotide sequences for the phylogenetic 
tree were obtained from GenBank. Accession numbers of the sequences are AF353511 
(PEDV.CV777), AF391541 (BCoV.ENT), AY585228 (HCoV.OC43.ATCC.VR.759), DQ001339 
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(Avian IBV.p65), DQ011855 (PHEV.VW572), DQ022305 (BtSARS.HKU3-1), DQ071615 
(BtSARS.Rp3), DQ412042 (BtCoV.Rf1), DQ412043 (BtSARS.Rm1), DQ415904 
(HCoV.HKU1.N6.GenotypeA), DQ445912 (HCoV.NL63.Amsterdam.496a), DQ648856 
(BtCoV.273.2005), DQ648857 (BtCoV.279.2005) , DQ811789 (TGEV), DQ848678 (FCOV), 
EF065505 (BtCoV.HKU4.1), EF065509 (BtCoV.HKU5.1), EF065513 (BtCoV.HKU9.1), 
EF065514 (BtCoV.HKU9.2), EF065515 (BtCoV.HKU9.3), EF065516 (BtCoV.HKU9.4), 
EF203067 (BtCoV.HKU.HK.33.2006), EU420137 (BtCoV.1B.AFCD307), EU420138 
(BtCoV.1A.AFCD62), EU420139 (BtCoV.HKU8.AFCD77), FJ647225 
(MurineCoV.MHV.A59), KC164505 (MERS-CoV.England1), NC002645 (HCoV.229E), 
NC004718 (SARS-CoV), NC009019 (BtCoV.HKU4.1), NC009657 (Scotophilus 
BtCoV.512.2005), NC009988 (BtCoV.HKU2) and KF430219 (Myotis CoV - USA.2006)). 
 
4.7. Results 
4.7.1. Detection of a coronavirus in hibernating little brown bats.  
To estimate the prevalence of coronavirus in little brown bats, and to determine the tropism 
of the virus, we performed PCR for coronavirus RdRp (RNA dependent RNA polymerase) gene 
on samples from brain, intestines, liver, kidney, and spleen of 157 little brown bats. We detected 
the coronavirus only in the intestines. On average, one third of the bats (Table 4.3) contained 
detectable coronavirus RNA. There was no difference in the prevalence of virus between 
experimental groups in the different cages/incubators (Chi-square test, n = 174, p value = 0.817). 





Table 4.3. Prevalence of the Myotis lucifugus-Bat coronavirus (Myl-CoV) in little brown bats 
intestines based on detection of a portion the viral RdRp gene. 
Year Incubator name Number of positive bats/Number of bats tested Percentage Positive 
2011 Incubator A 7/18 39 
2011 Incubator B 3/13 23 
2011 Incubator C 7/16 44 
2012 Incubator DC 6/21 29 
2012 Incubator DI 9/23 39 
2012 Incubator EC 3/10 30 
2012 Incubator EI 2/10 20 
2012 Incubator FC 4/10 40 
2012 Incubator FI 2/11 18 
2012 Incubator GC 2/10 20 
2012 Incubator GI 4/11 36 
2012 Incubator HC 3/11 27 
2012 Incubator HI 1/10 10 
Total  53/174 30 
 
We then compared the nucleotide sequences and the derived amino acid sequences of the 
PCR products. We included a corresponding segment from little brown bat coronavirus 
(KF430219) and from the Rocky Mountain coronavirus detected in a big brown bat (HQ336976) 
into the alignments.  Sequences segregated into two distinct clades (Figure 4.1. (A)). Clade 1 
sequences were most similar to KF430219 and Clade 2 sequences resembled sequences from 
HQ336976.  Most of the sequence differences within each clade were synonymous (Figure 4.1. 
(B)), while there were seven amino acid differences between clades 1 and 2 (Figure 4.1. (C)). 
Except for some bats in incubator D, the nucleotide inter-clade and intra-clade polymorphisms 
were scattered among the hibernation incubators. This suggested that the bats were infected before 




Figure 4.1. Comparison of nucleotide and amino acid sequence of PCR products from a 229 
bp portion of the coronavirus polymerase gene amplified from the intestine of bats. Groups of bats 
were isolated in incubators with little likelihood of cross infection during hibernation. (A) 
Maximum likelihood tree of nucleotide sequences variation. The colour of the box indicates the 
bat’s hibernation incubator. The first two digits indicate the year of the experiment (2010-2011 or 
2011-2012) and the bat’s identification number. For 2011-2012 each incubator contained two 
cages, designated either T or C.  Corresponding sequences from a coronavirus from Myotis 
lucifugus (Myotis-CoV-USA-2006 - Genbank accession number KF430219) and from Eptesicus 
fuscus (HQ336976) were included in the analysis and are in white boxes. The numbers at the nodes 
are the bootstrap values (percent) obtained for 1,000 replicates. The inter-clade distance (distance 
between clade 1 and 2) was much larger than intra-clade distances (distance between individual 
coronavirus sequences within a clade) and therefore, it has been depicted with a dotted line and is 





Figure 4.1. (B) Maximum likelihood tree for the amino acid sequence derived from the nucleotide 




Figure 4.1. (C) showing the ClustalW alignments used to generate the trees for nucleotide and 
amino acid sequences. Residues that differ from the consensus are highlighted in colour. 
 
4.7.2. Complete genome sequencing and phylogenetic analysis.  
We assembled the entire genome of the coronavirus from RNASeq data from intestines of 
7 bats (which contained clade 1 coronaviruses). The genome of the Myotis lucifugus bat 
coronavirus (Myl-CoV) is 28,173 bases. We assigned open reading frames based on the published 
KF430219 sequence. The assembled sequence includes a 3’ poly-adenine tail, which is missing 
from the annotated KF430219 sequence. 
Phylogenetic analysis of Myl-CoV and other representative coronaviruses places Myl-CoV 
within the genus Alphacoronavirus. Myl-CoV is more closely related to Scotophilus Bat 
coronavirus 512 and PEDV-CoV (CV777 strain). Other Alphacoronaviruses related to the Myl-
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CoV are human CoV 229E, NL63 and coronaviruses detected in other bat species (BtCoV-HKU2, 
HKU8, HKU-HK33, 1B-AFCD307, and 1A-AFCD62) (Figure 4.2.).  
 
Figure 4.2. Whole-genome phylogeny comparing Myl-CoV with representative 
coronaviruses. The whole genome sequences of 34 coronaviruses, including Myl-CoV, were 
aligned. Three distinct phylogenetic genera are shown: Alphacoronaviruses, Betacoronaviruses 
and Gammacoronaviruses. The location of Myl-CoV within Alphacoronaviruses is indicated by 
an arrow. Deltacoronaviruses are newly characterized and are not shown. Recognised subgroup 
clusters are marked as 2a-2d for the Betacoronaviruses and 1a and 1b for the Alphacoronaviruses. 
4.7.3. Detection of Myl-CoV in bronchial epithelium of bats.  
Several coronaviruses have a predilection for respiratory as well as intestinal tissue. 
Although we had detected Myl-CoV RNA only in intestinal samples, we performed 
immunohistochemistry (IHC) to further explore the tropism of the virus. We were unable to detect 
coronavirus antigen in any of the tissues except for lungs. We detected the Myl-CoV antigen in the 
 
 52 
lung of five bats, all of which were positive for viral RNA in intestines (Figure 4.3.(A)). In the 
lungs, the Myl-CoV antigen was present only in the bronchial epithelial cells. Cells containing 
nucleocapsid antigen showed degenerative changes in the form of vacuolation, and some cells 
appeared to have exfoliated.  
 
 
Figure 4.3. (A) Cells immuno-stained for Myl-CoV nucleocapsid in the bronchial epithelium 
of lungs. Immunohistochemistry performed using Myl-CoV N antiserum. Lungs 1 is from a bat 
with coronavirus detected in its intestine. Lung 2 is from an uninfected bat. Cells stained for Myl-
CoV N protein (indicated by arrows) were vacuolated and in some cases sloughing into the 
bronchial lumen. Only bronchial epithelial cells had detectable viral antigen. 
Figure 4.3. (B) Pathology of Myl-CoV infected lung. H&E staining of bat lung infected with 
coronavirus. Vacuolation of infected cells (shown by an arrowhead) were present along the 
bronchial epithelium. A portion of bronchial epithelium was sloughed off (shown by an arrow). 
Neutrophils were observed in the vicinity of the infected portion of the bronchus but the overall 




We also performed transmission electron microscopy on portions of the lung sections that 
contained viral antigen (Figure 4.4.). Although the quality was compromised due to formalin-
fixation, we observed electron dense particles in the cells that were positive for Myl-CoV antigen. 
The size of these particles were as expected for coronaviruses (approximately 125 nm [216]). 
Cellular degenerative changes were evident in the cells containing the particles. In the same 
section, other cells were healthy and did not contain such particles. Furthermore, the presence of 
viral RNA was confirmed by performing PCR on lung cDNA (obtained from RNA) using the 
primers against Myl-CoV nucleocapsid gene. Sanger sequencing of the amplified PCR product 




Figure 4.4. Transmission electron micrograph showing coronavirus-like particles in the 
bronchial epithelial cells. (A) A haematoxylin and immune-stained (Myl-CoV N protein) section 
of lung. The red square denotes the portion picked from a consecutive H&E section for electron 
microscopy. (B) Electron micrograph of cells selected in (A). Successive enlargement of portions 
of the section in a box with red dotted lines. (C) (D) Particles (around 125 nm in size) were 
observed in the bronchial epithelium (thin arrow). Those cells which contained the virus-like 
particles showed nuclear degradation (indicated by the arrow-head). Uninfected cell nucleus shows 
normal morphology (shown by thick arrow). 
 
4.7.4. Pathology in bat lung due to Myl-CoV infection.  
To assess pathology due to coronavirus infection, histologic sections of the Myl-CoV 
positive lungs of M. lucifugus were evaluated independently by two pathologists. Although lesions 
were very mild both pathologists had higher lesion scores for the categories of bronchiolar 
epithelial vacuolation and degeneration, bronchiolar epithelial hyperplasia and erosion of 
epithelium in virus-infected bats when compared to uninfected. There was no obvious consistent 
inflammation of the bronchus and, although there was mild diffuse inflammation of the interstitium 
and alveoli, there was no difference between virus-infected and uninfected bats (Figure 4.3. (B)). 
 
4.8. Discussion 
Although events of successful viral spillover to distantly related species are thought to be 
extremely rare, in recent years, coronaviruses including SARS-CoV [190], MERS-CoV [67,191–
193] and PED-CoV [195] have spilled over from bats to other species. Circumstantial evidence 
suggests that most alpha and beta coronaviruses parasitizing other mammals may also have 
originated in bats [217]. Little is known at present about the dynamics of coronavirus infection in 
the reservoir bat hosts or how the viruses are spread from bat to bat, or from bats to other mammals. 
In this study, we examined a coronavirus in its natural host, the little brown bat. This study system 
provides a useful model for understanding factors that may promote spillovers. Our results suggest 
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the following: a) the Myotis coronavirus (Myl-CoV) is mainly present in the intestines and lungs, 
b) co-hibernating little and big brown bats may share closely related coronaviruses, c) Myl-CoV 
can persist in M. lucifugus for up to 4 months, the hibernation period of our experiment, and d) the 
presence of Myl-CoV in bronchial epithelium is associated with minimal pathology or 
inflammation. However, a larger sample size under controlled conditions of exposure, with more 
rapid fixation of tissues, is required to fully characterize the lesions in lung and intestines. 
 Dominguez [218] and others [188] previously detected a coronavirus in little and big brown 
bats suggesting that the virus may infect bats of both species, crossing between the bats at shared 
co-hibernation sites. The virus originally detected in a big brown bat was named the Rocky 
Mountain coronavirus [218] for the location of its initial detection. The RNA amplified from little 
brown bats in this study appeared to be from two distinct clades. The sequences in Clade 1 were 
very similar to the archived sequence derived from little brown bats and sequences from Clade 2 
were more closely related to the archived sequence from big brown bats. This suggests that two 
closely related coronaviruses may circulate in little brown bats. Although the sequence traces did 
not suggest a mixture of PCR products, we cannot completely rule out the possibility that the 
individual bats were infected with viruses from both clades and that the PCR likely favoured the 
predominant viral component.   
Complex strategies allow viruses to remain endemic in populations. These include: 1) a 
continuous source of susceptible hosts for viruses that cause short-term acute infections with long-
lasting immunity (e.g., measles virus), 2) antigenic drift (e.g., influenza virus) of virus or waning 
immunity (e.g., respiratory syncytial virus) that allows reinfection, and 3) long-lasting latent (e.g., 
herpesviruses) or persistent infections (e.g., pestiviruses) with sustained or periodic shedding. How 
bat viruses are maintained in their natural host populations or how they avoid extinction as host 
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populations become immune and less susceptible, however, is not understood. It is possible to 
establish persistent infections in cultured cells with viruses that may have originated in bats, 
including Ebola virus [219] and SARS-CoV [220,221], but whether these viruses persist in their 
primary hosts is not known. The results of studies aimed at determining whether bat viruses persist 
in infected bats are controversial. There is no direct evidence for either persistence or transmission 
dynamics, and this is a knowledge gap in bat-virus ecology that needs to be addressed [12].  
Based on the sequence of the amplified portion on the RdRp gene we observed 
considerable polymorphism among the Myl-CoV with sequences segregating into distinct clades. 
Based on the maximum mutation rate possible for the RdRp gene [222], we should have observed 
only 1.16 random mutations in the 229bp segment. Most of the intra and inter-clade 
polymorphisms exceeded this rate. Also, while viruses detected in 2011 were primarily clade 1 
and 2012 viruses were primarily clade 2, both clades were detected in samples from either year. 
The differences between clades likely represent fixed nucleotide polymorphisms rather that 
random changes. Although recombination of coronavirus clades is possible, performing deep 
sequencing on the samples would enable us to negate this possibility. Ge and others also found co-
existence of a variety of coronavirus in bat colonies [223]. 
Osborne and others [217] were unable to detect virus in the rectal swabs of individual bats 
sampled over time in an extensive survey of New World Alphacoronaviruses. They concluded that 
these coronaviruses do not persist in their hosts but are maintained in populations by the 
introduction of new susceptible individuals. Their results, however, do not rule out persistence in 
individual animals with low levels of virus replication and undetectable shedding, interspersed 
with short periods of increased replication and shedding. Our observations suggest that the Myl-
CoV can persist in its hosts for at least the four-month hibernation period. Due to strict biosecurity, 
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spread of virus between incubators was unlikely and the distribution of variants among incubators 
(and cages) argues against spread within incubators (or cages). Our results therefore suggest that 
the bats were infected before they were collected.  
Whole genome phylogenetic analysis revealed that the Myl-CoV belongs to the genus 
Alphacoronavirus, which includes three coronaviruses that infect human lungs and pig intestines 
(HCoV-229E, HCoV-NL63 and PED-CoV). We confirmed the presence of virus in intestine via 
PCR and in the lungs by immunohistochemistry, electron microscopy and PCR. But, we were 
unable to detect the Myl-CoV in the intestines using immunohistochemistry. The reason for this 
might be that the part of the intestine used for RNA extraction had the virus in it, whereas the part 
used for histology did not.  
Our histological lung sections provide a novel insight into persistent infection of a 
coronavirus in its reservoir bat host. Firstly, we observed that the cells that were infected showed 
degenerative changes which resulted in rare multifocal areas of bronchiolar epithelial erosions with 
no obvious inflammation targeting these lesions. The absence of neutrophilic infiltration is 
contrary to what has been seen in non-bat species affected by similar coronaviruses. Previous 
studies in transgenic mice showed that HCoV-229E infection led to massive neutrophilic infiltrate 
[224]. Lung samples from piglets infected with PED-CoV showed presence of moderate 
neutrophilic infiltrate (even though PED-CoV has a predilection for intestines) [225].  Hibernating 
bats do appear to be capable of a local inflammatory response following fungal infection [226].  
Low level of neutrophilic infiltration in coronavirus-infected lungs reinforces the fact that bats are 
unique in the way they respond to a coronavirus infection. Lower inflammation might be due to 
fewer chemotactic factors being produced as a result of infection, which might be an inherent 
feature of M. lucifugus. It might also be that bat neutrophils are more efficient in controlling virus 
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infection and obviating a massive neutrophilic infiltrate. An alternative explanation for the lack of 
inflammation in bats may be that cell necrosis occurs at the epithelial surface with dead cells 
sloughing into the lumen. Cytokines required to stimulate inflammation and immunity might not 
enter the interstitium and the systemic circulation. An infection that is localized to epithelial cells 
without breaching the basement membrane is a good strategy for a virus to allow persistence of 
infection. However, in our study the sample size was low and it is difficult to reach a firm 
conclusion about the host’s response to coronavirus infection.  
Although our results demonstrate viral persistence during hibernation and do not address 
it in normothermic bats, we propose a model for the maintenance of the coronavirus in little brown 
bat populations (Figure 4.5): Bats are infected with one of closely related coronaviruses 
distinguishable from each other by minor nucleotide polymorphisms. The virus then persists at 
low levels, probably undetectable in fecal material. Due to limited replication in bronchial 
epithelial cells there is little host-response against the virus favouring persistence. Naïve and 
susceptible young individuals acquire the virus in maternity roosts when viral replication and 
shedding increases, caused by hormonal changes or other stress factors [47,227]. 
Our study demonstrates for the first time that several bats in a population can maintain a 
coronavirus infection through the hibernation as apparently non-pathogenic infection. Our 
observations also support growing evidence that natural and experimental viral infections in bats 




Figure 4.5. Proposed model of coronavirus maintenance in bat population. Bats are infected 
with one of closely related coronaviruses distinguishable from each other by minor nucleotide 
polymorphisms. The virus then persists at low levels during hibernation. Due to limited replication 
in bronchial epithelial cells there is little host-response against the virus favouring persistence. 
Naïve and susceptible young individuals acquire the virus in maternity roosts when viral 
replication and shedding increases, caused by hormonal changes or other stress factors Bats enter 
hibernation with the infection present in them. During hibernation, the virus persists due to low 





4.9. Supplementary Information 
 
 
Figure S4.1. Figure showing the process of developing antibodies. (A) SDS-PAGE showing 
the fusion protein (Myl-CoV nucleocapsid protein-GST) purified using Glutathione Sepharose 4B 
beads. Lane 1 contains protein ladder; Lane 2 contains the Eluate#1 (blue band showing the fusion 
protein); Lane 3 contains the Eluate#2; Lane 4 contains the Beads. (B) Immunoblot done using 
10ng of Myl-CoV N-GST protein to detect the titers of the antibody in rabbit serum. The first test 
bleed showed a titer of 6400. (C) Bat cells expressing Myl-CoV N with flag tag stained using rabbit 
serum (containing Myl-CoV N antibodies). Immunofluorescence assay showing the binding of the 
antibodies (N protein shown in green). 
 
Supplementary Fig. 1. Figure showing the process of developing antibodies. (A) SDS-PAGE 
showing the fusion protein (Myl-CoV nucleocapsid protein-GST) purified using Glutathione 
Sepharose 4B beads. Lane 1 contains protein ladder; Lane 2 contains the Eluate#1 (blue band 
showing the fusion protein); Lane 3 contains the Eluate#2; Lane 4 contains the Beads. (B) 
Western Blot done using 10ng of Myl-CoV N-GST protein to detect the titers of the antibody in 
rabbit serum. The first test bleed showed a titer of 6400. (C) Bat cells expres ing Myl-CoV N 
with flag tag stained using rabbit serum (containing Myl-CoV N antibodies). 
Immunofluorescence assay showing the binding of the antibodies (N protein shown in green). 
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4.10. Transition Statement 
In this chapter, I described our characterization of a coronavirus that infects many little 
brown bats. We obtained the nucleotide sequence of virus’ entire genome allowing us to predict 
its component open reading frames and to demonstrate that the bats were infected prior to 
hibernation and that the viruses persisted in bat intestines at least while they were in hibernation. 
We also demonstrated the presence of the virus in the lungs and intestines of the bats were there 
was little evidence of virus replication-induced tissue damage and inflammation.  
We had access to tissue samples archived from an earlier study of the pathophysiology of 
white-nose syndrome, a frequently lethal fungal disease of little brown bats. The data described in 
this chapter provided us with the information needed to test the hypothesis that the systemic effects 
fungal infection would cause changes in the gene expression patterns in bat intestines, the main 
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RNASeq data and contributed to the writing of the manuscript. LW, JMT, CKRW and VM 
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conducted the WNS pathogenesis experiments in 2009 from which all tissue samples were 
obtained. ND, EK, KN, YD, CKRW conducted the WNS pathogenesis experiment in 2017 and 
provided samples for the serological analysis. TKB conducted all pathological analyses. 
 
5.4. Abstract 
Spillover of viruses from bats to other animals may be associated with increased contact 
between them, as well as increased shedding of viruses by bats. Here, we tested the prediction that 
little brown bats (Myotis lucifugus) co-infected with the M. lucifugus coronavirus (Myl-CoV) and 
with Pseudogymnoascus destructans (Pd), the fungus that causes bat white-nose syndrome 
(WNS), exhibit different disease severity, viral shedding and molecular responses than bats 
infected with only Myl-CoV or only P. destructans. We took advantage of the natural persistence 
of Myl-CoV in bats that were experimentally inoculated with P. destructans in a previous study. 
Here, we show that the intestines of virus-infected bats that were also infected with fungus 
contained on average 60-fold more viral RNA than bats with virus alone. Increased viral RNA in 
the intestines correlated with the severity of fungus-related pathology. Additionally, the intestines 
of bats infected with fungus exhibited different expression of mitogen-activated protein kinase 
pathway and cytokine related transcripts, irrespective of viral presence. Levels of coronavirus 
antibodies were also higher in fungal-infected bats. Our results suggest that the systemic effects of 
WNS may down-regulate antiviral responses in bats persistently infected with M. lucifugus 





Bats are hosts for many viruses and are thought to be the source of some viruses that have 
spilled over to humans and other mammals, causing fatal disease. These include coronaviruses 
causing severe acute respiratory syndrome (SARS [190]), Middle East respiratory syndrome 
(MERS [191,192,228,229]), porcine epidemic diarrhoea (PED [195]) and swine acute diarrhoea 
syndrome (SADS [133]); paramyxoviruses such as Hendra [230] and Nipah [231]; and filoviruses 
like Marburg [232] and Ebola [233]. Four families of viruses that are pathogenic for other 
mammalian species (Coronaviridae [234], Paramyxoviridae [235], Rhabdoviridae [236] and 
Filoviridae [237]) may also have originated in bats. These viruses often cause serious disease in 
their secondary hosts, but most do not appear to cause clinical signs or pathology in bats 
[38,46,238], suggesting that uniquely benign relationships have co-evolved between the viruses 
and their primary bat hosts [14,20]. While relatively little is known about the dynamics of viral 
infections in bats, these viruses may be maintained in bat populations as a result of either 
persistently infected individuals, reinfection after waning immunity, or spatial transmission 
dynamics [12,239]. 
The rare spill-over of bat viruses to other animals may require a “perfect storm” of 
conditions that include increased contact between bats or fomites and other mammals, possibly 
due to human impacts on habitat quality [240], and the ability of the virus to infect, replicate, and 
transmit in the secondary host. The rate of viral shedding and the amount of detectable virus 
associated with bat colonies fluctuates, with periodic increases often linked to parturition, waning 
maternal immunity, nutritional stress or increased energy consumption [46,241–246]. Increased 
shedding of virus by a colony of bats may reflect an increase in the proportion and number of 
susceptible individuals, or an increase in the replication of persistent or latent virus normally 
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suppressed by the host. For herpesviruses, reactivation from latency is linked to perturbations 
caused by a variety of physiological, immunological and psychological stressors [247]. The 
mechanisms that trigger the reactivation of latent or persistently infecting viruses are not clearly 
understood, but the increased shedding of viruses is correlated with some incidents of spill-over 
of bat viruses to other animals [248]. 
The Canadian prairies are home to three species of bats, including the little brown bat 
(Myotis lucifugus), big brown bat (Eptesicus fuscus), and northern long-eared bat (Myotis 
septentrionalis). All three species hibernate from October to May, sometimes in shared 
hibernacula. We recently demonstrated that ~30% of hibernating M. lucifugus sampled over two 
years from hibernacula in Manitoba were infected with a coronavirus (Myl-CoV), which persisted 
at low levels in the intestine [44]. A closely related coronavirus also infects E. fuscus [218].  
Whereas bats appear to be relatively resistant to viral infections, a cold-adapted fungus that 
was recently introduced to North America has caused widespread mortality in some species of bats 
in eastern United States and Canada [189,249–251]. The fungus (Pseudogymnoascus destructans) 
causes white-nose syndrome (WNS) in hibernating bats, which is characterized by the growth of 
white fungal mycelia on the face and exposed skin of the wings and tail membranes. The visual 
and microscopic effects of P. destructans on the skin of the wings are associated with increased 
expression of several genes devoted to innate immunity and inflammation in wing tissue [226,252]. 
Profound systemic effects include dehydration, hypovolemia, metabolic acidosis, and fat 
depletion, which can lead to death [59–61]. Other systemic effects of bat WNS include an 
accumulation of neutrophils in the lungs, which is accompanied by an increase in the expression 
of several cytokine genes [253] suggesting that even the most severely afflicted hibernating bats 
are capable of at least some systemic immune response to fungal infection. 
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Previous studies on other species have demonstrated that a fungus and a virus could interact 
during co-infection and affect each other [254,255]. Similar interactive impacts of co-infection 
with P. destructans and viruses on bat immune responses are not known. We used M. lucifugus 
experimentally- infected with P. destructans and/or naturally infected with Myl-CoV as a model 
to understand how co-infections influence bat-virus interactions. This system allows us to avoid 
confounding factors of direct pathogen-pathogen interactions, because the fungus affects the skin, 
while the coronavirus infections occur internally, almost exclusively in the ileum and lungs [44]. 
We hypothesized that co-infection would alter the molecular response of bats to a persistent viral 
infection, and that viral shedding would change as a result of the increased or disrupted host 
immune response. To test this prediction, we examined tissues collected from M. lucifugus at the 
termination of an earlier study that quantified the effects and pathogenesis of P. destructans in 
hibernating bats experimentally infected with the fungus [189], some of which were naturally 
infected with Myl-CoV [44]. This combination of uninfected, virus-infected, fungus-infected and 
co-infected M. lucifugus allowed us to test our hypothesis that host responses to co-infection are 
synergistic and not simply additive.  
 
5.6. Materials and methods 
5.6.1. Sample acquisition 
Fifty-four male M. lucifugus were collected from a WNS-free cave in Manitoba, Canada 
in November 2010. Details of the experimental design as well as protocols for collecting and 
transporting bats, infection with P. destructans, maintenance of bats in hibernation and sample 
collection have been described previously [189,253]. Briefly, bats in groups of 18 were either 
sham-inoculated or inoculated with North American or European isolates of P. destructans. Bats 
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were housed at 7°C and > 97% relative humidity with ad libitum water. All bats were equipped 
with data loggers to monitor skin temperatures. Bats were euthanized during the experiment when 
humanely required or at the termination of the experiment 120 days after inoculation. Immediately 
following euthanasia samples from segments of wing as well as various tissues were preserved in 
RNAlater (Qiagen, Cat #76016) or in formalin. Samples in RNAlater were kept at -20°C until they 
were processed. North American and European isolates of P. destructans caused similar disease 
outcomes [189], so we did not differentiate between the strains in subsequent analysis. The 
procedures for care, handling and euthanasia of bats were approved by the University Committee 
on Animal Care and Supply of the University of Saskatchewan (Protocol #20100120). Bats were 
collected under the province of Manitoba Wildlife Scientific Permit WB11145. 
 In 2017, a further 129 M. lucifugus were collected from a WNS-free cave in Manitoba, 
Canada in January under the Manitoba Sustainable Development Wildlife Scientific Permit No. 
SAR16009. Bats were euthanized during the experiment when humanely required or at the 
termination of the experiment 70 days after infection and a similar experiment was performed at 
the University of Winnipeg as described above (Protocol #AE08399).  
5.6.2. Histological classification 
During necropsy, we collected representative samples for histopathology from all major 
organ systems. In addition, representative samples were taken from all areas of the wing and rolled 
on dental wax before placing in 10% neutral buffered formalin. Tissues were processed routinely 
for histology. Five µm sections were cut and stained with periodic acid-Schiff stain to highlight 
fungal hyphae. Liver and other tissues were processed routinely and stained with hematoxylin and 
eosin. Wings were scored on a scale of 0 to 5 with 5 being very severe with > 50% of wing covered 
in fungal hyphae. We used a bacterial score from 0 to 5, with 5 indicating wide-spread and 
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abundant bacteria being present in many areas within the dermis and underlying connective tissues. 
Average scores from 5 sections of wing were used for analysis. Interstitial lung neutrophil 
assessment was similarly evaluated on a scale of 0 to 5, with 5 being very severe. Average scores 
from the 5 sections were used for analysis. 
5.6.3. RNA Extraction 
Tissues preserved in RNAlater were homogenized in 2ml sealed vials with a 5mm stainless 
steel bead, 0.1g of 0.1mm zirconia/silica beads and 350μl Buffer RLT Plus (with β-
mercaptoethanol, RNeasy Plus Mini Kit, Qiagen, Cat #74136) using a Retsch MM400 Oscillating 
Mill at 30Hz for 4min. Total RNA was extracted following the manufacturers protocol. RNA 
integrity was assessed using RNA 6000 Nano Kit (Agilent, Cat #5067-1511) with the Agilent 2100 
Bioanalyzer. 
5.6.4. cDNA Synthesis 
cDNA was synthesized from 1μg of RNA (or less if concentrations were too low) per 
reaction using QuantiTect Reverse Transcription Kit (Qiagen Cat #205313). cDNA samples were 
stored at -80°C until they were used for PCR. 
5.6.5. Polymerase Chain Reaction (PCR) 
Tissue samples were identified by their submission numbers with no reference to treatment 
class prior to analysis with PCR, so that evaluation of the results could not be inadvertently biased 
by knowledge of the treatment. We used semi-nested PCR to detect Myl-CoV. Primers were 
designed from the partial sequence of Rocky Mountain bat coronavirus replicase (accession 
number EF544563) (Table S9). The primary reaction used primers MyCVF1 and MyCVR1 to 
yield a 441 bp product. The secondary or nested reaction used primers MyCVF2 and MyCV R1 to 
give a 273 bp product. PCR were performed in a MJ Research PTC-200 thermal cycler using 
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TopTaq DNA Polymerase (Qiagen, Cat #200205). Each reaction (50 μl) contained 2 μl cDNA (or 
1µl primary reaction), 200 nM of each primer, 200 µM of each dNTP (Invitrogen, Cat #10297018), 
TopTaq PCR buffer and 0.25 μl TopTaq. The thermal profile for the primary reaction was: 94°C 
for 3 min (denaturation), followed by 30 cycles of 94°C for 30 sec, 45°C for 30 sec (annealing), 
72°C for 1 min and finally 72°C for 10 min. The thermal profile used for the secondary reaction 
was 94°C for 3min (denaturation), then 30 cycles of 94°C for 30 sec, 55°C for 30 sec (annealing), 
72°C for 1 min and finally 72°C for 10min. PCR products were analyzed on ethidium bromide 
stained 1.0% agarose gels (Invitrogen, Cat #15510-027 in 0.5X TBE). PCR products were purified 
using MinElute PCR Purification Kit (Qiagen, Cat #28006) and verified by sequencing (Macrogen, 
Korea). If more than one DNA band was present, the appropriate size band was cut out and purified 
using QIAquick Gel Extraction Kit (Qiagen, Cat #28706) before sequencing. 
5.6.6. Reverse-Transcription Quantitative PCR (RT-qPCR) 
The Stratagene MX3005P qPCR System was used in conjunction with QuantiFast SYBR 
Green PCR Kit (Qiagen, Cat #204056). We quantified coronavirus with RNA primers MyCV F2 
and MyCV R1 (Table S9). For initial experiments data were normalized to two transcripts – 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta-actin [253]. As there were no 
differences in results, all subsequent experiments used only GAPDH as a normalizer using primers 
GAPDH US and GAPDH DS (designed for use in humans but also amplify M. lucifugus transcripts 
– Table S9). As well, a no-template (negative) control was included with every set of primers. 
Each 25 μl reaction contained: 1 μM of each primer set, 12.5 μl SYBR Green Master Mix and 8.5 
μl of diluted cDNA. 
 To verify the RNASeq data, cDNA from ileum samples in which coronavirus RNA had 
been detected via RT-qPCR were analysed using the following primers, IL22RA1, IRF1, RERG 
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and SRC (for sequence of primers see Table S9). Primers were designed by aligning primers 
described for quantitating human cytokines (PrimerBank) with annotated transcripts of M. 
lucifugus genes: c-jun (Accession number: XM_006096110.1), cyclin D1 (XM_006098046.1), 
IL10 (XM_006094865.1) and TNF alpha (XM_006104644.1). The interferon beta primers were 
designed using the annotated transcript for the E. fuscus gene (XM_008145044.1), which also 
amplify transcripts from M. lucifugus. Primer efficiencies were determined from cycle threshold 
(Ct) values of purified PCR products serially diluted and re-amplified. Primers amplified targets 
with an efficiency of about 100% and in all cases the identities of the PCR products were confirmed 
by their specific dissociation temperature, specific sizes on agarose gels and by sequencing. 
 We observed primer-dimers in some reactions in addition to the PCR product. The dimers 
dissociated at 77°C, while the specific coronavirus polymerase product dissociated at 83°C. To 
avoid false positives due to primer-dimers, the thermocycler was programmed to read at 80°C (in 
the cycle after the primer-dimer had dissociated, and before dissociation of the target product). 
The thermal profile used was 95°C for 5 min followed by 40 cycles of 95°C for 10sec, 60°C for 
30sec (readings taken at 80°C), and a final cycle of dissociation of product 95°C for 1 min, 55°C 
for 30 sec and 95°C for 30 sec (readings taken at every degree between 55°C and 95°C). Only 
results from reactions that yielded unambiguous results were used for analysis. 
5.6.7. RNASeq Analysis 
To explore the mechanisms driving high virus load in bats with WNS, we performed 
RNASeq analysis which could potentially screen all targets in the bat intestinal cells. We targeted 
the ileum transcriptome because this is the tissue in which Myl-CoV is present in detectable 
concentrations [44]. Extraction of RNA from ileum tissue, which includes the ileum and potential 
gut contents have been described in previous sections. Bats were screened for Myl-CoV using RT-
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qPCR, and bats were assigned post hoc to treatment groups representing four infection histories 
(Figure 5.2.(A)): 1) Uninfected (bats were not infected with virus or fungus; n = 5), 2) Virus-
infected (bats were naïve to the fungus but had a persistent Myl-CoV infection; n = 4), 3) Fungus-
infected (bats were experimentally infected with P. destructans and no virus was detected; n = 3), 
or 4) Co-infected (bats with persistent Myl-CoV infections that were also experimentally infected 
with P. destructans; n = 4). All samples had adequate RNA quality for sequencing (i.e. RIN value 
>7).  
5.6.8. RNA isolation 
Tissues were homogenized in 2 ml sealed vials with a 5 mm steel bead, 0.1 g of 0.1 mm 
zirconium silica beads, 350 µL of RLT buffer (with β-mercaptoethanol) (RNeasy Plus Kit, Qiagen, 
Cat #74106) using a Retsch MM400 tissue homogenizer at 30 Hz twice for 2 minutes each. Total 
RNA from tissues was extracted using the procedure provided with the RNeasy Plus Kit. 
5.6.9. cDNA library preparation and RNA Sequencing 
Total RNA was sent to The Centre for Applied Genomics at The Hospital for Sick Children 
(Toronto, Canada). RNA quality was assessed using a Bioanalyzer (Agilent Technologies). We 
retained all samples with a DV200 (percentage of RNA fragments greater than 200 nt) greater than 
85% (Table S1), discarding one Co-infected sample with a DV200 = 42%. Poly(A) mRNA was 
enriched using oligo dT-beads, and cDNA libraries were prepared using the NEBNext Ultra 
Directional RNA Library Prep Kit for Illumina (New England BioLabs). Barcoded libraries were 
pooled in equimolar quantities, and the sixteen libraries were sequenced on three lanes of a HiSeq 
2500 System (Illumina Inc.), which generated 126 bp paired-end reads.  
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5.6.10. RNA Sequencing read alignment and analysis 
We used FastQC v0.11.5 [206] to assess sequence quality and Trimmomatic v0.36 [207] 
to remove the adapter sequences and low-quality bases from reads with the following settings: 
Illumina clop:2:30:10, leading:3, tailing:3, slidingwindow:4:15, minlength:36. We used TopHat 
v2.1.1 [208] to align the trimmed paired-end reads from each library, separately, to the Ensembl 
M. lucifugus genome sequence (Myoluc2.0 [209]) in strand-specific mode (fr-firststrand) with 
mate-inner-dist values specific for the insert size of each library. We used featureCounts [256] to 
count reads mapped to the Myoluc2.0 genome annotation in strand-specific mode (reversely 
stranded), counting paired-end reads as fragments, counting only those fragments where both reads 
aligned successfully, counting multi-mapping fragments, and excluding chimeric fragments. We 
assessed the variability within and between the treatments using the R package SARTools v.1.3.0 
[257]. The featureCount-estimated gene counts were transformed by a variance stabilizing method 
(VST) using SARTools.  
 We identified differentially expressed genes between each of the treatments using DESeq2 
v.1.12.3, run in SARTools. Custom SARTools-based DESeq settings included: 
cooksCutoff=TRUE (perform outlier detection), independentFiltering=TRUE, alpha=0.05 
(threshold of statistical significance), pAdjustMethod=BH (benjamini hochberg p-value 
adjustment method), and locfunc=median (estimate size factors). Differentially expressed genes 
were identified as having a fold-change > 2 and false discovery rate (FDR)-corrected p-values < 
0.05 [258]. We produced volcano plots representing the differential expression comparisons by 
plotting the log of the adjusted p value as a function of the log ratio of differential expression. We 
used the Ensembl gene IDs identified by DESeq2 as input for the web-based g:Profiler [259] to 
test for gene ontology (GO) term enrichment among the differentially expressed genes, using a 
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FDR significance threshold <0.05. These GO-terms and their corresponding p-values were used 
in REViGO [260] to visualize significant enrichment of biological processes. 
5.6.11. IgG capture ELISA against Myl-CoV N protein 
Purified, glutathione-S-transferase (GST)-tagged Myl-CoV N protein expressed in infected 
E. coli BL21 cells was used as positive antigen, and GST-tagged protein expressed in uninfected 
BL21 cells was used as negative antigen. 96-well Costar high-binding round-bottom assay plates 
were coated with 0.05µg/well of either antigen diluted in 0.1M phosphate buffered saline (pH 7.4) 
in a total volume of 100µl. Plates were covered and incubated overnight at 4°C and washed three 
times with 300µl of PBS-Tween 20 (0.1%) immediately prior to use. Serum samples were diluted 
to 1:100 in PBS-Tween 20 (0.2%) supplemented with 5% fetal bovine serum (Gibco, 
Thermofisher, Cat #LS10082147). 100µl of each sample was added in parallel to a positive and 
negative antigen plate and incubated at 37°C for one hour and washed as above. A peroxidase-
labelled goat anti-bat IgG secondary antibody (0.05µg in 100µl per well, Bethyl labs, Cat #A140-
118P) was added, incubated for one hour at 37°C and washed as above. Peroxidase substrate (2,2’-
azino-bis (3-ethylbenzthiazoline-6-sulfonic acid)) was added to each well and colour development 
was quantified 30 minutes later by measuring the optical density at 405nm using an ELISA 
microplate reader. The ELISA cut-off value (0.39) was calculated as the [(mean bat plasma O.D. 
values for bats that were PCR-negative for Myl-CoV in the ileum) + (3x standard deviations of 
those O.D values)]. 
5.6.12. Statistical analysis 
Data from RT-qPCR and histopathological scores were analysed with SPSS Statistics 
version 23. The relative levels of a transcript for each bat were calculated as RT-qPCR Cycle 
threshold (Ct) normalized separately (ΔCt) to the “house-keeping” gene GAPDH. A ΔCt reduction 
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of one (1) indicates an approximately two-fold higher concentration of RNA. The significance of 
differences of mean values of ΔCt between co-infected bats and virus-infected bats were 
determined using an independent-samples Mann-Whitney U test. We calculated Pearson’s 
coefficients to test the correlation between ΔCt levels for coronavirus polymerase cDNA for bats 
in each treatment class, and average scores for fungal hyphae, secondary bacteria, oedema, 
necrosis and inflammation in wing lesions, as well as bacteremia and levels of neutrophils in lung, 
spleen and liver interstitium. 
5.6.13. Data Accessibility 
All RNASeq fastq files have been submitted to the NCBI Sequence Read Archive database 
(accession number SRX3752319- SRX3752333).  
5.6.14. Ethical Statement 
Bat studies were carried out in strict compliance with Canadian Council on Animal Care 
guidelines and the procedure for care, handling, and euthanasia of bats were approved by the 




Quantitation of Myl-CoV and M. lucifugus RNA through reverse transcription quantitative 
PCR (RT-qPCR) and dual-RNA Sequencing indicated that co-infected bats had significantly 
higher levels of Myl-CoV RNA than bats infected with virus alone. The amount of Myl-CoV RNA 
correlated with the severity of WNS pathology in co-infected bats. This phenomenon was 
associated with specific molecular responses to co-infection, even in the intestines of bats where 
only one of the two pathogens was directly interacting with the host tissue. The levels of antibodies 
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against Myl-CoV nucleocapsid (N) protein were also higher in co-infected bats. Each key result is 
discussed in detail below. 
 
5.7.1. Bats co-infected with the fungus P. destructans and the virus Myl-CoV contained higher 
levels of Myl-CoV RNA 
Myl-CoV genomic RNA was detected in bats infected only with Myl-CoV (virus-infected; 
7/18), co-infected bats (European P. destructans (3/13), or with North American P. destructans 
(7/16) [189]). There was no difference in the frequency of Myl-CoV detected among these 
treatments (chi-square statistics; p-value = 0.49). We pooled bats infected with the two P. 
destructans isolates for all further analyses and tested whether co-infection with P. destructans 
and Myl-CoV correlated with an increase in viral replication. Our RT-qPCR data showed that the 
co-infected bats contained 60-fold more Myl-CoV RNA on average than the virus-infected bats 
(Mann Whitney test; p-value = 0.014; Figure 5.1). 
 
Figure 5.1. Effect of white-nose syndrome on level of Myotis lucifugus coronavirus (Myl-CoV) 
RNA in hibernating little brown bats (M. lucifugus). Relative transcript levels for the 




































Fold Change 2 (∆CTMock-infected-∆CTP.destructans-infected) = 64
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normalized separately (ΔCt) for levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
transcripts in each sample. The horizontal bar represents the mean while the vertical bar indicates 
standard deviation from the mean. Significance (p value) is as calculated with an independent 
Mann-Whitney test. Virus-infected bats had lower 1/ΔCt values for coronavirus RNA than co-
infected bats. The average fold-differences between virus-infected and co-infected bats were 
calculated from the difference between the average ΔCt values. 
 
Relative quantities of Myl-CoV RNA detected in the ileum of the virus-infected bats were 
low and showed low variation (Standard Deviation of 1/DCT=0.005), compared to the relative 
quantities of Myl-CoV RNA in the co-infected bats (Standard Deviation of 1/DCT=0.108; Figure 
5.1). The severity of WNS fungal pathology varied in co-infected bats, and we therefore tested 
whether relative quantities of viral RNA in the ileum correlated with the severity of WNS 
symptoms. Levels of WNS severity were scored based on fungal hyphae on the wings, secondary 
bacteria in wing lesions, oedema, necrosis and inflammation in wing lesions, and levels of 
neutrophils in lung, spleen and liver interstitium. Severity scores for wing tissue, secondary 
bacteria in lesions, and neutrophils in the lung interstitium positively correlated with relative 
amounts of coronavirus RNA in hibernating bats (Table 5.1). 
 
Table 5.1. Correlation between level of Myotis lucifugus coronavirus RNA and disease 
severity of white-nose syndrome (WNS) in co-infected M. lucifugus, based on three measures 
of WNS severity and pathology. 
Correlate 
Level of coronavirus RNA 
Pearson Correlation1 Significance N 
Virus-infected/Co-infected -0.610 0.009 17 
Average hyphae score -0.630 0.016 14 
Average bacterial score -0.680 0.007 14 
Lung interstitial neutrophils -0.618 0.043 11 
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1Pearson’s coefficients were calculated for the ∆Ct levels for cytokine transcripts for bats in each treatment class and lung interstitial 
neutrophil scores and mean bacterial and hyphae scores for 5 wing sections for each bat. 
 
5.7.2. Bat responses to co-infection exceed the sum of responses to virus or fungal infection 
alone. 
To determine the extent to which Myl-CoV and P. destructans infection interact to 
influence gene expression in bat intestines, we performed a transcriptomic analysis on bat 
intestines comparing gene expression among the uninfected, virus-infected, fungus-infected, and 
co-infected treatments (Figure 5.2. (A)). RNA sequencing resulted in ~ 700 million paired-end 
reads passing filters, 65% of which aligned to the M. lucifugus genome (Table S1). Pairwise 
differential gene expression varied widely among the four treatments with relatively low overlap 
in differentially expressed transcripts (Figure 5.2. (B); 5.2. (C), Supplementary figure S5.1). 
Similar transcript expression occurred between the uninfected and virus-infected bats, and between 




Figure 5.2. Co-infection of little brown bats (Myotis lucifugus) with M. lucifugus coronavirus 
(Myl-CoV) and Pseudogymnoascus destructans results in non-additive patterns of gene 
expression compared to sole infection with the virus or fungus. (A) Experimental design, 
showing the four treatments of little brown bat (Myotis lucifugus) established by experimental 
inoculation with Pseudogymnoascus destructans and by qPCR detection of persistent Myl-CoV 
infections: uninfected, virus-infected, fungus-infected and co-infected (B) Differential gene 
expression identified by DESeq2 among virus-infected, fungus-infected and Co-infected bats as 
compared to the change each exhibited relative to uninfected bats. (C) Differential gene expression 
among the four treatments, detected by DESeq2 and visualized in volcano plots. The log of the 
adjusted p-value is plotted as a function of the log ratio of differential expression. Colored data 
points represent different groups of genes based on fold change and false discovery rate (FDR) 
cutoff; red (>2 fold change, FDR<0.05), dark grey (>2 fold change, FDR>0.05), light grey (<2 
fold change, FDR<0.05), black (<2 fold change, FDR>0.05).  
 
The fungus-infected bats exhibited a much stronger response, differentially expressing 324 
transcripts compared to the uninfected bats (Table S3). These transcripts were enriched for only 
two gene ontology (GO) terms (cell-cell junction and plasma membrane part; Table S8). The co-
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infected bats differentially expressed 634 transcripts relative to the uninfected bats (Table S4). 
These transcripts showed significant enrichment for 16 GO terms (Table S8). The co-infected and 
fungus-infected bats shared 108 similar differentially expressed transcripts and overlapped in one 
enriched GO term relative to the uninfected bats (plasma membrane part; Table S8).  
5.7.3. Effect of infection with the fungus P. destructans on the expression of genes linked to 
innate responses in the intestines of bats infected with the virus Myl-CoV.  
When we directly compared responses of bats among the four treatments, response of the 
virus-infected bats differed strongly from the responses of fungus-infected or co-infected bats 
(virus-infected vs. fungus-infected: 461 differentially expressed transcripts and 9 significantly 
enriched GO terms; virus-infected vs. co-infected: 473 transcripts and 43 enriched GO terms; 
Tables S5, S6, S7; Supplementary figure S5.1). These differences in gene expression patterns 
included genes that clustered in two processes relevant to host-pathogen interactions – the 
mitogen-activated protein kinase (MAPK) pathways and cytokine and innate immune responses. 
Table 5.2 lists genes from the two processes that were significantly either up or down-regulated 
when virus-infected bats were compared to co-infected bats.  For the MAPK pathway-related 
transcripts, genes such as RSU1 and RERG were up-regulated while those, such as STYK1, 
RRAD, MAP3K and SRC were down-regulated. For cytokine-related genes several transcripts 
were suppressed.  When we compared the expression of the same genes for bats with WNS 
(combining fungus-infected and co-infected bats) and all bats without WNS (combining uninfected 
and virus-infected bats), we found similar differences (last two columns of Table 5.2). This 
suggested that superficial infection with fungus, P. destructans, was the driving factor for altered 





Table 5.2. RNA Sequencing identified differential expression of transcripts related to the 
MAPK pathway and to cytokine-related processes, comparing gene expression in the ileum 
of little brown bats (Myotis lucifugus) infected only with the M. lucifugus coronavirus (Myl-
CoV; virus-infected) or co-infected with Myl-CoV and Pseudogymnoascus destructans. The 
last 2 columns show the same comparisons made after grouping bats that were not exposed to the 
fungus, and bats that were exposed to the fungus and exhibiting symptoms of WNS (irrespective 
of their viral infection status). 
  Virus-infected vs. Co-infected 
All bats “without fungus” vs. 
all bats “with fungus”1 
Ensembl Gene 
Name Ensembl Description Log2FoldChange
2 Padj Log2FoldChange2 Padj 
MAPK pathway-related transcripts   
STYK1 serine/threonine/tyrosine kinase 1 -1.268 0.025 -1.516 < 0.0001 
RSU1 Ras suppressor protein 1 1.102 0.004   
RRAD 
RRAD, Ras related glycolysis inhibitor 
and calcium channel regulator 
-1.297 0.028 -1.3 0.025 
RERG 
RAS like estrogen regulated growth 
inhibitor 
1.562 0.018 1.416 0.005 
MAP3K11 mitogen-activated protein kinase 11 -1.14 0.040 -1.13 0.0002 
SRC 
SRC proto-oncogene, non-receptor 
tyrosine kinase 
-1.539 0.013 -1.297 0.0037 
Cytokine-related transcripts   
IRF1 Interferon regulatory factor 1 -1.551 0.001 -1.444 0.0001 
IFI6 Interferon alpha inducible protein 6 -1.798 0.014 -1.352 0.039 
IL22RA1 Interleukin 22 receptor subunit alpha 1 -1.411 0.015 -1.314 0.002 
SOCS6 Suppressor of cytokine signaling 6 -1.278 0.008 -1.534 < 0.0001 
1(Uninfected + virus-infected) vs. (fungus-infected + co-infected) 
2Positive log2 fold-change values indicate higher expression in the second listed treatments relative to the first. 
 
To confirm the results of the RNASeq analysis, we selected 4 genes from Table 5.2, namely 
IRF1, RERG, SRC and IL22RA1, to be verified by RT-qPCR. We also included interleukin 10 
(IL10) due to its biological relevance to immune regulation and because we had previously 
observed an increase in its expression related to fungal infection [253]. As we wanted to confirm 
whether WNS was driving gene expression in the intestines of bats, we performed a two-group 
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analysis for the RT-qPCR data. We combined all the bats without WNS into a single group 
(uninfected + virus-infected) and all the bats with WNS into the other group (fungus-infected + 
co-infected; Figure 5.3. (A)). Expression of Ras-like estrogen regulated growth inhibitor (RERG) 
increased while expression of Interleukin 22 receptor subunit alpha 1 (IL22 RA1) genes decreased 
in bats with WNS, irrespective of viral infection (Figure 5.3. (C) and (E)). Expression of the 
immune modulatory cytokine IL10 tended to be higher in bats with WNS than in bats without 
WNS, but the difference was not statistically significant (p-value = 0.07) (Figure 5.3. (F)). 
 
Figure 5.3. Effect of white-nose syndrome (WNS) on the levels of immune genes IRF1, 
RERG, SRC, IL22RA1 and IL10 expressed in the ileum of little brown bats (Myotis 
lucifugus). (A) Summary of the four treatments, with a red arrow indicating the two groups (“with 
fungus” and “without fungus”) that were compared. (B-F) The relative transcript levels of each 
gene for bats with and without WNS, depicted as reciprocal of Cycle threshold (Ct) normalized 
separately (ΔCt) for levels of transcripts for GAPDH in each sample. Statistical significance was 
calculated based on the independent Mann Whitney test. The difference in the two groups was 
significant for RERG and IL22RA1 genes. 
 


























































































5.7.4. White-nose syndrome is associated with increased coronavirus antibody levels in the 
co-infected bats. 
In 2017, we performed a similar study, experimentally exposing 63 M. lucifugus to P. 
destructans as described in Warnecke et al [189]. We performed IgG ELISA on blood plasma to 
detect Myl-CoV (coronavirus) N protein antibodies and found that 21/63 were positive for 
antibodies against the coronavirus. Of those 21 bats, 7 had detectable coronavirus RNA in their 
intestines suggesting an active infection, and 3 out of the 7 had been experimentally infected with 
P. destructans during the course of the study. We compared the ELISA optical density (O.D.) 
values of these virus-infected bats to co-infected bats (Figure 5.4. (A)) and found that the presence 
of P. destructans was associated with increased levels of coronavirus antibodies (Mann Whitney 
test, p value = 0.03; Figure 5.4. (B)). 
 
Figure 5.4. Little brown bats (Myotis lucifugus) coinfected with M. lucifugus coronavirus 
(Myl-CoV) and Pseudogymnoascus destructans produce more antibodies against Myl-CoV 
than bats infected only with Myl-CoV. (A) Diagram summarizes the four treatments; the red 
arrow shows the two groups between which antibody levels were compared. (B) Antibody levels 









































(O.D.) values at 405nm. Co-infected bats had significantly higher antibody levels than bats 
infected only with Myl-CoV (independent Mann Whitney test; p value = 0.03). 
 
5.8. Discussion 
Our findings suggest that systemic responses of bats to WNS results in increased 
coronavirus replication and consequently, increased viral shedding, which may lead to subsequent 
infection of susceptible animals. Coronavirus infection may in turn increase the severity of WNS 
pathology. This is the first study to examine the systemic effects of co-infection on either bat 
coronavirus or WNS, and our results raise important questions in regard to zoonotic spillover 
events. Although events of successful viral spillover to distantly related species are thought to be 
extremely rare, in recent years several coronaviruses have spilled over, including SARS-CoV 
[190], MERS-CoV [191,192,228,229], PEDV-CoV [195] and SADS-CoV [133]. These viruses 
are thought to have originated in bats. In addition, circumstantial evidence suggests that most alpha 
and beta coronaviruses that parasitize other mammals may have originated in bats as well [217]. 
If so, then understanding host-pathogen interactions between bats and coronaviruses could inform 
our ability to predict or manage the risk of spillover. In this study, we showed that a coronavirus 
exhibits low activity in its natural host, M. lucifugus, but that co-infection with a fungus increases 
the quantity of viral RNA in the intestines. We have no reason to expect zoonotic transmission of 
the coronavirus i.e. Myl-CoV, but similar co-infection mechanisms may operate in tropical bat 
species harbouring potentially zoonotic viruses.  
Our results suggest that secondary skin infection with the fungus, P. destructans, 
substantially increases the level of viral RNA in the intestine of hibernating bats. We showed that 
infection of the skin with P. destructans can cause profound changes in gene expression in the 
intestines, despite a lack of direct contact between intestinal tissue and the fungus. Infection with 
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P. destructans causes modulation of a number of immune responses, including down-regulation 
of interleukin and cell proliferation genes which may compromise bats’ ability to suppress viral 
activity (Figure 5.5). Taken together, our results have implications for epidemiological studies of 
P. destructans, the WNS fungus and for research into viral spillovers, which should consider the 
potential implications of co-infections that increase viral shedding. 
 
Figure 5.5. Hypothesized model of pathways involved in increased coronavirus shedding and 
white-nose syndrome (WNS) severity in little brown bats (Myotis lucifugus) co-infected with 
M. lucifugus coronavirus (Myl-CoV) and Pseudogymnoascus destructans. Diagram 
summarizes the changes observed by comparing co-infected bats with virus-infected bats. Bats 
with persistent Myl-CoV infection exhibit relatively low viral shedding. When bats are also 
infected with P. destructans (shown in yellow arrow) and develop WNS, the level of coronavirus 
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IL10, which may have an effect on immune response and cell proliferation. The increase in 
coronavirus levels in co-infected bats is possibly due to the bats’ systemic response to WNS 
reducing innate antiviral responses. 
 
Complex strategies allow viruses to remain endemic in populations. These include a 
continuously replenished source of susceptible hosts for viruses that cause short-term acute 
infections with long-lasting immunity (e.g. measles virus), antigenic drift of virus (e.g. influenza 
virus) or waning immunity (e.g. respiratory syncytial virus) that allows reinfection, and long-
lasting latent (e.g. herpesviruses) or persistent infections (e.g. pestiviruses) with sustained or 
periodic shedding. It is not yet clear how bat viruses are maintained in their natural host 
populations, or how they avoid extinction as host populations become immune and less 
susceptible. Persistent infections can be established in cultured cells with viruses that may have 
originated in bats, including Ebola virus [219] and SARS-CoV [221,261,262], but whether these 
viruses persist in their primary hosts is not known. Studies of persistence of bat viruses in infected 
bats have produced equivocal results. The lack of direct evidence supporting specific models of 
persistence or transmission dynamics represents a major knowledge gap in bat-virus ecology [12].  
We maintained M. lucifugus in controlled laboratory hibernation chambers for four months 
during these experiments, and we detected the coronavirus i.e. Myl-CoV, at the end of hibernation. 
These data imply that the coronavirus can persist in its host for at least the duration of hibernation, 
particularly as nucleotide variability among the detected coronavirus isolates showed that spread 
of coronavirus among bats within a chamber was unlikely [44]. In an extensive study of New 
World Alphacoronaviruses, no target viruses were detected in the rectal swabs of individual bats 
sampled over time [217], suggesting that persistence and intensity of shedding varies among 
species or viruses. The authors concluded that the targeted coronaviruses do not persist in their 
hosts but are maintained in populations by the introduction of new susceptible individuals. 
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However, their results could also reflect viral persistence in individual animals, with low baseline 
levels of virus replication and undetectable shedding interspersed with periods of increased 
replication and shedding that did not occur during the sampling period.  
Periodic or seasonal increases in virus shedding associated with parturition, lactation, 
nutritional deprivation or environmental stress [12,246] suggest persistent or latent viruses may be 
activated by hormonal or other systemic cues. Direct evidence linking a specific trigger to 
increased shedding has not yet been found. However, viral replication in rodent and bat cells 
persistently infected with Ebola virus increased greatly following modulation of the Ras/MAPK 
pathway with lipopolysaccharides or phorbol esters, and with the resulting suppression of the cells’ 
interferon response [219,261,262]. In experimental systems, the immune modulatory cytokine 
IL10 also influences viral persistence and replication [263–265], although more study is required 
to clarify the effects of circulating cytokines on the replication of persistently infecting viruses. 
Nevertheless, these results suggest that circumstances which induce anti-inflammatory cytokines 
or suppress antiviral innate responses, may provide a trigger for increased shedding of persistently 
infecting virus.  
We discovered that bats with WNS (fungus-infected and co-infected) had significantly 
lower intestinal levels of transcripts for IL22RA1 and other interferon-related genes as compared 
to uninfected bats, and we observed the same trend in IL10 (although it was not significant; p value 
= 0.07). IL22RA1 is the receptor present on host cells, including intestinal cells, which help in 
initiating cellular signalling in response to IL22 produced by T-cells [266]. IL-22 leads to an 
increase in anti-microbial peptide production, cellular protection against damage and increases 
cellular proliferation [267]. Therefore, reduced IL-22 signalling in the intestines of bats with WNS, 
might suppress the bat defences that control the coronavirus infection. Additionally, previous 
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studies have shown that the anti-inflammatory gene, IL-10, is expressed more in the lungs of bats 
with WNS than in bats without it [253]. We saw a similar trend with the levels of IL-10 in the 
intestines which might play a role in suppressing the immune response against the coronavirus. 
Another altered cytokine gene which was of interest was the suppressor of cytokine signalling-6 
(SOCS6) gene. Fungal-infected bats showed lower levels of SOCS6 transcripts, lack of which has 
been implicated in mild growth retardation in mice [268]. Overall, our results suggest that WNS 
triggers changes in gene expression in the ileum (Figure 5.5). These may influence expression of 
interferon-stimulated-genes (ISGs), thereby leading to increased viral replication at the site of viral 
persistence. Interferon-related transcripts were more highly expressed in the ileum of virus-
infected bats that did not have WNS, suggesting that the bat’s response to WNS causes down-
regulation of interferon activity. Interferons may control coronavirus replication, as seen in cases 
of SARS-CoV [269] and MERS-CoV [270]. Therefore, a decrease in interferon activity might 
cause an increase in coronavirus (Myl-CoV) replication. In addition to interferon-related genes, we 
also found that RERG, which is related to growth inhibition, was upregulated in the fungus-
infected bats when compared to virus-infected bats. Upregulation of RERG could affect the rate 
of cell proliferation in the intestines [271]. Finally, this cascade of responses is associated with 
increased severity of WNS symptoms. 
Bats with WNS experience a range of systemic disturbances including dehydration, 
hypovolemia, metabolic acidosis and fat depletion [59,60], neutrophil infiltration of the lung 
interstitium, and increased expression of transcripts related to anti-microbial and pro- and anti-
inflammatory cytokines [253]. Taken together, this evidence suggests that hibernating bats respond 
systemically to superficial fungal infection, and this hypothesis is further supported by our 
observations of altered gene expression in the ileum of fungus-infected bats. 
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Based on our results, we propose a model for how secondary infections may increase the 
replication and subsequent shedding of persistently infecting virus (Fig. 5). The establishment of 
WNS (or other secondary infection) impacts the tissue with which that pathogen interacts (in the 
case of P. destructans, the skin). Direct interactions between the host and the secondary pathogen 
are limited to the affected tissue, but the systemic response to the disease triggers a cascade of 
immune responses, including increased release of cytokines or neutrophils. Affected cells such as 
intra-alveolar macrophages in the lungs or cells lining the intestine, may produce pro- or anti-
inflammatory molecules and influence cells that harbour viral genomes. This cascade of host 
responses disrupts the equilibrium between the persistently infecting virus and the cell’s innate 
immune response, leading to a dramatic increase in the expression of coronavirus (Myl-CoV) 
replication. 
Our assays were unfortunately limited to analysing viral and cytokine transcripts rather 
than protein, because reagents for detecting bat viral and host proteins are not yet available. We 
were not able to perform serial dilutions of the plasma to precisely quantify antiviral titre due to 
the limitation in the amount of plasma obtained from each bat. The sample size was also small for 
this assay, because only 7 of the sampled bats had detectable levels of coronavirus in their 
intestines and were positive for viral antibodies. Despite these limitations, we demonstrated higher 
antibodies against the coronavirus in the plasma of co-infected bats when compared with virus-
infected bats. This increased antibody level in co-infected bats might reflect an adaptive immune 
response to increased coronavirus replication in the intestines.  
Our proposed hypothesis for the mechanism driving increased viral replication following 
pathogenic co-infection was worth testing, but our results are also consistent with an alternative 
hypothesis. Increased viral replication or viral load may affect the severity and population-level 
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impacts of WNS. Bat mortality following the arrival of WNS varies widely from site to site, with 
populations decreasing from 30% to 99% [250]. Variation in the microclimate, and other 
ecological factors may drive some of this variation [272], but our data suggest that cryptic viral 
infections may also play a role in determining survival rates for bats hibernating in sites colonized 
by P. destructans. We recommend that future studies on population-wide impact of WNS 
incorporate viral sampling to help better understand the role of co-infections on bat populations in 
the wild.  
 
5.9. Suplementary Information 
 
Supplementary figure S5.1. Pairwise differential gene expression enriched for various gene 
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Table S1. Read statistics of RNASeq samples. 
Table S2. Differentially expressed genes determined by DESeq2 for the Negative (mock-infected) vs. MylCoV comparison. 
Table S3. Differentially expressed genes determined by DESeq2 for the Negative (mock-infected) vs. P. destructans comparison. 
Table S4. Differentially expressed genes determined by DESeq2 for the Negative (mock-infected) vs. Coinfected comparison. 
Table S5. Differentially expressed genes determined by DESeq2 for the MylCoV vs. P. destructans comparison. 
Table S6. Differentially expressed genes determined by DESeq2 for the Coinfected vs. MylCoV comparison. 
Table S7. Differentially expressed genes determined by DESeq2 for the Coinfected vs. P. destructans comparison. 
Table S8. Gene Ontology Enrichment Analysis (g:GOSt) summary using DESeq2 determined differentially expressed genes (>2 fold 
change, FDR<0.05). 
Table S9. Details of primers used for PCR 
 
5.10. Transition statement 
In this chapter, I described our studies showing that the extent of P. destructans-induced 
pathology in bat wings correlated with the amount of coronavirus in their intestines. Furthermore, 
the intestine of fungus-infected bats showed changes in gene expression suggesting suppressed 
innate anti-virus and increased apoptotic responses. To determine if these changes influenced the 
virus-host cell relationship in cells persistently-infected with the virus, we established a persistent 
coronavirus infection in cultured bat cells. Since we had not been able to isolate Myl-CoV, for 
these experiments we used the MERS-CoV, a virus thought to have originated in insectivorous 
bats. This cell culture model of coronavirus persistence allowed us to test the hypothesis that 
MERS-CoV would establish long-term persistent infections in bat cells because of the virus’ 
inability to completely suppress the host anti-viral responses, and that forced suppression of these 





Chapter 6: Host specific adaptations of Middle East Respiratory Coronavirus 
(MERS-CoV) for persistent infection of bat cells 
6.1. Citation 
Banerjee, A., S. Subudhi, N. Rapin, R. Jain, J. Lew, D. Falzarano and V. Misra. “Persistent 
infection of insectivorous bat cells with Middle East respiratory syndrome coronavirus.” 
Manuscript under preparation. AB and I contributed equally to the study and are co-first authors. 
 
6.2. Contribution 
 Several authors contributed significantly to this study. AB and I contributed equally to 
the work described in this chapter. AB and I prepared the initial draft of the manuscript and all 
authors were involved in editing and refining the manuscript. I designed experiments, performed 
in-situ hybridization, designed primers, quantitated RNA using real time PCR and analysed 
sequencing data. AB setup the initial persistent infection in bat cells and repeated the experiment. 
AB and NR performed cell culture related assays with MERS-CoV in level 3 lab. AB performed 
immunoblots, immunofluorescence imaging and siRNA knockdown. RJ, JL and DF performed 
sequencing of the mutated MERS-CoV. 
 
6.3. Abstract 
Many viruses that cause no apparent disease in their natural bat hosts are thought to have 
spilled over into people and other animals causing serious and often fatal illness. Coronaviruses 
such as those causing Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory 
Syndrome (MERS) may also have originated in bats as closely related viruses have been detected 
in insectivorous bat species. The mechanisms by which viruses are maintained in individuals or 
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populations of reservoir bat hosts is not known, but may involve long-term persistent infection 
with continuous low-levels of shedding and infection of susceptible individuals. The adaptations 
required for the viruses to infect and establish infections in spillover species are also not clearly 
understood. Here we describe the long-term persistent infection by MERS-coronavirus (MERS-
CoV) in bat cells. Continued survival of the cells, accompanied by low levels of virus production, 
was depended on the inability of the virus to suppress cellular innate responses. Knocking down 
of interferon response factor 3 (IRF3), a critical mediator of the antiviral response, increased virus 
replication in the cells and resulted in their death. Persistence of virus replication in bat cells led 
to rapid selection of MERS-CoV variants with inactivating mutations in the viral open reading 
frame 5 (ORF5). Our results support the hypothesis that at a low multiplicity of infection, cells 
infected by rare ORF5 mutants survive because higher levels of expression of interferon and 
interferon stimulated genes suppress apoptosis. The ORF5 mutant-infected cells then resist 
infection by wild-type virus, quickly supplanting virus with functional ORF5. Our studies may 
provide a model for examining stressors that may unbalance the delicate virus-host relationship in 
reservoir bat species leading to increased chances of spillover to other animals.   
 
6.4. Introduction 
Viruses, on rare occasions, spillover from reservoir species to other animals. Establishment 
in these new hosts requires viruses to adapt to the use of viral receptors as well as circumvent 
innate antiviral defense mechanisms unique to each host species. The mechanisms underlying 
these changes that govern new virus-host dynamics are not clearly understood. Bats have been 
speculated to be reservoirs of several emerging viruses, including coronaviruses (CoVs) that cause 
severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) in 
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humans, and porcine epidemic diarrhea (PED) and swine acute diarrhoea syndrome (SADS) in 
pigs [1,20,133,273]. MERS-CoV is an on-going concern as it causes periodic outbreaks in the 
Middle East with a mortality rate of about thirty-five percent [123]. Human to human transmission 
of the virus occurs through aerosol or close contact. Camels are known to harbor MERS-CoV and 
play an important role in the transmission of the virus to humans [141,274]. Although camels are 
the direct source of MERS-CoV infection, bats are considered as the evolutionary source of such 
coronaviruses. MERS-CoV belongs to betacoronavirus lineage C (2c) and several 2c 
coronaviruses, such as HKU4, HKU5 and NeoCoV, have been detected in bats [192,275]. 
Coronaviruses, such as MERS-CoV, are able to rapidly adapt to the species which they infect. 
Such adaptations usually occur in the spike protein as its interaction with host receptor is necessary 
for infection [276,277]. Coronavirus adaptations in genes, apart from spike, that are driven by 
factors of their bat reservoir host, are less well known. Although bats harbor such coronaviruses, 
they do not cause obvious signs of disease in bats.  In contrast, infection in spillover species such 
as humans and pigs, leads to disease with significant morbidity and mortality [39,122,199,278–
281].  
To understand the emergence of coronaviruses from bats, a more thorough understanding 
about the bat-virus relationship is needed. Currently, much of the information about these viruses 
derives from observations in the spillover species or from experimental animals; little is known 
about the molecular processes that govern the relationship of the viruses with their bat hosts. One 
of the studies conducted in our lab has shown that bat coronaviruses can persist in their natural 
host for at least four months of hibernation [44]. This persistent infection could be affected by 
stressful events such as secondary fungal infections [62]. Viral persistence in bats and its disruption 
 
 94 
during stressful events has been observed for other viruses such as henipavirus [282]. Further 
studies would help elucidate the molecular pathogenesis behind this phenomenon. 
Members of coronavirus family possess a high level of variability, specifically in their 
accessory proteins. These proteins are not required for replication but provide vital functions 
within the context of infection in a particular host. Primarily, these proteins are required for 
antagonizing the host response against the virus [283]. The MERS-CoV accessory proteins ORF4a 
and ORF4b are responsible for inhibiting the type I interferon response [283] and ORF5 has been 
shown to modulated the NF-kB pathway [284]. Despite these studies in cultured cells, interactions 
of these accessory proteins in their evolutionary ancestral bat hosts, is not fully understood. 
As insectivorous bats are thought to be the ancestral hosts of coronaviruses, studying the 
mechanisms that lead to persistent infections in bats will provide clues about how bats can harbor 
different coronaviruses. In this study, we sought to identify unique coronavirus and host factors 
that enable a long-term persistent infection in cultured bat cells. We show for the first time that 
cells from an insectivorous bat can be persistently infected with MERS-CoV over a period of 
several months and disrupting the interferon response factor 3 (IRF3) signaling or MAP kinase 
pathways leads to an increase in virus replication in these cells. Although growth in bat cells led 
to point mutations in several genes, inactivating mutations in the ORF5 gene were observed 
repeatedly. Our results suggest a mechanism for the benign relationship of coronaviruses with their 




6.5. Materials and methods 
6.5.1. Cell culture 
Eptesicus fuscus kidney cells [213] (Efk3 or bat cells) were grown in Dulbecco’s Minimal 
Essential Medium with GlutaGro (DMEM; Corning. Cat #MT10017CV) containing 10% fetal 
bovine serum (FBS; Sigma, Cat #F0392), penicillin/streptomycin (Gibco, Cat #15140122) and 1% 
GlutaMax (Gibco, Cat #35050061). Vero E6 (green monkey kidney; ATCC, Cat #CRL-1586) cells 
were grown in DMEM supplemented with 10% FBS and penicillin/streptomycin. Cells were 
incubated in a humidified incubator at 37°C with 5% CO2. 
6.5.2. Virus infection 
All work with MERS-CoV was performed under biosafety containment at Vido-intervac 
at University of Saskatchewan and was approved by the institutional biosafety committees. MERS-
CoV (isolate hCoV-EMC/2012 [285]) was propagated in Vero E6 cells in DMEM (Sigma) 
supplemented with 10% fetal bovine serum, 50 U/ml penicillin and 50 µg/ml streptomycin (Gibco, 
Cat #15140122).   
For establishing persistent infection, Efk3 cells were seeded at a concentration of 3 x 105 
cells/well in one well of a six well plate. The cells were infected with MERS-CoV (strain 
EMC/2012) at a multiplicity of infection (MOI) of 0.01. Growth medium on the cells was replaced 
regularly and surviving cells were split using 0.25% trypsin (Sigma, Cat #20233). Supernatant 
from each passage was saved at -80°C for virus titration. For acute infection, Efk3 cells were 
seeded at a concentration of 3 x 105 cells/well in a six well plate. The cells were infected with 
MERS-CoV (strain EMC/2012) at a multiplicity of infection (MOI) of 10 TCID50/ml. Virus 
infection and experiments with live MERS-CoV was carried out in a containment level 3 facility. 
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Following inactivation of the virus, other relevant studies were conducted in a containment level 
2 laboratory.  
6.5.3. Virus titration 
Supernatant from persistently infected bat cells were titrated in triplicates on Vero cells 
using tissue culture infectious dose 50 (TCID50) assay. Briefly, 10
4 cells were seeded in each well 
of a 96-well plate. The plates were incubated overnight to obtain a confluent layer of Vero cells. 
The virus sample (supernatant) was diluted ten-folds and 50µl of the diluted virus sample was 
added to each well of the 96-well plate. The plates were incubated at 37°C for 1hr. After 
incubation, the virus containing supernatant was discarded and 100µl of complete media with 5% 
FBS was added to the plates. The plates were incubated at 37°C for three days. The plates were 
incubated for 3 days and cytopathic effect was observed under a light microscope. Tissue culture 
infectious dose 50/ml (TCID50/ml) was calculated using the Spearman and Karber algorithm 
[286,287]. 
6.5.4. Immunoblot 
Persistently infected Efk3 cells were seeded at a concentration of 3x 105 cells/well in six 
well plates and incubated at 37°C overnight. Next day, cells were harvested in sample buffer for 
immunoblots. Immunoblots were carried out as previously mentioned [288]. Briefly, samples were 
denatured in a reducing sample buffer and electrophoresed on a reducing gel. Proteins were blotted 
from the gel onto polyvinylidene difluoride (PVDF, GE Healthcare, Cat #10600023) membranes 
and detected using primary and secondary antibodies. Primary antibodies used were: 1: 1,000 
mouse anti-GAPDH (EMD Milipore, Cat #AB2302) and 1: 1,000 rabbit anti-MERS-CoV N 
protein (Sino Biological, Cat #40068-RP01). Secondary antibodies used were: 1:10,000 goat anti-
mouse Alexa 488 (Molecular Probes, Cat #A-11001) and 1: 10,000 goat anti-rabbit Cy5 (GE 
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Healthcare, Cat #PA45012). Blots were observed and imaged using a Typhoon Scanner 
(Amersham Biosciences). 
6.5.5. Electron microscopy 
Persistently infected Efk3 cells were scraped in phosphate buffered saline and pooled in a 
15ml screw-cap centrifuge tube. The cells were recovered by centrifugation at 300xg for 5 mins 
and the supernatant was discarded. The cell pellet was resuspended in 10% neutral buffered 
formalin (10% NBF; Sigma, Cat #HT501128) for virus inactivation. The cells were later processed 
for electron microscopy. Briefly, cells were treated with osmium tetroxide (1% OsO4, 0.1 M 
sodium cacodylate buffer) for one hour at room temperature. Samples were quickly rinsed with 
water, gradually dehydrated in ethanol and en-bloc stained with uranyl acetate. After rinsing three 
times (5 min each) in propylene oxide, samples were infiltrated with Epon/Araldite (electron 
Microscopy Sciences, Cat #50-980-381). samples were placed in molds and freshly prepared 
Epon/Araldite was added. The samples were then polymerized at 60°C for 24–48 h. Sections of 
90 nm were cut and observed by transmission electron microscopy (TEM - Hitachi HT 7700, 
Tokyo, Japan).  
6.5.6. Immunofluorescence 
Persistently infected and mock/acute infected Efk3 cells were seeded at a concentration of 
3x104 cells/chamber in chamber slides (Nunc, Thermo Scientific, Cat #154534). Each chamber 
was harvested at the respective time points by removing media, a quick rise with PBS and addition 
of 10% NBF. 10% NBF was added to inactivate and fix the cells over a period of 48h. After 
removing the cells from containment, cells in each chamber were washed twice with phosphate 
buffered saline (PBS). The slides were permeabilized using 0.2% TritonX-100 (VWR, 97062-208) 
diluted in PBS for 5 minutes. Cells were incubated in a blocking solution [PBS, 10% donor calf 
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serum (Sigma, Cat #C9676) and 0.1% Tween 20 (Fisher Bioreagents, Cat #BP337-500)]. Primary 
staining for MERS-CoV nucleoprotein (N) and GAPDH was performed using 1:100 dilution of 
rabbit anti-MERS-CoV N (Sino Biological, Cat #40068-RP01) and mouse anti-GAPDH (EMD 
Milipore, Cat #AB2302). Secondary staining was performed using 4μg/ml goat anti-mouse Alexa 
488 (Molecular Probes, Cat #A-11001), 0.1μg/ml goat anti-rabbit Cy5 (GE Healthcare, Cat 
#PA45012) and 0.2μg/ml Hoechst 33342 (Molecular Probes, Cat #H3570) in blocking solution. 
Cells were observed under an Olympus IX83 fluorescence microscope.  
6.5.7. In-situ hybridization 
As for immunofluorescence, persistently infected and mock/acute infected Efk3 cells were 
seeded at a concentration of 3x104 cells/chamber in chamber slides (Nunc, Thermo Scientific). 
Each chamber was harvested at the respective time points by removing media, a quick rise with 
PBS and addition of 10% NBF. 10% NBF was added to inactivate and fix the cells over a period 
of 48h. MERS RNA was detected in the cells using ViewRNA ISH tissue 2-plex assay kit 
(Affymetrix, Thermofischer Scientific, Cat #QVT0012) and probes targeting MERS nucleocapsid 
sequence (Thermofischer Scientific, United States) as per manufacturer’s instructions, with the 
exception of xylene treatment of slides, which was omitted. Counterstaining of cells was done 
using Gill’s hematoxylin I (Sigma Aldrich, Cat #GHS-132). Coverslips were applied at the end of 
the assay and images were taken using brightfield microscope with 20X and 40X objectives. 
6.5.8. RNA extraction, cDNA preparation and quantitative real-time PCR (qRT-PCR) 
All RNA extractions were performed using the RNeasy Plus Mini kit (Qiagen, Cat #74136) 
as per manufacturer’s instructions. cDNA was prepared using iScript gDNA clear kit (Bio-Rad) as 
per manufacturer’s instructions. 500ng of RNA was used for cDNA preparation.  cDNA was used 
as a template for the quantification of target genes.  
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Quantitative real-time polymerase chain reaction (qRT-PCR) assays amplifying targeted 
cellular genes and the normalizer gene (Glyceraldehyde-3-phosphate; GAPDH) were performed 
for both MRC5 and Efk3 cells. Primer sequences are listed in Suplementary table S6.1. Primers 
for quantifying GBP1, IL8, Mx1, IRF3, MDA5, IRF7, TNFa and IFI6 were used as mentioned in 
Banerjee et al [29]. Bio-Rad’s CFX96  Touch PCR thermocycler was used in conjunction with 
Bio-Rad’s Ssofast Evagreen supermix (Bio-Rad, Cat #1725204) and samples were prepared as 
previously mentioned [253]. For qRT-PCR, after the initial denaturation step of 95°C for 5 minutes, 
two step cycling for 40 cycles was performed at 95°C/10s, 56°C/30s. Absorbance readings were 
acquired after each cycle. The final three steps were carried out at 95°C/1min, 55°C/30s and 
95°C/30s to generate the dissociation curve. Absorbance readings for the dissociation curve were 
acquired at every degree from 55-95°C. Relative fold change in gene expression was calculated 
after normalizing the Ct values using GAPDH. Difference of one Ct indicates a two-fold difference 
in gene expression. Graphs were plotted using GraphPad prism version 7. 
6.5.9. IRF3 knockdown and MAP kinase inhibition 
Dicer-ready siRNA (DsiRNA) specific to big brown bat and human IRF3 was designed 
and obtained through Integrated DNA Technologies (IDT). A 100nM final concentration of a 1:1 
mixture of two DsiRNAs per cell line (Table S1) targeting separate regions on the big brown bat 
IRF3 transcript was transfected into persistently infected Efk3 cells using Lipofectamine 2000 
(Invitrogen, Cat #11668019). Scrambled non-specific DsiRNA (NC DsiRNA; IDT) was used as a 
negative control.  
For MAP kinase inhibition, URMC-099 drug (Cayman chemicals, Cat #1229582-33-5) 
was used at a concentration of 1µM [289]. DMSO (1µM) was used as a negative control. Cells 
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were harvested after 24 and 48 hours and virus replication was quantified using MERS-CoV UpE 
primers and qPCR. 
6.5.10. Sequencing MERS-CoV 
cDNA was prepared using random hexamers and SuperScript III reverse transcriptase 
(ThermoFisher Scientific, Cat #18080044) according to the manufacturer's protocol. The genome 
was amplified in ~600-2000 bp overlapping fragments using iProof High-Fidelity DNA 
polymerase (Bio-Rad, Cat #1725301). Each PCR reaction was purified using QIAquick PCR 
Purification (QIAGEN, Cat #28104) or GenepHlow kits (Geneaid, Cat #DFH100). DNA was 
quantified and subjected to Sanger sequencing using the previous PCR as well as internal primers. 
6.5.11. Cloning MERS-CoV ORF5 
Conventional PCR was carried out to amplify MERS-CoV ORF 5 with restriction sites 
KpnI and BamHI from Efk3-MERS-CoV cDNA using ORF5 (full length) primers. Red fluorescent 
protein (RFP) with restriction sites BamHI and XhoI was amplified from pcDNA3-mRFP using 
mRFP primers. PCR was performed using the following thermal cycle profile: initial denaturation 
for 3 min at 94°C, 35 PCR cycles at 94°C/30s, 56°C/30s and 72°C/1min. The final extension was 
at 72°C for 10 min. The two PCR products were ligated into a pcDNA3 backbone that was digested 
with KpnI and XhoI. Plasmid resulting from the double ligation was used to transform DH5a 
E.coli cells. The bacterial cells were plated on 2YT plates with ampicillin. Resistant bacterial 
colonies were scanned for plasmids carrying the ORF5-RFP insert. Positive clones were amplified 
in broth culture. Plasmids were later purified and concentrated using a MaxiPrep kit (QIAGEN, 




Significance of the data was determined by two-tailed Mann Whitney U test for non-
parametric independent samples using IBM SPSS (Version 21).  
 
6.6. Results 
6.6.1. MERS-CoV persistently infects insectivorous bat cells 
 To investigate if MERS-CoV could persistently infect cells from an insectivorous bat, we 
infected big brown bat (Eptesicus fuscus) kidney cells (EfK) [213] with a low multiplicity of 
infection (MOI) of 0.01 TCID50/cell (Figure 6.1. (A)). Twelve days after infection, most of the 
cells were dead (Figure 6.1. (C)). We passaged the surviving cells and titrated the amount of virus 
in the supernatant every week. During the first 35 days of infection, the amount of virus produced 
by cells was variable (Mean = 2.98 x 104; coefficient of variation = 105.4%) but after the 42nd day, 
we detected a relatively low but stable amount of infectious virus produced in the growth 
supernatant (Mean = 1.5 x 104; coefficient of variation = 58.8%) (Figure 6.1. (B)). In comparison, 
human cells (MRC5) could not be persistently infected with MERS-CoV as all cells died several 
days after infection (data not shown). To determine if the persistently infected bat cells expressed 
viral proteins, we performed immune blots on cell lysates to detect MERS-CoV nucleoprotein (N). 
We detected N protein in cell lysates from every passage that was analysed (Figure 6.1. (E)). We 
also looked for virus particles in persistently infected bat cells by electron microscopy. We 
observed coronavirus-like particles in Golgi bodies and secretory vesicles of persistently infected 




Figure 6.1. Bat cells can be persistently infected with MERS-CoV. (A) Big brown bat kidney 
cells (Efk3B) were infected with MERS-CoV (MOI = 0.01 TCID50/cell) for 12 days and then 
passaged weekly. Samples were obtained during passages to determine the presence of virus by 
TCID50 assay, immunoblot and electron microscopy. (B) Levels of MERS-CoV at different time 
points following initial infection. (C) Phase contrast micrographs showing the cytopathic effect of 
MERS-CoV and subsequent recovery of the cells at various time points. (D) Electron micrograph 
showing the presence of particles similar to viral nucleocapsid (approximately 80 nm in size) in 
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persistently infected cells (red arrows). (E) Immuno blot showing the presence of MERS-CoV N-
protein at passage 4, 5 and 6. The house-keeping protein, GAPDH is shown as a control.  
 
6.6.2. MERS-CoV infects all bat cells in varying levels 
 To determine if all cells in our persistently infected cell population were infected, or if 
persistence was maintained by small numbers of lytically-infected cells producing virus to 
subsequently infect susceptible cells, we analyzed these cells for transcript and protein of the 
MERS-CoV N gene (Figure 6.2. (A)). Most of the persistently infected cells expressed very low 
levels of N protein compared to cells in an acutely infected culture (infected at a high MOI). A 
few cells expressed high levels of N protein (Figure 6.2. (B)). Consistent with our 
immunofluorescence data, we detected by in-situ hybridization varying levels of MERS-CoV N 
RNA in all cells in the persistently infected culture. We observed three types of cells in the 
population of cells persistently infected with virus based on the intensity of staining, we classified 




Figure 6.2. MERS-CoV RNA and protein can be detected in persistently infected cells. (A) 
Persistently infected bat cells with MERS-CoV were seeded in chamber slides for in-situ 
hybridization (ISH) and immunofluorescence assays (IFA). (B) IFA images to detect the presence 
of nucleocapsid protein in persistently infected bat cells (bottom row; red arrows). Acutely infected 
(middle row) and mock infected cells (top row) were considered as positive and negative controls 
respectively. (C) In-situ hybridization to detect the presence of MERS-CoV nucleoprotein RNA 
in persistently infected cells. High, intermediate and low levels of MERS-CoV nucleoprotein RNA 
have been highlighted. Acutely infected (right) and mock infected cells (left) were considered as 




6.6.3. All MERS-CoV genes are expressed in bat cells except ORF5 
 Persistent infection is often accompanied by altered levels of gene expression as the 
pathogen and the host establish a delicate balance between cytolytic viral factors and host defense 
responses. To determine if there were differences in MERS-CoV gene expression between acute 
and persistently infected bat cells, we infected bat cells with MERS-CoV (MOI = 10 TCID50/cell; 
acute infection) and compared virus gene expression with that of persistently infected cells at 0, 
12, 24 and 48 hours post infection (hpi) (Figure 6.3. (A)). For persistently infected cells, the time 
points in the figure indicate when RNA from these cells was harvested after seeding them in six-
well plates. MERS-CoV genes S, E, M, N, ORF3, 4a, 4b and 5 in acutely infected cells showed 
increasing levels of expression over time (Figure 6.3. (C-J)). This was concomitant with an 
increase in MERS-CoV genome quantities (UpE levels) (Figure 6.3. (B)) in acutely infected cells. 
In contrast, persistently infected bat cells maintained steady levels of genome (UpE) quantities 
and, with the exception of ORF5, of RNA from the various viral genes (Figure 6.3. (B-J)). We 
were unable to detect ORF5 mRNA in persistently infected bat cells. 
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Figure 6.3. MERS-CoV gene expression varies between acute and persistently infected bat 
cells. (A) RNA from persistently infected cells and acutely infected cells were harvested at several 
time points and processed for cDNA synthesis and real time PCR. (B-J) Graphs showing the gene 
expression (- (DCTgene-DCTGAPDH)) of MERS-CoV- UpE, S, ORF3, ORF4a, ORF4b, ORF5, E, M 
and N genes in acute (green) vs. persistent (purple) infections at 0, 12, 24 and 48 hours post-
infection or seeding (n=4, Mean±SD). (n = number of biological replicates; SD = standard 
deviation) 
 
6.6.5. Adaptation of MERS-CoV in bat cells 
 The MERS-CoV isolate used in our experiments was derived from a human infection and 
was subsequently propagated in primate cells. To determine if continuous growth in insectivorous 
bat cells leads to the selection of variants better adapted for replication in bats, we sequenced the 
genome of the virus from persistently infected bat cells that had been passaged 15 times over a 
period of 6 months.  We observed point mutations in various genes of the bat-adapted virus (Figure 
6.4. (A)), specifically in polymerase, spike and matrix genes. In addition, we observed a 347bp 
deletion in ORF5. The remaining ORF5 sequence in the bat-adapted MERS-CoV strain would 
only encode a putative 20 amino acid long protein. To identify when the ORF5 deletion mutant 
was selected during the establishment of persistently infected bat cells, we sequenced ORF5 from 
multiple early and late passage cells. We could detect the deletion in ORF5 as early as passage 2 
in the persistently infected bat cells (supplementary figure S6.1). In the following portion of this 
article we refer to the original human-derived virus as the MERS-CoV wild-type (W+) virus and 
the ORF5 deleted variant as the ORF5 mutant virus.  
 To determine if the establishment of a persistent MERS-CoV infection, and the subsequent 
selection of viral variants was reproducible, we again infected bat cells with the W+ MERS-CoV 
at a low MOI. We also recovered ORF5 coding sequences from passages 2, 3 and 4. In sequences 
obtained as early as passage 2 we observed a point mutation which resulted in a stop codon that 
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would lead to the termination of the protein at amino acid 107 (out of 225, Supplementary data 
S6.1).  
To determine if sequence variation led to changes in growth characteristics of the virus, we 
infected bat and human cells with W+ and mutant MERS-CoV, and we found that the mutant 




Figure 6.4. Sequence adaptation of MERS-CoV affecting growth characteristics. (A) Diagram 
showing the mutations (red arrows) in the MERS-CoV genome that were identified by sequencing 
the virus from persistently infected bat cells (Passage 15). (B) Comparing the growth of wild type 
and mutant MERS-CoV in bat and human cells. The 4 bars represent the level of MERS-UpE gene 
(- (DCTgene-DCTGAPDH)) with respect to uninfected cells. The mutant MERS-CoV (red) grows 
better in bat cells whereas the wild type MERS-CoV (green) grows better in human cells. (n=4, 
Mean ± SD)  
 
6.6.6. Differences in the fitness of mutant MERS-CoV in bat cells could be driven by 
interferon stimulated genes 
We had previously reported [290] that in contrast to its ability to suppress innate antiviral 
responses in human cells, MERS-CoV in bat cells induces a robust interferon response. Since the 
ORF5 mutant grew better in bat cells than W+ MERS-CoV, we examined whether this may be 
related to differences in their ability to induce cellular innate responses. We compared the levels 
of transcripts for interferon beta (IFNb) and IFN-induced genes: guanylate binding protein 1 
(GBP1), interleukin 8 (IL8), myxovirus resistance 1 (Mx1), interferon regulatory factors 3 and 7 
(IRF3 and 7), melanoma differentiation-associated protein 5 (MDA5) and interferon inducible 
protein 6 (IFI6) in human and bat cells infected with W+ or ORF5 mutant viruses.  
Bat cells infected with the ORF5 mutant contained significantly (p≤0.05) higher levels of 
transcripts for IFI6 (Figure 6.5 (B)) and MDA5 (Figure 6.5 (E)). While differences in the levels of 
the other genes were not significant (p = 0.08 to 0.13), in all cases there was a trend towards higher 
levels in the ORF5 mutant - infected cells. There were no noticeable differences between human 
cells infected with the mutant and W+ viruses. 
When comparing the effect of the viruses in human and bats cells – the W+ virus, consistent 
with our earlier reports [290], induced TNFa in human but not in bat cells (data not shown). The 
W+ virus induced IFI6 in bats cells but not in human cells (Figure 6.5 (B)). Similar to the W+ 
 
 109 
virus, the levels of most ISG transcripts in ORF5 mutant-infected cells were higher in bat cells 




Figure 6.5. Comparing innate immune related gene expression in bat (Efk) and human 
(MRC5) cells in the presence of wild type vs mutant MERS-CoV. Variation in gene expression 
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observed for interferon-b (A) and interferon stimulated genes, IFI6, GBP1, Mx1 and MDA5 (B-
E), between bat and human cells. Bars represent average fold changes (2-DDCT) in transcript levels 
as compared with mock-infected cells, normalized to levels of GAPDH in each sample (n=4; 
Mean±SD). 
 
6.6.7. Bat cells persistently infected with MERS-CoV are resistant to superinfection with wild 
type MERS-CoV 
 To explain the replacement of W+ MERS-CoV with the ORF5 mutant in the persistently-
infected cultures, we determined if the cells were resistant to superinfection with the W+ virus. To 
differentiate between growth of W+ and mutant MERS-CoV in the same cell, we examined the 
expression levels of UpE RNA (Figure 6.3 (B)), present in both strains, and ORF5 transcripts, 
specified only by the W+ virus (Figure 6.3 (G)). We observed that when bat cells persistently 
infected with the ORF5 mutant MERS-CoV were infected again with W+ virus (MOI = 0.1 
TCID50/cell), the cells failed to show an increase in UpE expression, suggesting lack of replication 
at 24 and 48 hours post infection (Figure 6.6. (A)). As a control, we infected naïve bat cells with 
the same amount of W+ MERS-CoV and observed that the replication resulted in an increase in 
UpE transcripts at 24 and 48 hours post infection. At 0 hours post infection, the ORF5 transcripts 
in superinfected bat cells (persistent infection + W+ virus) were higher than bat cells persistently 
infected with MERS-CoV, suggesting that the difference was due to the input virus (Figure 6.6. 
(B)). We further observed that the level of interferon-β expression was higher in bat cells 
persistently infected with MERS-CoV than naïve bat cells (p=0.08) and these naïve bat cells, when 






Figure 6.6. Bat cells persistently infected with MERS-CoV are resistant to superinfection 
with wild type MERS-CoV. Bat (EfK) cells persistently infected with MERS-CoV were 
superinfected with wild type virus (blue) and transcripts for UpE (A) and ORF5 (B) were 
measured. The levels for UpE and ORF5 (-(DCTgene-DCTGAPDH)) were also measured in bat cells 
persistently infected with MERS-CoV without additional virus (red) and naïve EfK cells infected 
with wild type MERS-CoV (green) with respect to time 0 of input wild type virus. IFN-β levels 
were also measured in these samples (C). IFN β fold changes were reported with respect to naïve 
uninfected bat cells (n=3, Mean±SD).    
 
6.6.8. Interferon response factor 3 (IRF3) and mitogen associated protein kinase (MAPK) 
signaling regulates persistent infection 
 To determine if the cellular antiviral innate response mediated by the IRF3 signaling 
pathway and IFNb expression played a role in the maintenance of persistent infection in bat cells, 
we compared the IFNb transcript levels in persistently infected cells with that of bat cells that were 
Superinfection of wild type MERS-CoV in EfK cells persistently infected with MERS-CoV
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acutely infected with MERS-CoV (MOI=10 TCID50/cell). We also reduced IRF3 expression in 
persistently infected cells using small-interfering RNA (siRNA) and quantified the amount of virus 
in the supernatant of these cells and mock siRNA treated cells. MERS-CoV infected cells showed 
a significant increase in IFNb transcript levels at 24 and 48 hpi relative to mock infected cells 
(Figure 6.7. (A)). Persistently infected bat cells expressed lower but consistent levels of IFNb 
transcripts (Figure 6.7. (A)). Reducing IRF3 protein levels (Figure 6.7. (B) and 6.7. (D)) in 
persistently infected bat cells significantly increased virus replication in these cells (Figure 6.7. 
(C)). Reducing IRF3 protein levels in the persistently infected cells led to increased cell death 
within 48 hours of siRNA treatment compared to mock siRNA treated persistently infected cells 
(data not shown). 
 In previous experiments, we had observed that in little brown bats with a secondary 
infection with the white-nose syndrome-causing fungus, suppression of the MAPK pathway may 
have led to an increase in coronavirus replication [62]. To test if this pathway played a similar role 
in regulating viral load in persistently-infected cells, we inhibited the MAPK signaling pathway 
using the MAP kinase inhibitor URMC-99 [291]. We observed that the MERS-CoV levels 
increased upon inhibition of MAPK pathway (Figure 6.7. (E)). Expression of Ras superfamily 
protein, RERG, (a MAPK pathway related protein) was altered in the presence of URMC-99, 





Figure 6.7. IRF3 and MAP kinase-mediated signaling regulates persistent infection in bat 
cells. (A) Interferon b levels (Fold change) in acute (green) and persistently (purple) infected bat 
cells at 0, 12, 24 and 48 hours post-infection or seeding. (B) Persistently infected cells were 
transfected with siRNA targeting IRF3 mRNA and the effect on virus replication was measured. 
(C) MERS-CoV titres in persistently infected bat cells 24 hours post treatment with siRNA (red 
bar; n=4, Mean±SD.). Scrambled siRNA (blue bar; nc-siRNA) was used as a negative control. (D) 
Immunoblot for IRF3 (and b-actin) in bat cells treated or mock treated with siRNA. (E) Effect of 
MAPK inhibitor on MERS-CoV transcript levels in bat cells. Quantification of MERS-CoV UpE 
RNA levels after 24 and 48 hours post seeding in cells with the MAPK inhibitor, URMC-99 (red), 
compared to the mock-treated cells (blue). (F) Quantification of IL10 and RERG transcripts after 
48-hours of treatment with URMC-99 shows the effect of the drug. (n = 4; Mean±SD) 
 
6.7. Discussion 
There is growing direct and circumstantial evidence that bats are reservoirs for viruses that 
have spilled over to humans and other mammals. However, little is known about how these viruses 
are maintained in the reservoir individuals and populations, or the adaptations necessary for 
efficient infection, maintenance and spread in the spillover hosts.  
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Viruses may be maintained in reservoir populations by reinfection of partially immune or 
non-immune recovered individuals or by the infection of a continuously replenished sources of 
susceptible individuals. For viruses that engender long-term protective immunity following 
infection, transmission of the virus to susceptible hosts may require long-term persistence of the 
virus in infected individuals that act as a source of infection. 
Successful spillover of a virus to a new host species requires viruses to adapt to the use of 
viral receptors as well as innate antiviral defense mechanisms unique to each host species. It is 
difficult to examine the process by which coronaviruses, such as those that cause SARS, MERS, 
PED and SAD, have adapted to infection and maintenance in bats or in the spillover species - 
humans, camels and pigs. While similar viruses have been detected in insectivorous bat species, 
the “culprit” viruses that initially spilled over have not been isolated or characterized.  
We have attempted to answer questions about the dynamics of the interaction of 
coronavirus with their reservoir and spillover hosts by examining how MERS-CoV, isolated from 
a human infection, adapts to replication in cells from an insectivorous bat. We show the following: 
1) At low multiplicities of infection, the virus established long-term persistent infections in bat 
cells (Figure 6.1) with viral RNA and proteins present in all cells (Figure 6.2). 2) Persistence 
depended on sustained innate antiviral responses (Figure 6.5) and the survival of infected cells that 
continuously produce low levels of progeny virus. Suppression of innate responses in the cells led 
to increased replication of the virus and death of the cells (Figure 6.7). 3) Viral persistence in bat 
cells led to the selection of MERS-CoV variants including the consistent selection of mutations in 
the accessory gene, ORF5 (Figure 6.5). 4) The ORF5 mutant grew more efficiently in bat cells 
than the W+ MERS-CoV (Figure 6.4). In contrast, the W+ virus grew more efficiently in human 
cells. 5) The ORF5 mutant induced a more robust innate response than the W+ virus (Figure 6.5). 
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This included significantly higher amounts of transcripts for IFI6, an anti-apoptotic protein (Figure 
6.6 (B) and (E)) [294]. 6) Cells persistently infected with the ORF5 mutant were resistant to 
superinfection with the W+ virus (Figure 6.6). 
Our results lead us to propose a model for the establishment of persistent MERS-CoV 
infection in bat cells and the rapid selection of variants with inactivated ORF5 (Figure 6.8). 
 
Figure 6.8. Proposed model for establishment of persistent MERS-CoV infection in bat cells. 
As with the stocks of most RNA viruses, the MERS-CoV inoculum is made up of the dominant 
wild-type virus as well as smaller numbers of variants, including variants with inactivating 
mutations in ORF5. The cells infected with the wild-type virus die while the small number of cells 
infected with the ORF5 mutant survive because of a more robust antiviral innate response. 
Apoptosis in these cells is suppressed by IFI6-mediated processes. The ORF5 mutant-infected 
cells are resistant to infection with the wild-type virus, which is soon diluted out. After a process 
of recovery, the ORF5 mutant infected cells survive and take over, leading to a culture of 
persistently infected cells that produce small amounts of virus over time.  
 
Our study shows that MERS-CoV, a virus thought to have originated in bats, can establish 
persistent infections in bat cells. These results do not tell us much about the original bat virus that 
spilled over to camels and then to people. However, our results are consistent with our previous 
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studies [62] which demonstrated that little brown bats are persistently infected with an 
autochthonous coronavirus and that the stress of a fungal infection leads to a suppression of innate 
responses, including IFI6 in the bat intestines – the site of viral persistence and replication. That 
study also demonstrated a suppression in the expression of genes related to the MAP kinase 
pathway in fungus-infected bats. This is also consistent with our current observation that inhibition 
of the same pathway in cells persistently-infected with MERS-CoV, led to an increase in virus 
replication. 
Our study also shows that infection of bat cells with MERS-CoV repeatedly led to the rapid 
selection of mutants with inactivated ORF5. In human cells, MERS-CoV structural proteins, such 
as M, and accessory proteins, such as ORF4a, 4b and 5, are known to effectively inhibit innate 
antiviral responses [283,295]. The virus also induces apoptotic cell death by upregulating Smad7 
and fibroblast growth factor (FGF2) [296]. We have previously shown that in contrast to human 
cells, MERS-CoV is unable to suppress innate antiviral responses in bat cells and here we confirm 
those observations. In addition, one of the interferon induced genes, IFI6, which is expressed in 
bat cells infected with the W+ virus, and to a significantly greater extent in ORF5 mutant, inhibits 
apoptosis pathways [294]. While our study does not identify genetic changes needed for a 
coronavirus to adapt to growth in a different host species, it clearly demonstrates that abrogation 
of a protein, ORF5, provides the virus with growth advantages in bat cells, while the presence of 
the protein assists in growth in human cells. ORF5, along with the other accessory MERS-CoV 
genes ORF4a, 4b and structural proteins, such as M, are known to inhibit an antiviral IFNb 
response in human cells [283,295]. Studies to determine the molecular mechanisms that allow 




6.8. Supplementary information 
Supplementry table S6.1. Sequences of siRNA and primers used for qPCR/conventional PCR 
Target gene Forward primer (5'-3') Reverse primer (5'-3') Product length 
(in bp) 
UpE GCAACGCGCGATTCAGTT GCCTCTACACGGGACCCATA 92 
S TGGTCTTTGCGATGCAGCTA TTGGAAGTCAATCCCGGTGG 238 
ORF3 TGAGAGTTCAAAGACCACCCAC TGATTCTGCAGATGGGACGT 200 
ORF4a GCACTTCATTGCACCCTGTG TGTAGCAACCAAGCGATTCG 127 
ORF4b TTCTGCGCCATGAAGACCTT GGCCGCCATAAGGTTTAAGC 141 
ORF5 TGTTTGACATGCGTTCCCAC TTGCAGGCACGAAAACAGTG 249 
E ATGTTACCCTTTGTCCAAGAAC TTAAACCCACTCGTCAGGTGG 249 
M TCGGTGCTTGTGACTACGAC CCGTAATAGGCGGACTCCTG 165 
N ACCACGAGCTGCACCAAATA ATGGACCCAAACGATGCCAT 277 















    
  5' 
rArArCrCrUrUrGrArCrCrArUrCrArCrUrArGrCrUrUr
CrUrUrGrGrU 3' 
    





    
  5' 
rUrGrArArArUrUrCrCrUrCrUrUrCrCrArGrGrUrUrG
rGrCrArGrGrU 3' 
    
 
Supplementary figure S6.1. Mutations in ORF5 selected when bat cells were persistently 





6.9. Transition statement 
In chapter 4, I described the characterization of the little brown bat coronavirus and our 
observations demonstrated that the virus could persist in its host. In chapter 5, I described our 
observations that the stress of fungal infection leads to a resurgence of virus replication. The study 
suggested that the fungal infection suppressed innate anti-viral responses at the site of viral 
persistence allowing the virus to replicate without hindrance. In chapter 6, using a cell-culture 
model of coronavirus persistence in bat cells, I described our studies to show that viral persistence 
could be disrupted by artificially suppressing the host cell’s innate antiviral response. These 
observations supported our contention that viruses establish long-term persistent infections in bats 
and that stress perturbs this relationship allowing the viruses to replicate more freely. 
To establish that the effect of stress on the disruption of low-level viral persistence held for 
viruses other than coronaviruses, I studied a bat herpesvirus. Herpesviruses establish life-long 
MERS-CoV ORF5 mutations in bat cells
Wild type ORF5 (225 Amino acid)
Mutated ORF5 in persistent infection (1st attempt)
Mutated ORF5 in persistent infection (2nd attempt)
20 Amino acid - short truncated ORF5
107 Amino acid - short truncated ORF5 formed due to mutation
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latent infections in their hosts and reactivate periodically from this quiescent state in response to 
stress. A brown bat herpesvirus would, therefore, allow us to examine the effects of natural internal 
and environmental stressors on bats and their relationship with their herpesvirus. In the next 
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Little is known about the relationship of gammaherpesviruses with their bat hosts. 
Gammaherpesviruses are of interest because of their long–term infection of lymphoid cells and 
their potential to cause cancer. Here, we report the characterization of a novel bat herpesvirus 
isolated from a big brown bat (Eptesicus fuscus) in Canada. The genome of the virus, tentatively 
named Eptesicus fuscus herpesvirus (EfHV), is 166,748 base pairs. Phylogenetically EfHV is a 
member of Gammaherpesvirinae, in which it belongs to the Genus Rhadinovirus and is closely 
related to other bat gammaherpesviruses. In contrast to other known gammaherpesviruses, the 
EfHV genome contains coding sequences similar to those of class I and II host major 
histocompatibility antigens. The virus is capable of infecting and replicating in human, monkey, 
cat and pig cell lines. Although we detected EfHV in 20 of 28 big brown bats tested, these bats 
lacked neutralizing antibodies against the virus. 
 
7.5. Introduction 
In recent years several bat viruses have been discovered, most appear to have little 
deleterious effect on their hosts [297,298]. These unique and benign virus-host relationships are 
likely a byproduct of evolutionary adaptations to flight and long-term associations between the 
bats and their viruses [15]. In addition to simply satisfying scientific curiosity, a better 
understanding of these unique relationships may provide clues to mitigating the much more serious 
pathologic virus-host interactions in other species. 
Gammaherpesviruses are a sub-family of Herpesviridae with a primary tropism for cells of 
lymphoid lineage [77]. Gammaherpesviruses establish latent infections in long-lived lymphoid 
cells and in some cases cause neoplasias, such as Burkitt’s lymphoma and Kaposi sarcoma in 
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humans [299]. One of the challenges in studying the reactivation and pathogenesis of these 
oncogenic viruses is the lack of a suitable animal model [300]. Murine gammaherpesvirus-68 in 
mice, the model used most extensively, is not ideal as the virus is not readily transmitted between 
laboratory mice [301]. Previous studies have shown that bats and primates harbor a large diversity 
of gammaherpesviruses that might have led to higher chances of cross-species transmission from 
these taxa to other mammals [143,302,303]. Therefore, a naturally occurring gammaherpesvirus 
in a readily accessible bat species may provide us with vital information on evolution of these 
viruses and serve as a model for studying pathogenesis. 
Even though there are a few reports of detection of gammaherpesvirus genomes [304–306], 
and a single report of isolation of a gammaherpesvirus from bats [147], knowledge about bat 
gammaherpesviruses is limited. As bats do not appear to normally display viral pathology, 
studying a gammaherpesvirus in its natural bat host may provide information about novel co-
evolutionary adaptations that lead to balanced and benign host-virus relationships.  
Here, we report the discovery, isolation and characterization of a novel bat 
gammaherpesvirus from the lungs of a North American big brown bat (Eptesicus fuscus). We 
provisionally name the virus, E. fuscus Herpesvirus (EfHV). The morphology and protein 
composition of EfHV are similar to those of other herpesviruses. Furthermore, we obtained the 
sequence of its genome, determined its ability to infect cells from several mammalian species and 
characterized its growth characteristics. A comparison of the sequence of EfHV with those of other 
herpesviruses indicates that the virus is closely related to other bat gammaherpesviruses. In 
addition to transducing host cytokine genes like interleukin 10 (IL-10), the EfHV genome is unique 
among gammaherpesviruses in that it contains the coding sequences for four putative host MHC-
I antigens and one MHC-II antigen.  
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7.6. Materials and methods 
7.6.1. Ethics Statement 
All procedures related to the handling and euthanasia of bats were submitted to and 
approved by the Committee on Animal Care and Supply of the University of Saskatchewan Animal 
Research Ethics Board (protocol #20090036) and were in accordance with regulations approved 
by the Canadian Council on Animal Care. 
7.6.2. Bats  
A male bat was submitted to the Canadian Wildlife Health Cooperative (CWHC). Organs 
were harvested for virus isolation. Some tissue was also preserved in 10% neutral buffered 
formalin for histological analysis. The 28 bat samples to determine the prevalence of EfHV were 
obtained from the University of Winnipeg. 
7.6.3. Virus isolation 
Tissues were screened for virus using a standard virus isolation protocol. Various tissues 
of the bat were placed in 250 µl Dulbecco’s modified Eagle’s medium (DMEM, Corning, Cat 
#MT10017CV) supplemented with 10% foetal bovine serum (Sigma-Aldrich, Cat #F0392) and 
penicillin, streptomycin and amphotericin B (Antibiotic-Antimycotic, Gibco, Cat #15290018) in 
tubes containing a stainless-steel ball and silica beads. The tubes were agitated at 30 Hz for 4 
minutes (Retsch Mixer Mill, Fisher scientific, Cat #08-418-241) followed by centrifugation for 3 
min at 16,000 ´g. The supernatants were added to E. fuscus kidney (EfK) cells suspended in 2.5 
ml DMEM supplemented with 50 µg/ml gentamicin (Gibco, Cat #15750060), 1 µg/ml TPCK 
trypsin (Invitrogen, Cat #20233) and 0.2% (w/v) bovine serum albumin (Sigma-Aldrich,Cat 
#A7284) (TPCK medium). The mixture was added to wells of 6 well plates (Greiner Cell Star, Cat 
#M0812). After 4 days, freshly dispersed EfK cells were added to each well. One week later, the 
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cells and supernatant from each well were collected. Portions were saved for RNA extraction, and 
future inoculation and reinfection of EfK cells. Four days later, discrete areas of rounded up cells 
were observed. When all cells had rounded up and detached from the monolayer, the cells were 
collected and a portion of cells were fixed with glutaraldehyde for electron microscopy.  
 Virus was further propagated in EfK cells. To purify virus, culture supernatant was 
separated from the cells and debris by centrifuging twice, 850 ´ g for 5 mins each. Cells were 
washed and resuspended in PBS containing 0.5% (v/v) Tween 20 (Fisher Bioreagents, Cat 
#BP337-500) and kept on ice for 10 min. After vortexing for 30 secs, nuclei were removed by 
centrifugation and supernatant added to the previously collected culture supernatant. Cell debris 
was removed by centrifuging at 10,000 ´ g for 15 mins. The supernatant, containing the virus was 
then centrifuged at 80,000 ́  g for one hour. The pellet was then resuspended in TNE buffer (0.01M 
Tris (pH7.5) 0.001M EDTA and 0.15M NaCl) overnight at 4ºC. Concentrated virus was placed on 
electron microscope grids, fixed in glutaraldehyde and processed further for electron microscopy 
(negative staining).  
7.6.4. Polymerase chain reaction 
Pan-herpesvirus nested PCR was done using multiple primers as previously described 
[307]. Qiagen TopTaq DNA polymerase (Cat #200203) was used for setting up the reaction as 
described by the manufacturer. The denaturation, annealing and extension conditions for the first 
and second reaction were 94 ºC for 30 secs, 47 ºC for 30 secs and 72 ºC for 1 min (39 cycles). 
Initial denaturation was done at 94 ºC for 3 mins and final extension was 72 ºC for 10 mins.  
 Degenerate primers used for cytochrome B PCR (Table 7.1) and the denaturation, 
annealing and extension conditions were same as the previously described PCR, except the 
annealing temperature, which was 45 ºC. To screen for EfHV infection in big brown bats we 
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amplified a portion of the BGLF4 (Protein kinase C-like superfamily) gene (Table 7.1). As a 
positive control, EfHV genomic DNA was added and a control without template DNA was also 
included. The denaturation, annealing and extension conditions were same as for previously 
described PCRs, except the annealing temperature, which was 60 ºC.  
 
Table 7.1. Details of Primers used for PCR 
Target gene Forward primer Reverse primer Product length 
Cytochrome B 
5' – TVG GHT AYG TVC TNC CVT GRG 
GMC AAA – 3'  
5' – GGR TRT TCH ACD GGY TGK CCN 
CCR ATT – 3' 
652 bp 
BGLF4 
5' – CAG CGT GAG CAG CCT ATG TA - 
3' 
5' - TAG AAT CCC GCA AGC GAC TC – 3' 238 bp 
MHC-I (1) (873-1745) 
5’ – ACG TCT AGG GTG CTG TTC ATC – 
3’ 
5’ – ACT GTC TTC TGT CTT CCG TCC – 3’ 253 bp 
MHC-I (2) (3692-4018) 
5’ – GGA GGC TTT AGC GTG TAC GG – 
3’ 
5’ – TGG CTA AGA TGT TGG CAC AGT – 
3’ 
178 bp 
MHC-I (3) (4118-4414) 
5’ – GAA AAG CTC ACC TCG AAC CG – 
3’ 
5’ – GGG CCG TTG TGT ATG TCT CT – 3’ 198 bp 
MHC-I (4) (5477-6247) 
5’ – AGG AGT CAA TGA GTG CCA CG – 
3’ 
5’ – GGA GTC TTT CGG CAC CTT GA – 3’ 332 bp 
MHC-II (6437-6895) 
5’ – TGG GTC ACC GGC TTT TAT CC – 
3’ 
5’ – CAT CCC GCA GTC TCT GTC TG – 3’ 328 bp 
MHC-I (5) (7374-7772) 
5’ – GTC AAG GGG TCG TGT CAA AC – 
3’ 
5’ – CAG TTT TGT GGT GTG GCT CC – 3’ 189 bp 
Interleukin 10 homolog 
5’ – TTT TCC ACT CTA GGC GAC CG – 
3’ 
5’ – TCA CAC GGA GGT GAC GTA AG – 3’ 204 bp 
GAPDH 
5’ – CAG GTT GTC TCC TGC GAC TT – 
3’ 
5’ – GAC TGA TCT GGG GCA AGG AC – 3’ 248 bp 
 
7.6.5. Electron microscopy 
Virus infected cells, which were fixed using glutaraldehyde, were processed for electron 
microscopy. Samples were then treated with osmium tetroxide (1% OsO4, 0.1M sodium cacodylate 
buffer) for one hour at room temperature. Samples were quickly rinsed with water, gradually 
dehydrated in ethanol and en-bloc stained with uranyl acetate. After rinsing three times (5 minutes 
each) in propylene oxide, samples were infiltrated with Epon/Araldite (electron Microscopy 
Sciences, Fisher scientific, Cat #50-980-381). Samples were placed in molds and freshly prepared 
 
 127 
Epon/Araldite was added. The samples were then polymerized at 60 ºC for 24-48 hours. Sections 
of 90 nm were cut and observed by transmission electron microscopy (TEM - Hitachi HT 7700). 
For the negative staining, a 300 mesh formvar/carbon grid was suspended on a drop of specimen 
for 1 min, after which the grid was passed through two drops of water to rinse it over a period of 
40 secs. The grid was then suspended on 0.5% phosphotungstic acid for 1 min. The excess stain 
was blotted followed by drying of the grid. It was then viewed under TEM.    
7.6.6. Restriction endonuclease site analysis and pulse-field gel electrophoresis 
EfHV DNA was digested using EcoRI, BglII, ClaI, SwaI, SpeI, PacI or PmeI restriction 
endonucleases at 37 ºC for 1 hour. The digested DNA fragments were separated in a 1% agarose 
gel by electrophoresis in 0.5´ TBE buffer at 14 °C for 20 hrs on a CHEF-DRIII electrophoresis 
system with an initial switch time of 2.16 secs, a final switch time of 54.17 secs, a 120° switch 
angle, and a gradient of 6.0 V/cm. Salmonella enterica serotype Branderup and 1 Kb Plus ladder 
(Invitrogen, Cat #10787018) was used as a reference ladder. Following electrophoresis, the gel 
was stained with 600 ml of distilled water containing ethidium bromide for 20 mins and de-stained 
with 600 ml of distilled water for 20 mins. DNA fragments were visualized with AlphaImager HP 
(Fisher Scientific, Cat #50-921-323) and photographed. 
7.6.7. Sequencing and assembly of the EfHV genome 
To extract EfHV DNA, purified virus in TNE buffer was incubated with SDS (0.5 % (w/v)) 
and Proteinase K (400 µg/ml) at 37 0C for 1 hr. After extraction with Tris saturated 
phenol:chloroform (Gibco, Cat #AM9730) DNA was recovered by spooling in ethanol. DNA was 
initially dissolved in TNE buffer and its integrity confirmed by electrophoresis on a 0.5% agarose 
gel. For paired-end sequencing on the MiSeq platform, the viral DNA was re-precipitated and 
suspended in 0.01M Tris (pH 7.5). The quantity and quality of DNA was assessed using Nanodrop 
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and Bioanalyzer (DNA 1000 chip, Agilent Technologies, Cat #5067). A genomic DNA library 
was prepared using the Nextera XT kit (Illumina, Cat #FC-121-1002) which was then sequenced 
on a MiSeq system (Nextera XT kit) (Illumina, Inc.) to generate 250 bp paired-end reads.  
 For Nanopore sequencing, 1-dimensional genomic DNA sequencing was performed on a 
MinION device (Oxford Nanopore technology, Cat #SQK-RAD004). Genomic DNA library was 
made based on the protocol provided by Oxford Nanopore Technologies.  
 De-novo assembly was first performed only using the MiSeq reads and the Geneious 
assembler [308]. Open reading frames (ORF) were predicted by MacVector software [309]. The 
translated amino acid sequences of the ORFs were compared to all existing amino acid sequences 
in the NCBI database using BLASTp [310] to determine whether they matched known proteins. 
Using these ORFs as a reference, we selected the longest forward and reverse long-read from the 
MinION reads which had several overlapping ORFs. By aligning the pair of reads, we were able 
to obtain the scaffold of the EfHV genome. We re-mapped all the Mi-seq and Minion reads onto 
this scaffold to improve the quality of the sequence. After mapping, we selected the consensus of 
all the mapped reads onto the EfHV scaffold. 
 The accuracy of the finally assembled genome was confirmed by matching restriction 
enzyme recognition sites with sizes of fragments observed in pulse-field gel electrophoresis. 
7.6.8. Virus quantification 
For testing susceptibility of cell lines for EfHV, 3T3, EfK, MDCK, MDBK, CRFK, 
BHK21, PK15, RK13, HEK293, Ederm and Vero cells (all, except for EfK3 cells were originally 
obtained from the American Type Tissue Culture Collection) were cultured to test susceptibility 
of mouse, bat, canine, bovine, feline, hamster, porcine, rabbit, human, equine and monkey 
respectively. The species from which the cell lines originated was confirmed by sequencing 
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fragments of the cytochrome B gene obtained by PCR using the primers mentioned above. Cell 
monolayers on 12-well plates were infected with EfHV with a MOI of 1 pfu/cell for one hour at 
37 0C. After infection, the monolayer was rinsed with citrate buffer (40 mM citric acid, 10 mM 
KCl, 135 mM NaCl, pH 3) for 1 min. to inactivate extracellular virus and then rinsed again with 
PBS to remove the citrate buffer [311]. Cells were then incubated in complete medium at 30 0C. 
A set of plates representing all cell lines was frozen (-80 0C) as the time=0 samples. Forty-two 
hour later all other plates were frozen at -80 0. The plates were frozen and thawed three times, and 
cellular debris was removed by centrifugation (300 x g for 5 min). The supernatant was collected 
and assayed to determine TCID50.  
 To assay for virus, samples were serially diluted (10-fold dilutions) in DMEM and 50 µl 
added onto a monolayer of EfK cells in a 96-well plate. After 1 hour of infection, 100 µl of 
complete media was added and plates incubated at 37 0C. Plaques were counted on an inverted 
microscope after 4 days. TCID50 was calculated using the Spearman and Kärber method [286,287] 
using the algorithm of Hierolzer and Killington [312]. The assays were done in triplicate. 
7.6.9. EfHV growth curve 
Bat (EfK) cells were seeded in a 6-well plate and infected with EfHV for an hour followed 
by inactivation of extracellular virus by citrate buffer. Supernatant and cells were harvested by 
freeze-thawing thrice at 0, 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 36 and 48 hours after infection. 
Cellular debris was removed and virus titre (TCID50) was determined on EfK cells. 
7.6.10. Mass spectrometry (MS) 
Polypeptides from purified virus were separated by SDS-PAGE using 10 % acrylamide 
gel. The gel was stained with Coomassie blue (Thermofisher Scientific, Cat #20278) and all visible 
bands excised. The gel segments were sent to the University of Alberta Proteomics and Mass 
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Spectrometry facility for MS. The results were matched against a database created using the 
translated ORFs of EfHV as determined from the assembled genome.  
7.6.11. Serum Neutralization Assay 
Bat plasma was heat inactivated at 56 ºC for 30 mins. 800 pfu/well (50 µl) of EfHV was 
added to equal volume of 1/10, 1/20, 1/40, 1/80, 1/160 and 1/320 dilution of plasma from big 
brown bats and the mixture was incubated at 37 ºC for an hour. After the one hour incubation, 100 
µl of the mixture was added to EfK monolayer cells that were rinsed with PBS. Cytopathic changes 
were microscopically observed after 48 hours. As controls, “no virus and no serum” was used as 
a negative control and “only virus” was used a positive control.  
7.6.12. EfHV infection, RNA extraction, cDNA synthesis and quantitative real time PCR 
For studying the Viral MHC gene and IL10 homolog expression, a monolayer of Bat cells 
(Efk) in a 6-well plate were infected with EfHV at a MOI of 5 pfu/cell. Uninfected bat cells were 
used as a negative control. RNA was extracted after 18 hours using QIAGEN RNAeasy kit 
(Qiagen, Cat #74136) as per manufacturers protocol. cDNA was prepared using iScript gDNA 
Clear cDNA synthesis kit (BioRad, Cat #172-5035) as per manufacturers protocol. A no reverse 
transcriptase control cDNA was prepared and used to rule out amplification of genomic DNA. 
Real time PCR was performed using 10 µl SsoFast Evagreen supermix (BioRad, Cat #172-5201) 
and 2.5 µl of 4 µM of forward and reverse primer for MHC-I (873-1745), MHC-I (3692-4018), 
MHC-I (4118-4414), MHC-I (5477-6247), MHC-II (6437-6895), MHC-I (7374-7772) and 
Interleukin 10 homolog (Table 3). Denaturation was at 95 ºC for 5 secs and, annealing and 
extension at 60 ºC for 5 secs for all primer pairs. The products were analysed on an agarose gel 
and were also sent for Sanger sequencing (Macrogen). 
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7.6.13. Phylogenetic analysis 
Analyses were performed at the level of encoded amino acid sequences of glycoprotein B 
and DNA polymerase selected based on [303] (Supplementary table S7.1). Sequence were aligned 
using ClustalW [214] and the portion of amino acid sequence that corresponded to previously 
available bat gammaherpesvirus sequences were used for the phylogenetic analysis. We 
determined the most appropriate amino acid substitution model using ProtTest 3.4.2 [313]. 
Maximum likelihood (ML) trees were constructed using MEGA7 [215]. Using Le and Gascuel 
model and a gamma distribution (G) of variation with invariant sites (I), we constructed trees for 
the glycoprotein B gene whereas the same model with gamma distribution alone was used for 
DNA polymerase gene [314]. Bootstrapping with 500 replicates was used to estimate the 
confidence of the tree nodes. Phylogenetic trees for the MHC genes were also constructed in a 
similar manner. The model of evolution used for MHC-I (1) and MHC-II was WAG model [315] 
whereas for MHC-I (2), (4) and (5) was JTT model [316]. 
 
7.7. Results 
7.7.1. Isolation of a novel herpesvirus from lungs of a big brown bat (E. fuscus) 
As part of ongoing surveillance of viruses in local North American bats, we observed 
cytopathic effects in EfK cells, a big brown bat kidney cell line [213], inoculated with a 
homogenate of lungs from a big brown bat submitted to the Canadian Wildlife Heath Cooperative 
(CWHC). Using pan-herpesvirus primers in a PCR [307] we established the presence of a 
herpesvirus. To further confirm this, we performed electron microscopy on the cells and observed 
virus particles having herpesvirus-like morphology (Figure 7.1. (A), (B) and (C)). In addition to 
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microscopy of the cells, we observed herpesvirus particles in negative stained preparations of 
purified virus (Figure 7.1. (D)). 
 
Figure 7.1. Electron micrographs of EfHV. Efk cells inoculated with homogenate of lungs from 
a big brown bat showing enveloped virions (approximately 200 nm in size) budding out from the 
cells (A), (B) and (C). Negative staining of purified virions showing a magnified image of the virus 
(D). The capsid is approximately 100 nm in size.  
 
7.7.2. Genome sequencing of EfHV 
To determine the nucleotide sequence of the EfHV genome, we used a combination of 
paired-end (Illumina MiSeq) and long read (Oxford Nanopore) sequencing. We obtained 
1,458,704 paired-end reads from an Illunima Mi-seq run, and de-novo assembly on these reads 
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(using Geneious Assembler [308]) led to the assembly of contigs of a maximum of ~100kb. As we 
were unable to join all the contigs, we resorted to performing a long read sequencing i.e. Nanopore 
sequencing, from which 27,002 long reads were obtained. Finally, we used Geneious assembler to 
combine the long reads and the paired end reads in order to get the complete genome of the 
herpesvirus which is 166,748 bp with a GC content of 59.6% (NCBI Accession number 
MF385016) [308]. The arrangement of the sequence contigs was verified by restriction enzyme 
mapping (Supplementary figure S7.2). We annotated the genome based on results of BLASTp 
comparisons of predicted open codon reading frames (ORFs) [309] from the assembled sequence 
to all sequences in the NCBI database, which resulted in the successful identification of 75 genes 






Figure 2. Map of the EfHV genome. The 166 kb genome contains 75 open reading frames. The putative identity of the ORFs, based 
on similarity to those of other gammaherpesviruses, is indicated in red. Although depicted as a circle, the viral genome is linear. Repeated 




Table 7.2. Genome annotation of EfHV and its similarity with other herpesviruses. The first and second column shows the 
nucleotide range and the orientation of ORFs on the EfHV DNA respectively. The third column indicates the superfamily to which the 
protein belongs, and the fourth column shows the closest match obtained after BLASTp search of the translated ORF against the NCBI 
database. The BLASTp similarity and percent coverage of the closest match is indictated in the fifth and sixth columns, respectively. 
The last three columns represent the coding of the ORF in three different formats used for viruses belonging to Gammaherpesvirinae. 






Protein superfamily Best Match from BLAST Search Blastp % similarity 
Percentage 
Coverage ORF# B# UL# 
873-1745 - MHC Class I MHC class I antigen [Saimiri sciureus sciureus] 49/90(54%) 16.90 
   
3692-4018 - MHC Class I 
major histocompatibility complex class I-
related gene protein-like [Labrus 
bergylta] 
40/77(51%) 37.04    
4118-4414 - MHC Class I HLA class I histocompatibility antigen, B-15 alpha chain-like [Myotis lucifugus] 34/69(49%) 34.69 
   
5477-6247 - MHC Class I MHC class I antigen [Ornithorhynchus anatinus] 57/108(52%) 22.27 
   
6437-6895 - MHC Class II 
DLA class II histocompatibility antigen, 
DR-1 beta chain-like [Latimeria 
chalumnae] 
68/135(50%) 44.74    
7374-7772 - MHC Class I 
HLA class I histocompatibility antigen, 
B-67 alpha chain-like isoform X2 [Myotis 
brandtii] 
48/102(47%) 36.36    
10060-12141 + Complement control protein (CCP) membrane cofactor protein-like isoform X2 [Pteropus vampyrus] 131/278(47%) 18.90 
   
12556-13143 - Ring-finger and U-Box domain 
Zinc finger, RING-CH-type domain and 
Zinc finger, RING/FYVE/PHD-type 
domain-containing protein 
[Strongyloides ratti] 
52/104(50%) 26.67    
18219-22577 + Phosphoribosylformylglycinamidine (FGAM) synthase 
protein G3 [Myotis gammaherpesvirus 
8] 552/1151(47%) 38.02 
   
23054-26713 + Viral DNA binding protein major DNA-binding protein [Saimiriine gammaherpesvirus 2] 790/1211(65%) 64.81 6 
  
27130-29439 + Herpesvirus processing and transport protein 
DNA packaging terminase subunit 2 
[Myotis gammaherpesvirus 8] 479/750(63%) 62.29 7 
  




32956-36099 + DNA polymerase family B DNA polymerase [Myotis ricketti herpesvirus 1] 751/994(75%) 71.73 9 BALF5 
 
36647-38089 + G protein coupled receptor membrane protein BILF1 [Equid gammaherpesvirus 5] 116/290(40%) 24.17 
 BILF1  
38008-39336 + Herpesvirus ORF10 unnamed protein product [Saimiriine gammaherpesvirus 2] 176/441(39%) 39.82 10 LF1 
 
39449-41116 + Herpesvirus ORF11 orf 11 [Ateline gammaherpesvirus 3] 201/394(51%) 36.22 11 LF2  
45167-47434 - Peptidase S21 ORF17 [Human gammaherpesvirus 8] 285/602(47%) 37.75 17 BVRF2  
47328-48302 + Herpesvirus UL79 ORF18 [Felis catus gammaherpesvirus 1] 170/257(66%) 52.47 18 BVLF1 79 
48335-50062 - Herpesvirus UL25 DNA packaging tegument protein UL25 [Myotis gammaherpesvirus 8] 341/581(58%) 59.30 19 BVRF1 25 
49851-50630 - Herpesvirus UL24 nuclear protein UL24 family [Myotis gammaherpesvirus 8] 138/210(65%) 53.28 20 BXRF1 24 
50660-52870 + Herpesvirus Thymidine kinase thymidine kinase [Equid gammaherpesvirus 5] 206/330(62%) 27.99 21 BXLF1 
 
52891-55245 + Herpesvirus Glycoprotein H ORF22 [Felis catus gammaherpesvirus 1] 374/715(52%) 47.70 22 BXLF2 75 
55242-56411 - Herpesvirus BTRF1 (Tegument Protein) 
ORF23 [Macaca nemestrina 
rhadinovirus 2] 115/264(43%) 29.56 23 BTRF1 88 
56802-59612 - Herpesvirus UL87 hypothetical protein [Bovine gammaherpesvirus 4] 459/752(61%) 49.04 24 BcRF1 87 
59611-63771 + Herpesvirus Major Capsid Protein major capsid protein [Bovine gammaherpesvirus 4] 1082/1379(78%) 78.07 25 BcLF1 
 
63963-64880 + Herpesvirus VP23 like capsid protein 
capsid protein [Bovine 
gammaherpesvirus 4] 238/301(79%) 78.03 26 BDLF1 
 
65092-66189 + hypothetical protein; Provisional ORF27 [Bovine gammaherpesvirus 6] 96/229(41%) 26.30 27   
66619-67026 +  ORF28 (Hypothetical protein-1)   28   
67187-68278 - DNA packaging terminase subunit 1 (2 exons) 
DNA packaging terminase subunit 1 
[Myotis gammaherpesvirus 8] 516/660(78%) 64.42 29 BGRF1/BDRF1 89 72050-73366 
68588-68857 + Protein of unknown function (DUF717) 
protein UL91 [Myotis 
gammaherpesvirus 8] 44/62(70%) 49.44 30 
 91 
68755-69531 + Herpesvirus UL92 family orf 31 [Ateline gammaherpesvirus 3] 134/222(60%) 51.94 31 BDLF4 92 
69474-71105 + Herpesvirus UL17 protein viral DNA cleavage/packaging protein [Bovine gammaherpesvirus 4] 240/545(44%) 44.20 32 BGLF1 17 
71098-72153 + Herpesvirus UL16/UL94 family (Tegument protein) 
ORF33 [Felis catus gammaherpesvirus 
1] 203/334(60%) 57.83 33 BGLF2 94 
73365-74648 + UL95 family hypothetical protein [Saimiriine gammaherpesvirus 2] 205/419(48%) 48.01 34 
 95 
74687-75256 + Gammaherpesvirus protein of unknown function (DUF848) 
hypothetical protein [Harp seal 
herpesvirus] 87/192(45%) 46.03 35 
 14 
75087-76844 + Protein kinase C like superfamily tegument serine/threonine protein kinase [Myotis gammaherpesvirus 8] 228/424(53%) 38.97 36 BGLF4 
 




78347-78619 + Protein of unknown function (DUF2733) 
ORF29 [Callitrichine gammaherpesvirus 
3] 36/57(63%) 40.00 29 
  
78930-80219 - Herpesvirus glycoprotein M envelope glycoprotein M [Equid gammaherpesvirus 5] 265/419(63%) 61.77 39 BBRF3 
 
80570-82348 + Herpesvirus DNA helicase/primase complex associated protein 
hypothetical protein [Bovine 
gammaherpesvirus 4] 201/484(41%) 33.95 40 
  
82434-83117 + Herpesvirus helicase-primase complex component 
ORF41 [Macaca nemestrina 
rhadinovirus 2] 72/141(51%) 31.72 41 
 8 
83103-84122 - Herpesvirus UL7 tegument protein (virus egress protein) 
tegument protein UL7 [Delphinid 
gammaherpesvirus 1] 162/283(57%) 47.79 42 BBRF2 7 
84076-85974 - Herpesvirus UL6 like capsid portal protein [Myotis gammaherpesvirus 8] 449/592(75%) 71.04 43 BBRF1 6 
85811-88720 + helicase-primase subunit BBLF4 DNA helicase-primase complex component [Harp seal herpesvirus] 594/812(73%) 61.30 44 BBLF4 
 
89378-90847 - Tegument Protein tegument protein G45 [Delphinid gammaherpesvirus 1] 16/21(76%) 3.27 45 BKRF4 
 
90912-91724 - Uracil DNA glycosylase superfamily 
uracil-DNA glycosylase [Delphinid 
gammaherpesvirus 1] 200/272(73%) 74.07 46 BKRF3 
 
91660-92163 - Viral glycoprotein L envelope glycoprotein L [Myotis gammaherpesvirus 8] 56/106(52%) 33.53 47 BKRF2 
 
92716-95328 - Herpesvirus protein of unknown function (DUF832) 
tegument protein G48 [Equid 
gammaherpesvirus 5] 122/219(55%) 14.02 48 
 92 
97184-101290 + Herpesvirus transcription activation factor (transactivator) 
protein Rta [Equid gammaherpesvirus 




 Hypothetical protein-2      
103225-
103761 + 
 Hypothetical protein-3      
104121-
106964 + Envelope glycoprotein 
envelope glycoprotein [Myotis 
gammaherpesvirus 8] 136/349(38%) 14.36 
 BLLF1  
107104-
107808 - Herpesvirus BLRF2 protein 
hypothetical protein [Bovine 
gammaherpesvirus 4] 72/116(62%) 30.77 52 BLRF2 
 
107661-
108050 - UL73 viral envelope glycoprotein 
ORF53 [Felis catus gammaherpesvirus 
1] 43/49(87%) 33.33 53 BLRF1 73 
108129-
109538 + Trimeric dUTP diphosphatases orf 54 [Ateline gammaherpesvirus 3] 143/276(51%) 30.49 54 
  
109729-
110454 - Herpes virus U44 protein 
tegument protein UL51 [Equid 
gammaherpesvirus 5] 154/237(64%) 63.90 55 BSRF1 51 
110412-
113177 + 
Herpesviridae UL52/UL70 DNA 
primase 
helicase-primase primase subunit 








137/241(56%) 24.04 57   
115582-
116214 - Apoptosis regulator 
apoptosis regulator BALF1 [Delphinid 
gammaherpesvirus 1] 35/69(50%) 16.67 




117817 - Herpesvirus BMRF2 protein 
envelope protein UL43 [Delphinid 
gammaherpesvirus 1] 181/344(52%) 49.18 58 BMRF2 43 
117849-
119357 - 
Herpes DNA replication accessory 
factor 
DNA polymerase processivity subunit 





reductase small subunit 
ribonucleotide reductase subunit 2 





reductase large subunit 
ribonucleotide reductase subunit 1 




Herpesvirus capsid shell protein 
VP19C 
unnamed protein product [Saimiriine 
gammaherpesvirus 2] 218/333(65%) 58.92 62 BORF1 
 
124954-
128085 + Herpes virus tegument protein U30 
tegument protein [Bovine 
gammaherpesvirus 4] 502/980(51%) 48.13 63 BOLF1 37 
128015-
138883 + Large tegument protein 
tegument protein [Bovine 
gammaherpesvirus 4] 870/1828(47%) 24.02 64 BPLF1 36 
138932-
139387 - Gammaherpesvirus capsid protein 
ORF65 [Macaca nemestrina 
rhadinovirus 2] 45/65(69%) 29.80 65 BFRF3 
 
139542-
141089 - UL49 family 
protein UL49 [Delphinid 
gammaherpesvirus 1] 212/385(55%) 41.17 66 BFRF2 49 
140900-
141898 - Herpesvirus virion protein U34 
nuclear egress membrane protein 
[Equid gammaherpesvirus 5] 162/225(72%) 48.80 67 BFRF1 
 
142016-
142351 - DNA packaging protein UL33 
hypothetical protein [Bovine 
gammaherpesvirus 4] 57/76(75%) 51.35 67A BFRF1A 33 
142561-
144108 + 
Herpesvirus putative major 
envelope glycoprotein 
DNA packaging protein UL32 [Myotis 
gammaherpesvirus 8] 298/503(59%) 57.86 68 BFLF1 32 
144249-
145379 + 
nuclear egress lamina protein 
UL31 
hypothetical protein [Harp seal 
herpesvirus] 191/288(66%) 50.80 69 BFLF2 31 
146542-
147135 - Interleukin-10 family 
interleukin-10 [Equid 
gammaherpesvirus 2] 92/158(58%) 46.70 
 BCRF1  
152249-
155281 - 
Latency associated nuclear 
antigen 
latency-associated nuclear antigen 
(lana) DNA binding domain [Harp seal 
herpesvirus] 










 The genome length of EfHV was well within the range of known herpesviruses, i.e. 124 kb 
to 295 kb [77]. Based on BLASTp percent similarity, most of the genes matched with orthologues 
in other gammaherpesviruses. Within the first 8 kb of the 5’ end of the genome, we detected four 
putative major histocompatibility complex (MHC) class I genes and one MHC class II gene 
(Figure 7.2). In addition to MHC antigens, we detected an interleukin-10 homolog in the genome. 
We verified expression of all the MHC-I, MHC-II and IL-10 homolog genes in bat cells infected 
with EfHV by analyzing transcripts from virus-infected cells - we used quantitative real time PCR 
(qRT-PCR) followed by analysis of the products by agarose gel electrophoresis (Supplementary 
figure S7.3) and determined their nucleotide sequence. EfHV also encoded proteins similar to the 
latency associated nuclear antigen (LANA1) and replication and transcription activator (Rta), 
proteins that are key regulators of Kaposi sarcoma virus latency and lytic cycles [317,318]. 
7.7.3. EfHV belongs to the Genus Rhadinovirus in Gammaherpesvirinae 
We initially compared the amino acid sequence of the entire DNA polymerase protein of 
EfHV with that of homologues in representative alpha, beta and gammaherpesviruses 
(Supplementary figure S7.4). EfHV clustered with gammaherpesviruses, and most closely aligned 
with the Rhadinoviruses Kaposi’s sarcoma herpesvirus and Saimirine herpesvirus 2. We next 
aligned the amino acid sequences of the DNA polymerase and glycoprotein B gene of 
representative viruses from Gammaherpesvirinae based on sequences reported by Escalera-
Zamudio et al. [303] (Supplementary table S7.1). As complete sequences were not available for 
all viruses, we aligned sequences from portions of each protein that were common to all sequences. 
Maximum-likelihood trees were constructed using MEGA7 (Kumar et al., 2016) using LG+G 
phylogenetic model for DNA polymerase (Figure 7.3. (A)) and LG+G+I for glycoprotein B (Figure 
7.3. (B)) genes, as determined by ProtTest 3.4.2 [313] followed by 500 bootstrap replications. In 
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both the trees, EfHV sequences were found to cluster with those of other bat Rhadinoviruses. EfHV 
sequences most closely resembled those of bat Rhadinoviruses detected in Myotis nattereri 
(MYNARHV1, in Figure 7.3. (A)) and Pipistrellus nathusii (PIPNARHV1), both of which are 
European bats, and Eptesicus serotinus (EPSERHV1), a Eurasian bat.  
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Figure 7.3. Phylogenetic comparison of EfHV with other gammaherpesviruses. To determine 
the phylogenetic relationship of EfHV with other gammaherpesviruses, sequences of DNA 
Polymerase (A) and glycoprotein B (B) were compared. Only a portion of the amino acid 
sequences of EfHV polymerase and gB proteins, that corresponded to the reported partial 
sequences for those of orthologues in other gammaherpesviruses, could be used in the comparison. 
Alignment lengths were 42 amino acids and 106 amino acids for DNA Polymerase and gB, 
respectively. Gammaherpesviruses derived from bats are indicated in green. EfHV (arrows) was 
related to the Myotis nattereri rhadinovirus, Pipistrellus nathusii rhadinovirus-1 and Eptesicus 
serotinus rhadinovirus-1. Bootstrap values (>50%) are shown at the branch points. Detail of the 
sequences [303] included in the phylogenetic tree are in Supplementary table S7.1. 
 
7.7.4. Cell tropism of EfHV 
To understand the spectrum of species that EfHV could infect, we infected different cell 
lines (bat kidney epithelial cell line), mouse (embryonic fibroblast cell line), canine (kidney 
epithelial cell line), bovine (kidney epithelial cell line), feline (kidney epithelial cell line), hamster 
(kidney fibroblast cell line), porcine (kidney epithelial cell line), rabbit (kidney epithelial cell line), 
human (kidney epithelial cell line), equine (skin fibroblast cell line) and monkey (kidney epithelial 
cell line) with EfHV at a multiplicity of infection of 1 plaque forming unit (pfu) per cell, followed 
by inactivation of extracellular residual virus. We then measured virus yields 42 hours after 
infection. Virus yields were highest from bat cells (EfK). Human, monkey, feline and porcine cell 
lines yielded moderate amounts of virus whereas mouse, hamster, canine, and bovine cells 




Figure 7.4. EfHV infection of cell lines from various species. Bars represent virus yields 
(average of three experiments) expressed as TCID50 per ml of growth supernatant recovered 42 hr 
after infection. Error bars represent standard deviations.  
 
7.7.5. Growth kinetics of EfHV 
We infected bat cells with EfHV followed by inactivation of extracellular residual virus. 
We quantified the virus at various time points following infection to plot a one-step growth curve. 








































































































Figure 7.5. Growth curve of EfHV. To understand the growth kinetics of EfHV in bat cells, EfK 
cells were infected at a MOI of 4 pfu/cell for 1 hour followed by the inactivation of residual virus. 
Dots represent virus yields (average of three experiments), expressed as TCID50/ml of lysed cells 
and growth supernatant. Error bars represent standard deviation from means. 
 
7.7.6. Protein composition of EfHV 
To identify EfHV proteins present in the virion, we performed mass spectrometry on 
segments of a polyacrylamide gel used to separate virion proteins. A comparison of the masses of 
separated tryptic peptides with EfHV ORFs confirmed the identity of the ORFs (Table 7.3). In 
addition, proteins present in EfHV virions resembled those in other gammaherpesvirus virions 
[319]. 
  
























Table 7.3. Proteins present in the EfHV virion. The first column mentions the identity of the 
ORF (Table 7.2). The second and third column shows the molecular mass of the protein and 
coverage by the peptides obtained using mass spectrometry.  
 
Protein Name with ORF codes Molecular Mass (kDa) Coverage 
BcLF1; ORF25; major capsid protein 153.7 75.32 
BNRF1; ORF75; herpesvirus tegument protein/v-FGAM-synthase 158.2 79.55 
BPLF1; ORF64; Large Tegument Protein 397.5 51.13 
BOLF1; ORF63; Herpes virus tegument protein U30 116.1 81.69 
ORF48; Herpesvirus protein of unknown function (DUF832) 94.8 55.29 
BALF4; ORF8; Envelope Glycoprotein B (gB) 108.8 43.9 
BXLF2; ORF22; Glycoprotein H (gH) 85.6 47.19 
BXLF1; ORF21; Thymidine Kinase 79 54.76 
BKRF4; ORF45; Tegument Protein 52.9 48.26 
BBRF1; ORF43; Capsid Portal Protein 71.4 37.5 
BGLF4; ORF27; Probable Inactive Protein Kinase 38 65.3 39.32 
LF2; ORF11 61.2 56.94 
BVRF1; ORF19; DNA packaging tegument protein 63.6 39.13 
BGLF1; ORF32; viral DNA cleavage/packaging protein 58.7 35.36 
BTRF1; ORF23; Tegument Protein 41.9 24.94 
BLLF1; Envelope Glycoprotein 100.88 9.5 
BaRF1; ORF60; Ribonucleoside diphosphate reductase small subunit 41.7 19.24 
BGLF2; ORF33; Herpesvirus UL16/UL94 family (Tegument protein) 38.7 42.74 
BORF1; ORF62; capsid shell protein VP19C 41.4 41.89 
 
7.7.7. Prevalence of EfHV in Canadian big brown bats 
Using PCR, we detected EfHV DNA in blood cells from 20 of 28 bats (71%). The 250 bp 
PCR product detected was the same size as the PCR product obtained from EfHV genomic DNA 
(positive control). The identity of the products was confirmed by determining their nucleotide 
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sequences. Although most bats appeared to be infected with EfHV, we were unable to detect virus 
neutralizing antibodies in the plasma of any of the bats.  
 
7.8. Discussion 
Gammaherpesviruses have been studied in human and other animal hosts, but very little is 
known about these viruses in bats. Here, we report the characterization of a novel 
gammaherpesvirus isolated from E. fuscus, the North American big brown bat. Thus, we named 
the virus E. fuscus herpesvirus. We determined the complete sequence of the viral genome and its 
phylogenetic relationship to existing gammaherpesviruses. We discovered that EfHV is 
structurally similar to other gammaherpesviruses. The protein composition of EfHV is also similar 
to that of other gammaherpesviruses [319]. 
While gammaherpesviruses have been detected in other bat species, the Myotis 
gammaherpesvirus 8 is the only other bat gammaherpesvirus that has been isolated [147]. This 
virus belongs to the genus Percavirus within Gammaherpesvirinae along with Equid 
herpesviruses 2 and 5. A comparison of two EfHV ORFs with the partial reported sequences from 
other bat gammaherpesviruses revealed that it is related to European and Eurasian bat 
gammaherpesviruses, which also belong to the genus Rhadinovirus. Since many of the sequences 
used in this analysis were incomplete and represented a conserved portion of the DNA polymerase 
and gB proteins, the boot strap values for several of the other nodes tended to be low. 
 Although databases contain complete genomes of gammaherpesviruses isolated from other 
mammals, existing sequences of bat gammaherpesviruses in the NCBI database are limited to short 
sequence segments or partial genomes. The EfHV genome is the first bat gammaherpesvirus whose 
complete sequence has been determined, including repeated sequences. In addition to ORFs with 
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strong similarities to those of other gammaherpesviruses and an ORF resembling mammalian IL-
10, which is also transduced by other gammaherpesviruses, we found four ORFs that resembled 
putative MHC-I and one that resembled putative MHC-II in the 5’ end of the genome. These were 
not sequencing artefacts because of accidental sequencing of host DNA or because of assembling 
errors, since we confirmed the assembly of contigs by comparison with long stretches of 
contiguous sequences generated by Nanopore sequencing, and also by restriction endonuclease 
mapping. Protein BLAST of these MHC antigen sequences allowed us to select the MHC 
sequences of other species that resembled the EfHV MHC sequences. Based on these sequences, 
we performed phylogenetic analysis and showed that one of the MHC I antigens, matched those 
of other bat species (Figure 7.6 (E)), implying that the virus might have acquired them during 
virus-host coevolution. Another MHC I antigen, closely resembled that of a rodent species (Figure 
7.6 (A)). For the remaining MHC I and II antigens, the sequences did not cluster with any species 
(Figure 7.6 (B), (C) and (D)). Previously, MHC I antigens have been discovered in 
betaherpesviruses [320–323] and in one rodent gammaherpesvirus [324]. These MHC antigens 
might have a role to play in the immune evasion mechanisms of the virus. In-vivo studies using a 
betaherpesvirus (murine cytomegalovirus) has revealed that the absence of MHC I homologues 
led to restricted virus replication in the host [325]. Such MHC I homologues might serve as decoy 
ligands to allow virus to hide from natural killer cells, which are specialized to detect and target 
cells that have lost MHC class I [326]. Although MHC II homologues are present in a bat 
betaherpesvirus [320], this is first time that an MHC II homolog has been detected in a 
gammaherpesvirus. The MHC class II homologue may have a role to play in interfering with 





Figure 7.6. A comparison of EfHV MHC antigens with those of other species (Maximum 
likelihood method). Comparison of EfHV ORFs that resemble MHC antigens, with the most 
similar sequence from other species as determined by BLASTp search of the entire NCBI database. 
For MHC-I molecules (A and E), the EfHV ORFs form a distinct branch closely related to bank 
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II molecules (C), however, EfHV sequences did not cluster with any specific species. Bootstrap 
values (>50%) are shown at the branch points. 
 
EfHV was shown to grow in cells from humans, monkeys, cats and pigs, and to a lesser 
extent in canine, bovine, and rodent cells. Although gammaherpesviruses show narrow species 
tropism in-vivo [327], they are able to produce non-permissive (or latent) infection in many cell 
lines apart from those of their primary host [328–330]. Our results indicate that EfHV could 
productively infect cultured cells of mammalian species like human, monkey, feline and porcine, 
consistent with what had been previously described for bat gammaherpesviruses [143,302,303]. 
As the ability of a virus to grow in a cell line derived from an animal does not necessarily confirm 
its tropism for that species, further studies would be needed to understand the in-vivo susceptibility 
of these animals to EfHV.   
We detected EfHV in the blood of over 70% of bats tested (20/28). However, our study 
involved populations of captured bats kept in two hibernating chambers, so we cannot rule out the 
possibility of transmission during hibernation. Further field studies would provide us with more 
robust evidence of EfHV prevalence in big brown bat populations. Despite detecting EfHV DNA 
in the blood of most big brown bats, we failed to observe any neutralizing antibodies against EfHV 
in bat plasma. In the absence of a neutralizing plasma as a positive control, it is difficult to state 
with certainty the sensitivity of the assay. Nonetheless, this would serve as a preliminary data 
regarding antibodies against EfHV in big brown bats. Waning IgG antibody in bats has also been 
noted in other viral infections like Nipah [38,41,46], Hendra [46], Japanese Encephalitis [331], 
and Marburg [332] suggesting transient antibody responses to viruses in several species of bats.  
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 Our report provides the first complete sequence of a bat gammaherpesvirus, EfHV, that 
appears to belong to the genus Rhadinovirus in Gammaherpesvirinae. It is unique among 
gammaherpesviruses in transducing MHC II genes.  
 
7.9. Supplementary Information 
Supplementary table S7.1. Accession numbers for the DNA polymerase (dpol) and 




Name Accession number Abbreviation Common host name Name Accession number Abbreviation
Alcelaphine herpesvirus 1 NC_002531.1 ALC_HV1 Wildebeest Alcelaphine herpesvirus 1 NC_002531.1 ALC_HV1
Apodemus sylvaticus rhadinovirus 1 EF128051.2 APSY_RHV1 Wood mouse Apodemus sylvaticus rhadinovirus 1 EF128051.2 APSY_RHV1 
Ateline herpesvirus 3 NC_001987.1 ATE_HV3 Woolly monkey Ateline herpesvirus 3 AF083424.1 ATE_HV3 
Babyrousa babyrussa rhadinovirus 1 AY177146.2 BABA_RHV1 Golden babirusa hog Babyrousa babyrussa rhadinovirus 1 AY177146.2 BABA_RHV1
Bandicota indica rhadinovirus 4 EF128043.1 BAIN_RHV4 Greater bandicoot rat Bandicota indica rhadinovirus 4 EF128043.1 BAIN_RHV4
Bandicota savilei rhadinovirus 1 DQ821581.1 BASA_RHV1 Savile's bandicoot rat Bandicota savilei rhadinovirus 1 DQ821581.1 BASA_RHV1 
Bovine herpesvirus 4 AF318573.1 BOS_HV4 Cattle Bovine herpesvirus 4  AF318573.1 BOS_HV4 
Bovine herpesvirus 6 NC_024303.1 BOS_HV6 Cattle Bovine herpesvirus 6 KJ705001.1 BOS_HV6 
Bovine lymphotropic herpesvirus AF327830.1 BOS_LHV Cattle Bovine lymphotropic herpesvirus AF327832.1 BOS_LHV
Callitrichine herpesvirus 3 AF319782.2 CAL_HV3 Marmoset Callitrichine herpesvirus 3 AF319782.2 CAL_HV3 
Caprine herpesvirus 2 HQ116812.1 CAP_HV2 Goat Caprine herpesvirus 2 AF283477.2 CAP_HV2 
Crocuta crocuta gammaherpesvirus 1 DQ789371.2 CRO_GHV1 Spotted hyena Crocuta crocuta gammaherpesvirus 1 DQ789371.2 CRO_GHV1
Cynopterus sphinx CS/12GZ1 KR261850 CYSP_M102 Greater short-nosed fruit bat Cynopterus sphinx 13HN70 KR261906 CYSP_70
Cynopterus sphinx CS/14GZ24 KR261898 CYSP_M24 Greater short-nosed fruit bat
Diceros bicornis gammaherpesvirus 1 AY197560.2 DIBI_GHV Black rhinoceros Diceros bicornis gammaherpesvirus AY197560.2 DIEC_SD12
Elephas maximus gammaherpesvirus 1 EU085379.1 ELMA_GHV1 Asian elephant Elephas maximus gammaherpesvirus 1 EU085379.1 ELMA_GHV1
Eptesicus fuscus herpesvirus MF385016 EFHV Big Brown bat Eptesicus fuscus herpesvirus MF385016 EFHV
Eptesicus serotinus rhadinovirus 1 DQ788623.2 EPSE_RHV1 Serotine bat Eptesicus serotinus rhadinovirus 1 DQ788623.2 EPSE_RHV1
Equid herpesvirus 2 U20824.2 EQ_HV2 Horse Equid herpesvirus 2 U20824.2 EQ_HV2 
Equid herpesvirus 5 KM924295.1 EQ_HV5 Horse Equid herpesvirus 5 KM924295.1 EQ_HV5 
Equus zebra gammaherpesvirus 1 AY495965.2 EQZ_GHV1 Zebra Equus zebra gammaherpesvirus 1 AY495965.2 EQZ_GHV1
Felis catus gammaherpesvirus 1 NC_028099.1 FECA_GHV1 Cat Felis catus gammaherpesvirus 1 NC_028099.1 FECA_GHV1 
Gorilla gorilla lymphocryptovirus 1  AF534225.3 GOGO_LCV Gorilla Gorilla gorilla lymphocryptovirus 1 AF534225.3 GOGO_LCV
Gorilla rhadinovirus 1 AY177144.2 GOGO_RHV1 Gorilla Gorilla rhadinovirus 1 AY177144.2 GOGO_RHV1
Hexaprotodon liberiensis gammaherpesvirus 1AY197559.2 HELI_GHV1 Pygmy hippopotamus Hexaprotodon liberiensis gammaherpesvirus 1 AY197559.2 HELI_GHV1 
Hipposideros diadema herpesvirus AB490083.2 HIDI_HV Diadem leaf-nosed bat Hipposideros diadema herpesvirus AB490083.2 HIDI_HV  
Hipposideros larvatus HL/11HN1 KR261841 HL_HN1 Intermediate roundleaf bat
Hipposideros pomona HP/11HN104 KR261843 HP_104 Pomona roundleaf bat Hipposideros pomona 211HN104 KR261902 HP_104
Hipposideros pomona HP/11HN110 KR261845 HP_110 Pomona roundleaf bat
Human herpesvirus 4 LN831023.1 HS_HV4 Human Human herpesvirus 4 NC_007605.1 HS_HV4 
Human herpesvirus 8 AF005477.2 HS_HV8 Human Human herpesvirus 8 AF092928.1 HS_HV8
Lynx rufus gammaherpesvirus 1 KF840716.1 LYRU_GHV1 Bobcat Lynx rufus gammaherpesvirus 1 KF840716.1 LYRU_GHV1
Macaca fascicularis lymphocryptovirus 1 AF534221.2 MAFA_LCV Crab-eating macaque Macaca fascicularis lymphocryptovirus 1 AF534221.2 MAFA_LCV 
Macaca fascicularis rhadinovirus 2  EU085377.1 MAFA_RHV2 Crab-eating macaque Macaca fascicularis rhadinovirus 2 EU085377.1 MAFA_RHV2 
Macaca fuscata rhadinovirus AY528864.1 MAFU_RHV Japanese macaque Macaca fuscata rhadinovirus AY528864.1 MAFU_RHV
Miniopterus schreibersii MS/11HN95 KR261846 MSC_95 Common bent-wing bat Miniopterus schreibersii 11HN110 KR261903 MSC_110
Miniopterus schreibersii MS/12HN28 KR261851 MSC_28 Common bent-wing bat Miniopterus schreibersii 211HN16 KR261901 MSC_16
Murid herpesvirus 4 NC_001826.2 MUR_HV4 Mouse Murid herpesvirus 4 NC_001826.2 MUR_HV4 
Mus cervicolor rhadinovirus 1 DQ821582.1 MUCE_RHV1 Fawn-colored mouse Mus cervicolor rhadinovirus 1 DQ821582.1 MUCE_RHV1 
Mus musculus rhadinovirus 1 AY854167.1 MUMUS_RHV1 House mouse Mus musculus rhadinovirus 1 AY854167.1 MUMUS_RHV1 
Mustelid herpesvirus 1 AF376034.1 MUST_HV1 Ferret Mustelid herpesvirus 1 AF376034.1 MUST_HV1 
Myodes glareolus rhadinovirus 1 AY854169.2 MYGLA_RHV1 Bank vole Myodes glareolus rhadinovirus 1 AY854169.2 MYGLA_RHV1 
Myotis nattereri rhadinovirus 1 DQ788625.1 MYNA_RHV1 Natterer's bat
Myotis ricketti herpesvirus 1 JN692429.1 MYRI_HV1 Rickett's big-footed bat Myotis ricketti herpesvirus 1 JN692429.1 MYRI_HV1 
Myotis ricketti herpesvirus 2 JN692430.1 MYRI_HV2 Rickett's big-footed bat Myotis ricketti herpesvirus 2 JN692430.1 MYRI_HV2 
Myotis velifer gammaherpesvirus 8 KU220026.1 MYVE_HV8 Cave myotis Myotis velifer gammaherpesvirus 8 KU220026.1 MYVE_HV8 
Nyctalus noctula rhadinovirus 1 DQ788626.1 NYNOC_RHV1 Common noctule bat
Nyctalus noctula rhadinovirus 2 DQ788627.2 NYNOC_RHV2 Common noctule bat Nyctalus noctula rhadinovirus 2 DQ788627.2 NYNOC_RHV2 
Ovine herpesvirus 2 NC_007646.1 OVI_HV2 Sheep Ovine herpesvirus 2 NC_007646.1 OVI_HV2
Pan troglodytes rhadinovirus 2 EU118145.1 PATR_RHV2 Common chimpanzee Pan troglodytes rhadinovirus 2 EU085378.1 PATR_RHV2
Pan troglodytes rhadinovirus 3 GQ995451.1 PATR_RHV3 Common chimpanzee Pan troglodytes rhadinovirus 3 GQ995451.1 PATR_RHV3 
Panthera leo gammaherpesvirus 1 DQ789370.2 PALEO_GHV1 Lion Panthera leo gammaherpesvirus 1 DQ789370.2 PALEO_GHV1
Papio hamadryas lymphocryptovirus 2 AF534229.3 PAHAM_LCV2 Hamadryas baboon Papio hamadryas lymphocryptovirus 2 AF534229.3 PAHAM_LCV2
Pipistrellus nathusii rhadinovirus 1 DQ788629.2 PIPNA_RHV1 Nathusius's pipistrelle bat Pipistrellus nathusii rhadinovirus 1 DQ788629.2 PIPNA_RHV1




Supplementary table S7.1. Contd. 
 
Plecotus auritus rhadinovirus 1 DQ788628.1 PLAUR_RHV1 Brown long-eared bat
Porcine lymphotropic herpesvirus 1 AF478169.1 SUS_LTV1
Porcine lymphotropic herpesvirus 2 AF191043.1 SUS_LTV2 Pig Porcine lymphotropic herpesvirus 2 AY170317.1 SUS_LTV2
Porcine lymphotropic herpesvirus 3 AY170316.1 SUS_LTV3 Pig Porcine lymphotropic herpesvirus 3 AY170316.1 SUS_LTV3 
Procavia capensis gammaherpesvirus 2 JF705865.1 PROCA_GHV2 Rock hyrax Procavia capensis gammaherpesvirus 2 JF705865.1 PROCA_GHV2
Ptenochirus jagori gammaherpesvirus LC008326.1 PTEJA_GHV Greater musky fruit bat
Pteropus giganteus herpesvirus 1 KC692446.1 PTGIG_HV1 Indian flying fox
Pteropus giganteus herpesvirus 2 KC692449.1 PTGIG_HV2 Indian flying fox
Pteropus giganteus herpesvirus 3 KC692450.1 PTGIG_HV3 Indian flying fox
Pteropus giganteus herpesvirus 5 KC692447.1 PTGIG_HV5 Indian flying fox
Pteropus giganteus herpesvirus 6 KC692448.1 PTGIG_HV6 Indian flying fox
Puma concolor gammaherpesvirus 1 KF840717.1 PUCON_GHV1 Cougar Puma concolor gammaherpesvirus 1 KF840717.1 PUCON_GHV1 
Rhinolophus blythi RB/13YF11 KR261856 RHIBLY_F11 Blyth's horsehoe bat Rhinolophus blythi 13HN56 KR261905 RHIBLY_56
Rhinolophus blythi RB/13YF3 KR261882 RHIBLY_YF3 Blyth's horsehoe bat Rhinolophus blythi 13YF104 KR261913 RHIBLY_104
Rhinolophus blythi RB/13YF6 KR261883 RHIBLY_YF6 Blyth's horsehoe bat Rhinolophus blythi 13YF79 KR261908 RHIBLY_79
Rhinolophus blythi RB/13YF84 KR261887 RHIBLY_F84 Blyth's horsehoe bat Rhinolophus blythi 13YF82 KR261910 RHIBLY_F82
Rhinolophus blythi RB/13YF87 KR261889 RHIBLY_F87 Blyth's horsehoe bat Rhinolophus blythi 13YF84 KR261909 RHIBLY_F84
Rhinolophus blythi RB/13YF89 KR261891 RHIBLY_F89 Blyth's horsehoe bat Rhinolophus blythi 13YF87 KR261911 RHIBLY_F87
Rhinolophus blythi RB/13YF96 KR261893 RHIBLY_F96 Blyth's horsehoe bat Rhinolophus blythi 13YF96 KR261912 RHIBLY_F96
Rhinolophus blythi RB/13YF99 KR261895 RHIBLY_F99 Blyth's horsehoe bat
Rupicapra rupicapra gammaherpesvirus 1 DQ789369.2 RURUP_GHV1 Chamois Rupicapra rupicapra gammaherpesvirus 1 DQ789369.2 RURUP_GHV1
Saimiri sciureus gammaherpesvirus 2 AY138584.2 SAMCI_GHV2 Common squirrel monkey Saimiri sciureus gammaherpesvirus 2 AY138584.2 SAMCI_GHV2
Saimiriine herpesvirus 2 NC_001350.1 SAM_HV2 Common squirrel monkey Scotophilus kuhlii 11HZ76 KR261904 SCKUH_76
Scotophilus kuhlii SK/11HZ84 KR261848 SCKUH_84 Lesser Asiatic yellow bat Scotophilus kuhlii 13Y234 KR261920 SCKUH_234
Scotophilus kuhlii SK/13YF121 KR261858 SCKUH_M121 Lesser Asiatic yellow bat Scotophilus kuhlii 13YF106 KR261914 SCKUH_106
Scotophilus kuhlii SK/13YF14 KR261863 SCKUH_14 Lesser Asiatic yellow bat Scotophilus kuhlii 13YF114 KR261915 SCKUH_114
Scotophilus kuhlii SK/13YF146 KR261865 SCKUH_146 Lesser Asiatic yellow bat Scotophilus kuhlii 13YF15 KR261907 SCKUH_15
Scotophilus kuhlii SK/13YF15 KR261866 SCKUH_15 Lesser Asiatic yellow bat Scotophilus kuhlii 13YF155 KR261916 SCKUH_155
Scotophilus kuhlii SK/13YF16 KR261872 SCKUH_16 Lesser Asiatic yellow bat Scotophilus kuhlii 13YF160 KR261917 SCKUH_160
Scotophilus kuhlii SK/13YF185 KR261876 SCKUH_M185 Lesser Asiatic yellow bat Scotophilus kuhlii 13YF187 KR261918 SCKUH_187
Scotophilus kuhlii SK/13YF239 KR261880 SCKUH_239 Lesser Asiatic yellow bat Scotophilus kuhlii 13YF206 KR261919 SCKUH_206
Scotophilus kuhlii 13YF244 KR261921 SCKUH_244
Sorex araneus gammaherpesvirus 1 EU085380.1 SORA_GHV1 Common shrew Sorex araneus gammaherpesvirus 1 EU085380.1 SORA_GHV1
Sus barbatus rhadinovirus 1 AY177147.2 SUSBA_RHV1 Bornean bearded pig Sus barbatus rhadinovirus 1 AY177147.2 SUSBA_RHV1
Symphalangus syndactylus lymphocryptovirus 2GQ921924.1 SYMSY_LCV2 Siamang gibbon Symphalangus syndactylus lymphocryptovirus 2 GQ921924.1 SYMSY_LCV2
Tapirus terrestris gammaherpesvirus 1 AF141887.3 TATER_GHV1 South American tapir Tapirus terrestris gammaherpesvirus 1 AF141887.3 TATER_GHV1
Tupaia belangeri gammaherpesvirus 1 AY197561.2 TUBEL_GHV1 Northern treeshrew Tupaia belangeri gammaherpesvirus 1 AY197561.2 TUBEL_GHV1
Type 2 ruminant rhadinovirus of mule deer HM014314.1 T2MDRHV Mule deer Type 2 ruminant rhadinovirus of mule deer HM014314.1 T2MDRHV
Suid alphaherpesvirus 1 JQ809330.1 SUS_AHV1 Pig Suid alphaherpesvirus 1 NC_006151.1 SUS_AHV1
Human herpes simplex virus type 1 M10792.1 HS_AHV1 Human Human herpes simplex virus type 1 JN555585.1 HS_AHV1
Pteropus dasymallus alphaherpesvirus 1 NC_024306.1 PTEDA_AHV1 Ryukyu flying fox Pteropus dasymallus alphaherpesvirus 1 AB825953.1 PTEDA_AHV1
Cynopterus sphinx betaherpesvirus CS/14GZ13KR261896 CYSP_A13 Greater short-nosed fruit bat




Supplementary figure S7.2. Restriction digestion analysis of EfHV genomic DNA. (A) EfHV 
DNA was digested using 7 restriction enzymes and ran on a Pulsed-field gel electrophoresis. (B) 
The bands obtained were matched with that of the predicted sizes based on complete EfHV genome 
LEGEND
1 – Salmonella braenderup ladder
2 – Undigested EfHV DNA
3 – EfHV DNA digestion with ECoRI
4 – EfHV DNA digestion with  BglII
5 – Salmonella braenderup ladder
6 – 1kb Plus ladder
7 – EfHV DNA digestion with ClaI
8 – EfHV DNA digestion with SwaI
9 – EfHV DNA digestion with SpeI
10 – Salmonella braenderup ladder
11 – EfHV DNA digestion with PacI
12 – EfHV DNA digestion with PmeI






















Fragment  Left      Cut by                    Cut by   Right
  Size    Overhang  Enzyme      From : To     Enzyme   Overhang
  23286    [+ 4]    BglII      142752:166037  BglII     [+ 4]
  14212    [+ 4]    BglII       95017:109228  BglII     [+ 4]
  13478    [+ 4]    BglII       40966:54443   BglII     [+ 4]
  13362    [+ 4]    BglII       59866:73227   BglII     [+ 4]
  10777    [+ 4]    BglII       73228:84004   BglII     [+ 4]
   9405    [+ 4]    BglII      110158:119562  BglII     [+ 4]
   7017    [+ 4]    BglII        3774:10790   BglII     [+ 4]
   6970    [+ 4]    BglII       33996:40965   BglII     [+ 4]
   5928    [+ 4]    BglII      136211:142138  BglII     [+ 4]
   5744    [+ 4]    BglII       84005:89748   BglII     [+ 4]
   5268    [+ 4]    BglII       89749:95016   BglII     [+ 4]
   4675    [+ 4]    BglII       15790:20464   BglII     [+ 4]
   3788    [+ 4]    BglII      127419:131206  BglII     [+ 4]
   3679    [+ 4]    BglII       10791:14469   BglII     [+ 4]
   3374    [+ 4]    BglII       20465:23838   BglII     [+ 4]
   3249    [+ 4]    BglII       26080:29328   BglII     [+ 4]
   3200    [+ 4]    BglII      131207:134406  BglII     [+ 4]
   3086    [+ 4]    BglII      122642:125727  BglII     [+ 4]
   3079    [+ 4]    BglII      119563:122641  BglII     [+ 4]
   3036    [+ 4]    BglII       54444:57479   BglII     [+ 4]
   2559    [+ 4]    BglII       30025:32583   BglII     [+ 4]
   2386    [+ 4]    BglII       57480:59865   BglII     [+ 4]
   2241    [+ 4]    BglII       23839:26079   BglII     [+ 4]
   1804    [+ 4]    BglII      134407:136210  BglII     [+ 4]
   1691    [+ 4]    BglII      125728:127418  BglII     [+ 4]
   1669    [+ 4]    BglII        2105:3773    BglII     [+ 4]
   1412    [+ 4]    BglII       32584:33995   BglII     [+ 4]
   1320    [+ 4]    BglII       14470:15789   BglII     [+ 4]
   1003    [+ 4]    BglII         673:1675    BglII     [+ 4]
    929    [+ 4]    BglII      109229:110157  BglII     [+ 4]
    711    [+ 4]    BglII      166038:166748  3' end
    696    [+ 4]    BglII       29329:30024   BglII     [+ 4]
    672             5' end          1:672     BglII     [+ 4]
    613    [+ 4]    BglII      142139:142751  BglII     [+ 4]
    429    [+ 4]    BglII        1676:2104    BglII     [+ 4]
Digest with ClaI:
Fragment  Left      Cut by                    Cut by   Right
  Size    Overhang  Enzyme      From : To     Enzyme   Overhang
  50870    [+ 2]    ClaI         3354:54223   ClaI      [+ 2]
  43429    [+ 2]    ClaI       123320:166748  3' end
  22748    [+ 2]    ClaI        95847:118594  ClaI      [+ 2]
  14045    [+ 2]    ClaI        64358:78402   ClaI      [+ 2]
   9677    [+ 2]    ClaI        86170:95846   ClaI      [+ 2]
   7767    [+ 2]    ClaI        78403:86169   ClaI      [+ 2]
   4725    [+ 2]    ClaI       118595:123319  ClaI      [+ 2]
   4211    [+ 2]    ClaI        60147:64357   ClaI      [+ 2]
   4000    [+ 2]    ClaI        56147:60146   ClaI      [+ 2]
   3353             5' end          1:3353    ClaI      [+ 2]
   1923    [+ 2]    ClaI        54224:56146   ClaI      [+ 2]
Digest with EcoRI:
Fragment  Left      Cut by                    Cut by   Right
  Size    Overhang  Enzyme      From : To     Enzyme   Overhang
  39569    [+ 4]    EcoRI       84177:123745  EcoRI     [+ 4]
  23619    [+ 4]    EcoRI      123746:147364  EcoRI     [+ 4]
  20518    [+ 4]    EcoRI       63659:84176   EcoRI     [+ 4]
  20441    [+ 4]    EcoRI       41308:61748   EcoRI     [+ 4]
  14908             5' end          1:14908   EcoRI     [+ 4]
  13229    [+ 4]    EcoRI       23154:36382   EcoRI     [+ 4]
  10371    [+ 4]    EcoRI      147365:157735  EcoRI     [+ 4]
   9013    [+ 4]    EcoRI      157736:166748  3' end
   8245    [+ 4]    EcoRI       14909:23153   EcoRI     [+ 4]
   4925    [+ 4]    EcoRI       36383:41307   EcoRI     [+ 4]
   1230    [+ 4]    EcoRI       61749:62978   EcoRI     [+ 4]
    680    [+ 4]    EcoRI       62979:63658   EcoRI     [+ 4]
Digest with PacI:
Fragment  Left      Cut by                    Cut by   Right
  Size    Overhang  Enzyme      From : To     Enzyme   Overhang
 102984             5' end          1:102984  PacI      [- 2]
  45999    [- 2]    PacI       120750:166748  3' end
  17765    [- 2]    PacI       102985:120749  PacI      [- 2]
Digest with PmeI:
Fragment  Left      Cut by                    Cut by   Right
  Size    Overhang  Enzyme      From : To     Enzyme   Overhang
 111343             5' end          1:111343  PmeI      [+ 0]
  55405    [+ 0]    PmeI       111344:166748  3' end
Digest with SpeI:
Fragment  Left      Cut by                    Cut by   Right
  Size    Overhang  Enzyme      From : To     Enzyme   Overhang
  54074    [+ 4]    SpeI        89378:143451  SpeI      [+ 4]
  44211    [+ 4]    SpeI        45167:89377   SpeI      [+ 4]
  30916    [+ 4]    SpeI        13512:44427   SpeI      [+ 4]
  23297    [+ 4]    SpeI       143452:166748  3' end
  13511             5' end          1:13511   SpeI      [+ 4]
    739    [+ 4]    SpeI        44428:45166   SpeI      [+ 4]
Digest with SwaI:
Fragment  Left      Cut by                    Cut by   Right
  Size    Overhang  Enzyme      From : To     Enzyme   Overhang
  86381    [+ 0]    SwaI        80368:166748  3' end
  50171             5' end          1:50171   SwaI      [+ 0]





obtained from mi-seq and nanopore sequencing. Two DNA ladders were used namely Salmonella 
Braenderup and 1kb plus DNA ladder. 
 
 
Supplementary Figure S7.3. Expression of MHC-I and MHC-II antigen in bat cells. Agarose 
gel images showing bands obtained by real-time PCR. The contents of the lanes are mentioned 
above the gel images in orange boxes and the gene targeted is mentioned at the bottom. For every 
target, a 1kb DNA ladder, an EfHV genomic DNA (positive control), an EfHV infected bat cell 
cDNA without reverse transcriptase (genomic DNA contamination control), an EfHV infected bat 
cell cDNA with reverse transcriptase, a bat cell cDNA and a no template control was used for 
PCR. All targets showed amplification in the EfHV genomic DNA and EfHV infected bat cell 
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cell cDNA showed a band but EfHV genomic also showed a faint band (mostly due to residual bat 
cellular DNA in the viral DNA).   
 
 
Supplementary figure S7.4. Alignment of entire amino acid sequences of DNA polymerase 
gene of representative alpha-, beta- and gammaherpesviruses. Phylogenetic tree was generated 
using Maximum likelihood method (JTT substitution model). Numbers at nodes indicate bootstrap 
values. 
 
7.10. Transition statement 
In this chapter, I described the first isolation and detailed characterization of a big brown 
bat gammaherpesvirus. Our studies allowed us to develop techniques for detecting the virus as 

































































































Supplementary figure 1. Alignment of entire amino acid sequences of DNA polymerase  gene of representative alpha, 
beta and gammaherpesviruses. Phylogenetic tree was generated using Maximum likelihood method (JTT substitution 
model). Numbers at nodes indicate bootstrap values.
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studied till date establish life-long latent infections and reactivate periodically from this quiescent 
state in response to a variety of stressors, we could use the tools we developed to test the hypothesis 
that most big brown bats are latently-infected with the gammaherpesvirus and that natural 
stressors, such as arousal from winter hibernation would lead to reactivation of the virus.  
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Chapter 8: Stress of arousal from hibernation reactivates gammaherpesvirus 
in big brown bats 
8.1. Copyright 
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Many viruses that cause serious and often fatal disease in humans have spilled over from 
bats. Recent evidence suggests that stress may enhance virus shedding by bats increasing the 
possibility of transmission to other species. To understand the reasons for spillover it is therefore 
important to determine the molecular pathways that link stress to virus reactivation and shedding 
in bats. We recently isolated and characterized a gammaherpesvirus (Eptesicus fuscus herpesvirus, 
EfHV) autochthonous to North American big brown bats. Since herpesviruses are known to 
reactivate from latent infections in response to a wide variety of stressors, EfHV presents us with 
an opportunity to study how physiological, behavioural or environmental changes may influence 
the big brown bats’ relationship with EfHV. To understand the biology of the virus and how the 
extended periods of torpor experienced by these bats during hibernation along with the stress of 
arousal might influence the virus-host relationship, we attempted to detect the virus in the blood 
of wild-caught non-hibernating bats as well as captive bats arising from hibernation. We compared 
the prevalence of EfHV in the blood (using PCR) and EfHV-specific antibodies (using ELISA) 
between captive hibernating bats and wild-caught non-hibernating bats. We detected EfHV only 
in the blood of captive hibernating bats (27.8% = 10/36) and not in wild-caught non-hibernating 
bats (0.0% = 0/43). In contrast, the EfHV-specific antibody titres were higher in the non-
hibernating bats compared to the hibernating bats. Our study suggests that: (1) viral DNA in blood 
indicates reactivation from latency, (2) long periods of hibernation lead to suppression of 
immunity, (3) stress of arousal from hibernation reactivates the virus in bats with lower levels of 
antiviral immunity (indicated by humoral immune response), and (4) levels of antiviral immunity 





 Bats harbour many viruses and some of them have been implicated in epidemics like Nipah, 
Hendra and SARS (Severe Acute Respiratory Syndrome) [12]. Bat-borne viruses can either 
directly infect humans or spillover to humans via an intermediate host. There are over a thousand 
different bat species and they are the second most diverse group of mammals on the planet [14]. 
Unlike other mammalian species, bats do not appear to suffer from overt disease due to the viral 
infections (with the exception of rabies virus and Tacaribe virus) [16,37]. Bats are the only flying 
mammals and their tolerant immune system may have co-evolved with flight [21]. Flight elevates 
the body temperature and metabolism of bats, which might provide a selective advantage for 
controlling virus replication [20]. A recent large scale analysis found that the zoonotic potential of 
bats has surpassed that of rodents [333] and that bats harbour significantly more potentially 
zoonotic viruses than all other mammalian orders [334]. Studying bats and their viruses is therefore 
important for public health and safety around the world. 
The causes of viral spillover are complex and rely to a large extent on interactions between 
the reservoir host and their viruses. Disruption of balanced host-virus relationships due to stressors, 
such as habitat loss or secondary infections, may increase virus shedding, and enhance the 
likelihood of spillovers [12,62,335]. Much is known about viruses in spillover hosts or in surrogate 
laboratory animals. However, there is little information on the relationship of viruses within their 
natural bat reservoir hosts. The purpose of the present study is to better understand the interaction 
between the North American big brown bat, Eptesicus fuscus, and its autochthonous 
gammaherpesvirus (EfHV). 
Gammaherpesviruses belong to the herpesvirus family, members of which have been 
detected in numerous vertebrate hosts, including humans [327]. The lifecycle of 
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gammaherpesviruses starts with a lytic infection of epithelial cells (primary infection) followed by 
a life-long latent infection in lymphoid cells (B cells) present in lungs and spleen [336,337]. The 
virus can reactivate from latency in response to a variety of stressors [338,339], leading to its 
detection in the blood by using relatively non-invasive procedures. This approach allows the study 
of virus-host cell dynamics without sacrificing the animal. Furthermore, we are able to examine 
the effects of stress-related changes in the virus-host relationships leading to increased virus 
shedding. This makes the “EfHV – big brown bat” system an ideal model for our research. 
Arousal from hibernation is a stressful event for bats [55]. In a previous study, we detected 
EfHV in the blood cells of 80% of E. fuscus arousing from hibernation [56]. We therefore 
hypothesized that hibernation is a contributing factor to the reactivation of EfHV within the big 
brown bat. To study the effects of hibernation on the bat-virus relationship, we compared the 
prevalence of EfHV DNA and antibody titres against EfHV between captive bats emerging from 
hibernation and wild-caught non-hibernating bats. Our results suggest that EfHV is latent in a large 
proportion of the big brown bat population and that hibernation reduces immunity to EfHV, 
contributing to its reactivation. 
 
8.6. Materials and methods 
8.6.1. Bat collection 
From May to August 2018, hibernating and non-hibernating bats were collected in and 
around Saskatoon, Saskatchewan, Canada. The hibernating bats had originally been rescued from 
a house on Tobin Crescent, Saskatoon (Figure 8.2. (A)) by a rehabilitation Centre. These bats were 
allowed to overwinter at the rehabilitation Centre. In the beginning of May 2018, the bats were 
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transferred to the animal facility in the WCVM where they were sampled and subsequently 
released. 
To find areas with foraging non-hibernating bats, an echo locator device was placed in 
areas in and around Saskatoon. Some of the other areas were chosen based on anecdotal evidence 
of bat captures from previous studies. Two mist nets for trapping bats, (10 – 12 m wide, 6 m high), 
were set in the evenings just before sunset. The mist nets were attached to two poles with shower 
curtain rings. The poles were secured using rebar stakes hammered into the ground. Captured bats 
were removed from the mist net, placed into a small cotton bag and put inside a plastic container. 
Bats were removed from the mist net as soon as possible to prevent excessive entanglement and 
damage to the bat or the net. We clipped the hair from the dorsal aspect of bats to facilitate 
identification so that resampling was avoided. The non-hibernating bats were released after 
sampling and the hibernating bats were returned to the care of the rehabilitator for subsequent 
release into the wild. 
8.6.2. Sample Collection 
For both hibernating and non-hibernating bats, leather and latex gloves were worn during 
handling of the bats, which were changed between bat sampling to prevent cross contamination. 
The weight of each bat was obtained using a 100 g scale and the radius/ulna length was measured 
using a 30 cm standard ruler. 
Blood was collected by puncturing the saphenous vein of the left leg with a 27G x ½” 
monoject standard hypodermic needle and the blood droplet formed was collected into a 
heparinized capillary tube. Plasma and blood cells were separated using a fixed speed centrifuge 
(6,900xG) for 1 min. The capillary tube was cut at the junction of the plasma and blood cells and 
the two halves were stored separately at -20°C in Eppendorf tubes. 
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8.6.3. DNA extraction 
Bat blood cells were removed from the cut capillary tube by centrifugation at 1500xG for 
1.5 minutes. The blood cells were resuspended in 195 µL of sterile PBS and DNA was extracted 
using the Qiagen DNeasy Blood & Tissue Kit (Cat #69506) as per manufacturer’s instructions. 
The final elution step was done using 100 µL of Buffer AE. The DNA concentration was 
determined using a Nanodrop 2000c (spectrophotometer). 
8.6.4. Polymerase Chain Reaction 
To detect EfHV DNA in big brown bat blood cells, we amplified a 238 bp segment of the 
BGLF4 gene (Protein kinase C-like superfamily) using 5' – CAG CGT GAG CAG CCT ATG TA 
− 3' (Forward) and 5' - TAG AAT CCC GCA AGC GAC TC – 3' (Reverse) primers. Qiagen 
TopTaq DNA polymerase (Cat #200203) was used to set up the PCR reaction as described by the 
manufacturer. Denaturation, annealing and extension cycles for the PCR reaction were 94°C for 
30 secs, 60°C for 30 secs and 72°C for 1 min (40 cycles). An initial denaturation at 94°C for 3 
mins and a final extension at 72°C for 10 mins were also included. To test each bat, 5 µL of blood 
cell DNA was used as a template. EfHV genomic DNA was used as a positive control. PCR 
products were analysed on a 1% agarose gel. DNA from 238 bp bands was purified (QIAquick gel 
extraction kit; Cat #28704) and sent for Sanger sequencing (Macrogen, Rep. of Korea). BLAST 
search was performed using the sequencing file and we considered the first and closest match to 
the PCR product as the true sequence. 
8.6.5. IgG capture Enzyme-Linked Immunosorbent Assay (ELISA) against EfHV capsid 
protein 
We used an ELISA to detect antibodies against EfHV in the blood of the bats. Purified, 
glutathione-S-transferase (GST)-tagged EfHV Capsid protein (GST-BFRF3) expressed in E. coli 
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BL21 cells was used as a positive antigen to capture antibodies. GST (without any protein attached) 
also expressed in BL21 cells was used as a negative antigen to determine non-specific antibody 
binding against GST. The difference in optical density (OD) between the capsid-GST and GST 
alone represent the levels of EfHV antibodies for each plasma sample. The wells of ultra-high 
binding polystyrene flat-bottomed microtiter plates (96 well, Thermoscientific, Cat #3855) were 
coated with 0.05 µg of either antigen (GST-BFRF3 or GST) diluted in 0.1 M phosphate-buffered 
saline (pH 7.4) in a total volume of 100 µL. The coated plates were incubated overnight at 4°C 
and washed three times with 300 µL of PBS-Tween20 (0.1%) immediately prior to use. In a non-
binding 96-well plate (Greiner Bio-One, Cat #655901), serum samples were diluted 1:200 in PBS-
Tween 20 (0.2%) supplemented with 5% foetal bovine serum (Gibco, Thermofisher, Cat #16210-
072). Serum from rabbits immunized with GST-BFRF3 was used as a positive serum control. 
For each bat, 100 µL of diluted serum was added simultaneously to wells coated with either 
positive (GST-BFRF3) or negative (GST) antigen. Plates were incubated at 37°C for one hour then 
washed three times with 300 µL of PBS-Tween (0.1%). A peroxidase-labelled goat anti-bat IgG 
secondary antibody (0.05 µg in 100 µL per well, Bethyl labs, Cat #A140-118P) was added, 
incubated for one hour at 37°C and washed as above. Peroxidase substrate (2,2’-azino-bis (3-
ethylbenzthiazoline-6-sulfonic acid) – TMB One component HRP microwell substrate, Bethyl 
labs, Cat #E102) was added to each well and colour was allowed to develop for 15 min. The colour 
reaction was stopped by adding 100 µl of 0.18M H2SO4. Optical density was measured at 450 nm 
using an ELISA microplate reader (Vmax, Molecular devices).  
For each bat, we calculated the corrected OD value by subtracting the OD for the negative 
antigen from the OD for the positive antigen: ODcorrected = ODpositive – ODnegative. To determine the 
cut-off value for ELISA, we performed change-point analysis on the whole set of ODcorrected values, 
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as this analysis does not need known positive or negative samples. Change-point analysis detects 
abrupt steps in the mean level of a series so that seropositive and seronegative ODcorrected values 
would be separated by a step in the series. This approach is an efficient alternative to the usual cut-
off formula of the form “mean + 3 standard deviations of the known negative controls” [340]. We 
used the R package “changepoint” [341] and selected the Pruned Exact Linear Time (PELT) 
algorithm to detect change-points [342,343].  
8.6.6. Statistical Analysis and graphs 
P values < 0.05 were considered statistically significant. We used R studio version 1.1.453 
to analyze the data. Graphs were made using Graphpad prism 7.  
A Student’s two samples t-test was used to compare the mean EfHV antibody titres 
between bats with positive versus negative EfHV PCR status for the subsample of hibernating bats. 
A two samples proportion test was used to compare the percentage of seropositive bats between 
hibernating and non-hibernating bats. A one-way analysis of variance (ANOVA) was used to 
compare the EfHV antibody titres between locations. The two samples t-test, two samples 
proportion test, and one-way ANOVA were run using the t.test(), prop.test(), and lm() functions, 
respectively, which are in the base package of R.  
We used linear mixed models (LMMs) with normal errors to model body weight (g). The 
fixed effects were radius length (mm), sex (2 levels: female, male), and hibernation state (2 levels: 
hibernating, non-hibernating). Location (6 levels: Buckwold Park, Diefenbaker Park, Meewasin 
Park, Vikram’s Acreage, Tobin Crescent and Wilson Park) was modeled as a random effect. We 
used generalized linear mixed models (GLMMs) with binomial errors to model bat infection status 
(negative, positive). The fixed effects were hibernation state, sex, radius length (mm), body weight 
(g), and antibody titre (OD). Location was modeled as a random effect. We used LMMs with 
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normal errors to model bat antibody titres. The fixed effects were hibernation state, sex, radius 
length (mm), body weight (g), and bat infection status (negative, positive). Location was modeled 




We obtained samples from 36 hibernating bats that were kept at a local rehabilitation center 
over the winter. We also sampled 43 non-hibernating bats captured at various locations around 
Saskatoon, Saskatchewan, Canada (Figure 8.2(A)).  
8.7.1. Relationships between body weight, radius length, and sex 
We used linear mixed models with normal errors to investigate the relationship between 
body weight and three fixed effects: radius length, sex, and hibernation status. We found a positive 
relationship between radius length and body weight (Figure 8.1; slope = 0.45 g/mm, S.E. = 0.120 
g/mm, t = 3.715, p < 0.001). Males were 2.6 grams lighter than females, and this difference was 
significant (Figure 8.1; supplementary figure S8.1. (A); contrast male – female = -2.63, S.E. = 
0.464, t = -5.665, p < 0.001). Non-hibernating bats had a higher body weight than hibernating bats, 
but this difference was not significant (contrast non-hibernating – hibernating = 1.03, S.E. = 0.681, 




Figure 8.1. Relationship between body weight (grams) and radius length (mm) is shown for 
female and male bats. Bats with longer radius have a larger body weight and females are larger 
than males. Lines of best fit are shown for females (solid red) and males (stippled blue). 
 
8.7.2. Hibernating big brown bats have detectable EfHV DNA 
To estimate the prevalence of EfHV in big brown bats, we used PCR to amplify the 
herpesvirus BGLF4 gene in DNA extracted from bat blood cells. We detected EfHV DNA in 
27.8% (10/36) of captive bats emerging from hibernation (6 positive males and 4 positive females), 
but in none of the non-hibernating bats (0/43) caught in the wild. The numbers of bats sampled at 
various locations are shown in Figure 8.2. (A). Infection with EfHV was verified by sequencing; 
all the PCR products matched 100% with the EfHV sequence (Accession number MF385016). To 
rule out the possibility that the non-hibernating bats were naïve to EfHV, we screened all bats for 
the presence of antibodies against the EfHV capsid protein.  

















Figure 8.2. (A). Map representing areas in and around Saskatoon, Saskatchewan, Canada 
where North American big brown bats were captured and sampled. The map depicts the total 
number of bats caught in each area and the average optical density (OD) values at 450 nm of bat 
gammaherpesvirus antibodies (anti-Capsid). The size of the bat icon denotes the number of bats 
captured at each site and the density of the fill indicates the level of anti-EfHV antibody. Pink 
boxes are captured non-hibernating bats while the yellow box represents hibernating bats.  
Figure 8.2. (B). Comparison of levels of EfHV antibody levels (Capsid) in the plasma of 
hibernating and non-hibernating big brown bats. Antibody levels against the EfHV capsid 
protein are expressed as corrected OD values at 450 nm. These values were obtained by subtracting 
OD for the negative antigen (GST) from that of the positive antigen (GST-tagged EfHV Capsid 
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protein). Non-hibernating bats had significantly higher antibody levels than hibernating bats 
(Welch two sample t-test: p < 0.001).  
Figure 8.2. (C). Comparison of EfHV antibody levels (Capsid) and viral DNA detected by 
PCR in individual big brown bats. Antibody levels against the EfHV capsid protein are 
expressed as optical density (OD) values at 450 nm and arranged in an ascending order to show 
the change in mean based on which cut-off was determined (change-point analysis). Positive EfHV 
DNA status and hibernation status is depicted as described in the legend. All bats that tested 
positive were hibernating and their levels was lower than the ELISA cut-off. More number of non-
hibernating bats (18/43) were above the cut-off than hibernating bats (4/36) (χ2 = 7.754, df = 1, p-
value = 0.005). 
 
8.7.3. Seroprevalence of EfHV antibodies in bats 
We performed IgG capture ELISA on blood plasma obtained from 36 hibernating and 43 
non-hibernating bats. Using change-point analysis, we determined the seropositive cut-off 
ODcorrected as 0.871 (Change-point type: change in mean, PELT analysis, penalty: MBIC with 
value, 13.1). Bats having ODcorrected values higher than the cut-off were considered seropositive for 
EfHV. For the hibernating bats and non-hibernating bats, 11.1% (4/36) and 41.8% (18/43) were 
considered seropositive, respectively. This result shows that both groups were exposed to the virus, 
and that the percentage of seropositive bats was higher in the non-hibernating group (Two sample 
proportion test: χ2 = 7.754, df = 1, p-value = 0.005). Counter-intuitively, the ODcorrected values of 
the 9 hibernating bats with reactivated virus were below the cut-off value (for the tenth bat that 
tested positive for EfHV DNA, we did not obtain enough plasma to perform an ELISA) (Figure 
8.2. (C)), which indicates that seronegativity does not rule out the possibility of EfHV infection. 
Therefore, instead of assigning seropositive or seronegative status to bats, we decided to analyse 




8.7.4. Lower EfHV antibody levels in bats containing EfHV DNA in their blood cells 
For the sample of hibernating bats, the antibody levels of bats that were PCR-negative for 
EfHV (n = 27 bats, 0.448 ± 0.109) were 2.2 times higher than the PCR-positive bats (n = 9 bats, 
0.205 ± 0.189; two samples t-test: t = 1.652, df = 32.82, p = 0.108; Figure 8.2. (C)). This counter-
intuitive result (although not significant) shows that bats with detectable levels of EfHV DNA have 
lower antibody levels than bats with no detectable levels of EfHV DNA. 
8.7.5. Higher levels of EfHV antibodies in non-hibernating bats 
The mean level of capsid-specific antibodies was 2.5 times higher in the non-hibernating 
bats (mean = 0.983 ± 0.111) compared to hibernating bats (mean = 0.387 ± 0.122), and this 
difference was significant (t-test: t = 3.736, df = 73.89, p < 0.001; Figure 8.2. (B)). However, there 
were also significant differences in bat antibody titres based on the location where bats were 
captured (ANOVA: F5, 73 = 4.184, p = 0.002) (Figure 8.2. (A), supplementary figure S8.1. (B)). 
Specifically, non-hibernating bats from Buckwold Park (t = 3.983, p < 0.001) and Wilson Park (t 
= 2.850, p = 0.006) had significantly higher antibody titres than bats from all other locations. These 
results suggest that both location and hibernation state have an important effect on bat antibody 
titres. These analyses of antibody titres are limited because they only consider one explanatory 
variable at a time.  
The independent samples t-test comparing the antibody levels between hibernating and 
non-hibernating bats did not consider other explanatory variables. We therefore used LME models 
to investigate the fixed effects (hibernation state, sex, radius length, body weight, and infection 
status) that influenced bat antibody levels against EfHV. After including the other explanatory 
variables, the antibody titres were still higher in the non-hibernating bats compared to the 
hibernating bats, but this difference was no longer significant (Table 8.1: mean contrast of non-
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hibernation – hibernation = 0.55, standard error of contrast = 0.368, t-value = 1.512, p = 0.266). 
None of the other explanatory variables had a significant effect on antibody titres (Table 8.1). 
 
Table 8.1. Bat antibody titre was modeled as an LME with normal errors. Parameter estimates 
are shown from the model that contains an intercept and five fixed effects: hibernation state, sex, 
radius, body weight, and infection status. For each parameter, the estimate, standard error, z value, 
and p-value are shown. 
Fixed effects Estimate Std. Error df t value p 
Intercept 0.50 3.170 72.19 0.157 0.875 
Non-hibernation - hibernation 0.56 0.368 2.06 1.512 0.266 
Male - female -0.12 0.314 72.86 -0.371 0.712 
Radius (mm) 0.01 0.074 72.89 0.198 0.843 
Weight (g) -0.04 0.067 72.92 -0.62 0.537 
Positive - negative -0.21 0.284 70.34 -0.756 0.452 
 
8.7.6. Hibernation is the most important factor for EfHV reactivation 
We used GLME models to investigate the fixed effects (hibernation state, sex, radius 
length, body weight, and antibody titre) that influenced reactivation of EfHV. Of the five fixed 
effects, only hibernation state had a significant effect on the prevalence of EfHV infection. The 
prevalence of EfHV infection was higher in the non-hibernating bats compared to the hibernating 
bats (Table 8.2: mean contrast on the logit scale of hibernating – non-hibernating = 2.84; standard 





Table 8.2. Bat infection status was modeled as a GLME with binomial errors. Parameter 
estimates are shown from the model that contains an intercept and five fixed effects: hibernation 
state, sex, radius, body weight, and antibody titre. For each parameter, the estimate, standard error, 
z value, and p-value are shown. 
Fixed effects Estimate Std. Error z value p 
Intercept -4.44 15.275 -0.291 0.771 
Non-hibernation - hibernation -2.84 1.268 -2.24 0.025 
Male - female 0.98 1.255 0.784 0.433 
Radius (mm) -0.05 0.353 -0.144 0.886 
Weight (g) 0.33 0.288 1.153 0.249 
Antibody titre -0.74 0.806 -0.922 0.357 
 
8.8. Discussion 
Gammaherpesviruses are known to establish long-term latent infection in their hosts with 
periodic reactivation of the virus leading to lytic replication, virus shedding from the skin and 
mucosae, and transmission to new uninfected hosts. Previous studies in lab mice have shown that 
the latent gammaherpesvirus is sequestered in cells in the spleen and can be reactivated by stress 
[52,53]. Various stressors, such as unfolded protein responses and hypoxia, can induce the 
expression of viral immediate early genes that initiate the lytic cycle [54]. Although numerous 
studies have studied the switch from latent infection to reactivation, the exact mechanism is still 
not understood. This is also true for bat gammaherpesviruses.  
Studies in bats and other hibernating mammalian species have shown that hibernation has 
a profound effect on innate and adaptive immune systems. Hibernation decreases leukocyte count, 
lymphocyte proliferation, cytokine levels and antibody production [344–346]. Arousal from 
hibernation is a stressful event. In arctic ground squirrels, for example, arousal from hibernation 
induces oxidative stress [347]. Studies in cell culture models have shown that oxidative stress 
induces reactivation of the Kaposi Sarcoma herpesvirus [339]. In the present study, we detected 
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EfHV DNA in the blood cells of bats arousing from hibernation, but not in the non-hibernating 
bats caught in the wild. The high prevalence of EfHV in hibernating bats was in agreement with 
our previous study on a research colony of bats that found EfHV DNA in the blood of 20 of 28 
hibernating individuals [56]. Our study suggests that the hibernation and/or the stress of arousal 
from hibernation caused the reactivation of the gammaherpesvirus in the big brown bats. An 
alternative explanation is that the stress of being housed at a rehabilitation centre contributed to 
the reactivation of EfHV, but we view this explanation is unlikely. 
To show that both hibernating and non-hibernating bats had been exposed to EfHV, we 
screened the bats for EfHV-specific antibodies. Importantly, the change point analysis showed that 
both hibernating and non-hibernating bats had been exposed to the virus and were possibly latently 
infected. Interestingly, the seroprevalence was lower in the hibernating bats than the non-
hibernating bats, even though we detected virus only in the blood of hibernating bats. For 
hibernating bats, the antibody titres were higher for the EfHV-negative bats than for the EfHV-
positive bats. This suggested that while the presence of high levels of anti-EfHV antibody may 
indicate prior exposure to the virus, low levels of antibody did not indicate an absence of infection. 
Interestingly, we were only able to detect EfHV in the blood of hibernating bats with low levels of 
antiviral antibody (below the seropositive cutoff of the change-point analysis). This result suggests 
that detection of virus in the blood indicates viremia due to reactivation rather than cells infected 
with latent virus, and this inference is in agreement with previous studies on murine herpesvirus-
68 [52,337]. 
The immune response is crucial in controlling mammalian gammaherpesvirus infection. 
The virus-specific antibody response helps to contain persistent murine gammaherpesvirus-4 in 
mouse models [348,349]. We found that the antibody titres against EfHV were higher in the non-
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hibernating bats compared to the hibernating bats and this difference was highly significant when 
hibernation status was the only explanatory variable. (although when we included other 
explanatory variables in the analysis, the direction of the effect remained the same, but it was no 
longer significant). One explanation for the difference in antibody titres between the two groups 
is as follows. In hibernating bats, the antibody response waned over the duration of hibernation 
resulting in lower antibody titres in this group at arousal. In contrast, in the non-hibernating bats, 
recent exposure to the virus or recent re-activation of the virus triggered a strong antibody 
response, which subsequently cleared the virus from the blood and driven to latency in the spleen 
cells. An alternative explanation for the differences in antibody titres is that the bats were sampled 
from different locations in Saskatoon and these locations may differ in infection prevalence. Since 
the non-hibernating bats were captured while flying, we do not know the precise location of their 
roosts. As big brown bats can have a flight range of 4.4 km [350], these bats sampled (except 2 
bats from Vikram’s Acreage) might be considered as a random sampling of Saskatoon area bats. 
Therefore, it is crucial to note the higher antibody titres in the non-hibernating bats suggesting that 
while these individuals have been exposed to EfHV they were successful in preventing the virus 
from reactivating. 
How do stress and the host immune system interact to allow EfHV to reactivate in the 
blood? The detection of EfHV only in the blood of hibernating bats with low levels of antibody 
(below change-point analysis cut-off) suggests reactivation of virus from latency may require two 
conditions – low levels of antiviral immunity, as indicated by low levels of antibody, and arousal 
from hibernation. A combination of suppressed antiviral response during hibernation and the stress 
of arousal may allow the virus to reactivate and replicate in lymphoid cells. Antibody titres are not 
the only immunological mechanisms that control replication of gammaherpesviruses. T-cell 
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mediated responses are also important for controlling gammaherpesviruses [351]. We propose a 
preliminary model whereby decreased immunity and oxidative stress (due to arousal) explain 
reactivation of EfHV in the big brown bat (Figure 8.3). 
 
Figure 8.3. A model based on our results of hibernation related EfHV reactivation. Long 
periods of hibernation leading to suppression of immunity, coupled with the stress of arousal from 
hibernation results in reactivation of latent EfHV. Subsequently, antiviral immunity increases in 
non-hibernating bats reducing viral DNA in circulating blood cells. Latent EfHV DNA is 
sequestered away from circulating blood, possibly in the spleen. 
 
Ideally, to demonstrate that a decrease in antiviral antibodies correlated with viral 
reactivation upon arousal from hibernation, we could have assessed antibody levels and viremia 
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in the same bats before and after hibernation. However, we were unable to obtain paired samples 
from the bats in this study because we did not have access to the hibernating bats until just before 
their release in the spring. Controlled experiments with paired sampling of individual bats before 
and after hibernation are needed to confirm our observations. It would also be interesting to study 
if hibernation has an effect on other bat-virus interactions.  
 
8.9. Supplementary information 
 
Supplementary figure S8.1. (A). Body weight (grams) of bats is shown as a function of 
hibernation status and sex. Females are heavier than males and non-hibernating bats are heavier 
than hibernating bats. Shown are the medians (black lines), 25th and 75th percentiles (edges of the 
box), minimum and maximum values (whiskers), and outliers (open circles). (B) Herpes virus-
specific antibody titres of bats are shown as a function of location. One-way ANOVA found that 
location had a significant effect on the antibody titre (F5, 73 = 4.184, p = 0.002). Posthoc Tukey 
HSD tests found that the bats at the WCVM had antibody titres that were significantly lower than 
bats from Buckwold Park (p < 0.001) and Wilson Park (p = 0.029). Shown are the medians (black 
lines), 25th and 75th percentiles (edges of the box), minimum and maximum values (whiskers), 























































Chapter 9: General discussion 
9.1. Summary 
 Bats are considered as the reservoir and ancestral host of several viruses that are now 
established as pathogens in other animals [1]. Although numerous studies have been done to 
understand the bat-virus relationship using surrogate viruses, very few studies have looked at the 
native viruses and their relationship with their natural host. Understanding this bat-virus 
relationship is crucial to further comprehend the mechanism behind spillovers. Spillover events 
are dependent upon numerous factors such as pathogen shedding, environmental conditions, 
pathogen persistence in environment and recipient host susceptibility. These factors must align, in 
a “perfect storm” leading to a spillover [12]. Although several groups have studied the various 
factors responsible for such spillovers, the molecular mechanism of spillover is largely unknown. 
 In my thesis, I set out to prove the general hypothesis that bats have a long-term balanced 
and benign relationship with viruses and natural stressors disrupt this balance leading to an 
increase in virus replication. In this section, I have summarized my findings which help in proving 
the general hypothesis in a step by step manner using two virus-bat models.   
9.1.1. Characterization of a coronavirus autochthonous to North American bat species 
To study factors altering the bat-virus relationship, we required models which could be 
used to test hypotheses describing the relationship. The first model that I used was of a bat 
coronavirus, detected in North American little brown bats. We showed that coronaviruses were 
able to persist in intestines of hibernating bats, at least for a period of 4 months during which they 
were in hibernation. The tissues infected with bat coronavirus did not show any overt inflammation 
or pathology. Since we had access to tissue samples archived from an earlier study on the 
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pathophysiology of white-nose syndrome, we further studied the effect of this secondary fungal 
infection on the bat-coronavirus relationship. 
9.1.2. Secondary infection increases coronavirus levels in little brown bats 
Using the coronavirus-bat model, we showed that the presence of secondary infection by 
P. destructans, leads to increased severity of the fungal disease and viral shedding and molecular 
responses in the tissue harbouring the persisting coronavirus (Chapter 5). We identified MAP 
kinase and cytokine-related genes (like IFI6) altered in the intestines in the presence of fungal 
infection in wings of the bat. To summarize, my results suggested that the systemic effects of 
secondary fungal infection downregulates antiviral responses and upregulates apoptotic pathways 
in bats persistently infected with coronavirus in the intestines and increases the potential of virus 
shedding. Since manipulating persistent viral infection in bats is difficult, we established a 
persistent coronavirus infection in bat cell culture, which enabled me to study molecular pathways 
that disrupt viral persistence leading to an increase in viral replication. 
9.1.3. Bat cells can be persistently infected with coronavirus and altering interferon and 
MAP kinase pathways leads to increased viral replication 
 After identifying innate immune pathways altering persistent coronavirus infection in in-
vivo models, we exploited persistent infection of cultured bat cells by the MERS-CoV to explore 
the molecular mechanism that regulate coronavirus persistence in bat cells (in-vitro model). We 
discovered that infection of bat cells rapidly selected for variants in the accessory gene ORF5. 
Long-term infection of bat cells without significant cellular pathology was mediated through 
antiviral innate mechanisms and activated MAP kinase pathways. Suppressing these pathways, led 
to an increase in virus replication. We also showed that activation of the IFI6-mediated anti-
apoptotic pathway, and resistance to superinfection with the more cytolytic wild-type MERS-CoV, 
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may prevent death of the cells and contributed to persistence of coronavirus (Chapter 6). The innate 
immune pathways that alter persistent virus infection in cell culture model, namely MAP kinase 
and IFI6, were comparable with pathways affected in little brown bats infected with white-nose 
syndrome fungus which increased the level of Myotis lucifugus coronavirus. Using the in-vivo and 
in-vitro bat-coronavirus system, we showed that bats have a long-term balanced and benign 
relationship with coronaviruses and stressful events affecting the innate antiviral pathways, could 
lead to increased coronavirus replication. To understand if stressors could disrupt low-level 
persistent infection of viruses other than coronavirus, I studied a bat herpesvirus relationship to 
big brown bats.   
9.1.4. Characterization of a gammaherpesvirus autochthonous to North American bat 
species 
 The second bat-virus model that I tested was that of a gammaherpesvirus isolated from 
North American big brown bats. We established that the gammaherpesvirus was widely prevalent 
in big brown bats and could be detected in the blood. We were also able to monitor the adaptive 
antibody response of the bat against this virus. These observations allowed us to monitor infections 
in non-hibernating bats caught in the wild and bats emerging from hibernation. Since all 
herpesviruses examined to date establish long-term latent infections from which they reactivate in 
response to various stressors, the gammaherpesvirus-bat model, also enabled us to study the effects 
of stress on viral reactivation from latency.  
9.1.5. Arousal from hibernation reactivates gammaherpesvirus in big brown bats 
 Using the gammaherpesvirus-bat model, we demonstrated that bat arousing from 
hibernation tend to have lower antibody levels and have detectable gammaherpesvirus in their 
blood. My findings suggest that long periods of hibernation lead to suppression of immunity and 
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stress from arousal reactivates the virus in bats with lower levels of antiviral immunity (Chapter 
8). But after hibernation, antibody levels and, perhaps other components of the antiviral immune 
response, tend to increase and the gammaherpesvirus is no longer detectable. A controlled study 
on bats before and after hibernation would enable us to obtain paired samples, which would further 
confirm our findings. My findings show that big brown bats are latently infected with the 




 In my doctoral thesis, I tested the broad hypothesis that bats have long-term balanced and 
benign relationships with viruses, with whom they have co-evolved, and that a variety of stressors 
disrupt this balance allowing increased viral replication. My disseration provides evidence that 
viruses persistently infect bats and shows the characteristics of such infections. It also provides 
definitive clues about two factors that alter balanced bat-virus relationship, namely secondary 
fungal infection increasing coronavirus persistence and arousal from hibernation reactivating bat 
gammaherpesvirus. I also describe a mechanism of persistent coronavirus infection in bat cells and 
molecular pathways that alter the persistent infection. To summarize, my thesis outlines factors 
that alter balanced bat-virus relationships (using in-vitro and in-vivo models), which may increase 
the probability of spillover of these viruses to humans and other animals. 
 
9.3. Challenges, limitations and future prospects 
 Although my thesis describes factors that affect bat-virus relationships, there were a few 
limitations to these studies. We studied the effect of secondary infection on bat coronavirus using 
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archived samples. We did not have access to fecal samples of these individual bats. Using fecal 
samples coronavirus shedding could have been monitored with and without the fungal infection. 
Also, since coronavirus was present in the intestines of these bats, it was not possible to know what 
bats were positive before harvesting the organs at the termination of the experiment.  
 Due to the white-nose syndrome, little brown bats are now considered endangered wildlife 
species [352]. This has made it challenging to perform in-vivo studies on this species. Recovery of 
little brown bat populations in the coming years, may allow further such studies on these bats. 
 Another challenge that we faced was during the study of arousal from hibernation on 
reactivation of gammaherpesvirus. We were unable to obtain paired samples from bats before and 
after hibernation because of the study design. We used statistically modelling tool to circumvent 
this challenge. But future studies using paired samples would confirm the findings obtained durng 
our study. 
In the future, attempt to generate the bat coronavirus using reverse genetics could be 
attempted. If successful isolation of the bat coronavirus occurs, then appropriate controlled in-vivo 
studies could be conducted. Experimental inoculation of the bat coronavirus to a large sample size 
of bats followed by secondary infection by P. destructans would enable us to confirm our findings. 
Also, montoring fecal samples would allow us to test our hypothesis that stress of secondary 
infection leads to increase in viral shedding. By having a native bat coronavirus, future studies 
could also look at effect of other stressors such as pregnancy and climate change. 
 The ability of bats to promote viral persistence, may exert evolutionary pressure on the 
virus. The emergence of new viral strains due to such pressure is poorly understood. Future studies 




 Studies on bats and their viruses is an emerging field. It is challenging to obtain species 
specific reagents, especially reagents (antibodies) that specifically detect bat viral proteins. As the 
field advances, we would be able to perform studies such as those examining the activation of 
enzyme-mediated pathways. Using cellular markers, we would also be able to examine the role of 
various bat immune cells and determine the cellular tropism of bat viruses. These studies would 
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